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ABSTRACT 
 
Fibrocytes are monocyte-derived cells that morphologically look like fibroblasts, but express 
both stromal and haematopoietic markers, and have been reported as being involved in 
wound healing and fibrosis. Fibrocytes can be differentiated in-vitro in both the presence 
and absence of serum and we wanted to study the relationship between them; which 
potentially could be involved at different time points of a wound-healing site. 
 
Differences between these two potential cell types were found in how they differentiated, 
and the way they reacted to serum. However they were both found to differentiate from 
two populations of monocytes. The relationships between these two fibrocytes, as well as 
macrophages were also examined using transcriptome analysis, clustering the samples 
based on all the genes, and identifying those that were significantly different between the 
populations. This demonstrated that both fibrocyte populations are distinct from each other, 
as well as from macrophages.  
 
These data demonstrate that these two fibrocytes have different characteristics, suggesting 
that they may have different roles at a wound-healing site. Potentially with serum-
containing derived fibrocytes emerging first to assist other immune cells, and begin the 
wound healing process, and serum-free later, when the environment changes, to continue 
with the process of repair.  
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1.0 INTRODUCTION 
1.1 Haematopoiesis 
Blood cells of all lineages are generated through the process of haematopoiesis. Each adult 
produces approximately 200 billion erythrocytes, 100 billion leukocytes, and 100 billion platelets 
every day1 and this can increase by more than 10 fold during a high demand for particular cells1. 
The correct development of the immune system from the haematopoietic stem cell is extremely 
important in its ability to protect the body from invasion and attack, therefore the 
differentiation pathways of the cells of the immune system have been researched for many 
years. 
 
It was 30 years ago that Abramson demonstrated that myeloid and lymphoid cells are derived 
from the same pluripotent stem cells in mice2 and the dichotomy model of differentiation 
developed (Figure 1.1). Over the years various studies have supported the concept that the 
lymphoid cells, T and B lymphocytes are closely related. Due to their ability to recognize antigen 
specifically, their morphology and the observation that patients with severe combined immune 
deficiency have neither of these cells3. Two studies in mice in the 1990’s indicated that early 
progenitors in the adult thymus had T and B cell differentiation potential but only limited 
myeloid potential4;5. Until more recently comparably little work has been done specifically on 
the myeloid lineage, other than in the development of red blood cells (reviewed in Kaushansky 
et al
1). 
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Figure 1.1 Dichotomy model of haematopoiesis. Schematic diagram of the dichotomy model of 
haematopoietic cell differentiation2. 
 
In 2002 work on myeloid lineage in humans supported the dichotomy model of haematopoiesis, 
Manz et al stated that the evidence available, as well as their own published work in humans, 
indicated that the commitment to either the lymphoid or myeloid lineages are exclusive 
events6. They reported that human common myeloid progenitors are the clonogenic 
progenitors of the granulocyte/macrophage and megakaryocyte/erythrocyte progenitors. They 
also stated that none of these myeloid progenitors exhibit in vitro differentiation activity for B 
or NK cells, or express CD7 or CD10, markers of early lymphocytes6. 
 
Haematopoietic 
stem cell 
Common 
Lymphoid 
precursor 
Common myeloid 
precursor 
T Cell 
B Cell NK Cell 
CD4+ CD8+ 
Monocyte 
Erythrocyte 
Basophil 
Neutrophil 
Eosinophil 
Platelets 
Chapter 1: Introduction  Marianne Fairclough 
 3
Following work investigating lineage commitment during lympho-haematopoeisis an alternative 
model of haematopoiesis was proposed in 2006 by Kawamoto et al, using a clonal assay 
system3;7. In this system an environment that equally supported the development of various cell 
lineages was developed on the cultural foetal thymus lobes from which endogenous thymocytes 
had been deleted. Cytokines were added to enhance the production of cells other than T cells 
and the single cells were cultured under high oxygen submersion conditions. The cells 
generated were collected and analyzed by flow cytometry to determine which cell lineages 
were generated in which culture. Although the results did not always reflect a complete 
developmental potential of the initially seeded progenitor cell, careful analysis of the frequency 
of progenitors in each organ and cellular subpopulations, along with the flow cytometry results, 
could determine the developmental potential3. From this work the group proposed a new 
model for haematopoiesis in which cells with myeloid potential could differentiate from many 
different cell types (Figure 1.2), as they found that common lymphoid progenitors still had the 
capacity to produce myeloid cells3. 
Chapter 1: Introduction  Marianne Fairclough 
 4
 
Figure 1.2 Alternative model of haematopoiesis. Schematic diagram of the model of 
haematopoietic cell differentiation proposed by Kawamoto et al3;7. 
 
However foetal thymus lobes in which thymocytes are not present is not physiologically possible 
and the whole experimental system was extremely artificial, therefore it is perhaps not 
surprising that cells with myeloid potential could differentiate from many different cell types 
due to the cytokine cocktail they were being given, and the lack of antagonistic signals. During 
haematopoiesis a cell does not just receive one set of signals sending it down a certain 
differentiation pathway, it can receive many conflicting signals and how the cell responds to all 
of these signals determines how it goes on to differentiate. 
 
Haematopoietic 
stem cell 
Common 
Lymphoid 
precursor 
Common 
myeloid/erythroid 
precursor 
T Cell 
B Cell NK Cell 
CD4+ CD8+ 
Erythrocyte 
Myeloid 
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Myeloid 
potential Myeloid potential 
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Evidence was provided in 2005 that suggested that a population of FMS-like tyrosine kinase 3 
(Flt3) positive lympho-myeloid stem cells exist that lack the potential of erythro-megakaryocytic 
lineages, suggesting an update to the lineage map of haematopoiesis8. Flt3 is a tyrosine-kinase, 
a cell membrane bound enzyme that will signal into the cell when it binds with itself as a 
homodimer. It was shown that multipotent progenitor (MPP) cells that do not express Flt3 
differentiate specifically down the erythroid/megakaryocyte pathway, whereas those which do 
express Flt3 have a reduced erythroid/megakaryocyte potential and give rise to both lymphoid 
and myeloid populations. This suggested that cells of both the innate and adaptive immune 
response arise from the same common progenitor8. The genetic basis of this separation, 
identified by Flt3 expression, has been shown previously to be due to the transcription factors 
PU.1 and globin transcription factor 1 (GATA-1). Transcription factors are proteins that bind to 
specific sequences of DNA controlling transfer, or transcription. Gene disruption studies in mice 
have shown the importance of GATA-1 for erythroid and megakaryocyte differentiation9 and 
PU.1 for myeloid and lymphoid development10. PU.1 and GATA-1 were found to be functional 
antagonists of each other, due to the inhibition of transactivation potential, respectively, by 
direct physical interaction between the two proteins11-14. More recently work has shown that 
the reciprocal activation of GATA-1 and PU.1 primarily organises the hematopoietic lineage fate 
decision to form the earliest hematopoietic branch point, separating cells of 
erythroid/megakaryocyte potential from those of myeloid/lymphoid potential15 (reviewed16). 
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Figure 1.3 Second alternative model of haematopoiesis. Schematic diagram based on the 
model of haematopoietic cell differentiation proposed by Laslo et al 200816. 
 
The level of the transcription factor PU.1 has been found to continue to affect the outcome of 
cell differentiation, as having dictated a common lymphoid/myeloid precursor the amount 
available determines a myeloid over lymphoid direction of differentiation. B-cell development 
requires the presence of a small amount of the transcription factor PU.1, however 4-5 times 
that concentration will drive macrophage differentiation, at which point B-cell development is 
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actively inhibited16;17. The molecular determinates for this graded response to PU.1 are 
unknown however PU.1 does not act independently, many other signals are also required for a 
cell to be committed to either myeloid or B-cell fates. It is believed that at the 
lymphoid/myeloid progenitor stage signals are already being released to prime a cell for a 
certain lineage, although still allowing the cell to have the potential for other pathways 
(reviewed16).  
 
The transcription factor E2A is known to be important for the generation of B lymphocytes, 
however before determining that lineage it is thought to promote the generation of the 
lymphoid myeloid progenitors by blocking the expression of a critical erythroid and 
megakaryocytic lineage determinant. It is also thought to prime the transcription of B 
lymphocyte lineage specific genes16. Ikaros is another transcription factor required for B 
lymphocyte development, it activates the recombination activating gene (RAG) expression and 
IgH gene rearrangements18. Ikaros deficient mice were still able to generate lymphoid/myeloid 
progenitor cells, however from that point all B-cell development was blocked and there was an 
excessive myelopoiesis16;18. The loss in B-cell development due to the lack of Ikaros could be 
reversed however by the expression of the transcription factor early B-cell factor (EBF)19. It is 
thought that Ikaros acts on the lymphoid myeloid progenitor by not only inducing further B-cell 
lineage genes but also by repressing the expression of myeloid lineage ones16. 
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Many transcription factors are required for T lymphocyte commitment, such as PU.1, 
arabidopsis ME12-like protein 1 (AML1), globin transcription factor 3 (GATA-3) and E2A, 
however the most important factor is Notch-1. Notch-1 signalling is blocked in the bone marrow 
by the transcription factor leukaemia/lymphoma related factor (LRF), disruption of which leads 
to the development of T cell progenitors. However in the thymic cortex Notch-1 signalling 
promotes T lymphocyte development and has been shown to inhibit B-cell development, which 
may be due to Notch-1 inhibiting B-cell specific transcription factors (reviewed16). So despite B 
and T lymphocyte development being quite similar with the distinctive use of the RAG genes for 
recombination of their receptor genes, and their role in recognising antigen, their 
developmental pathways diverge quiet early on, due to their dichotomous response to Notch 
signalling20.  
 
Once the transcription factor PU.1 has ensured the myeloid/lymphoid lineage development 
rather than erythro/megakaryocyte10;15;21, it then goes on to be involved in the further 
development of the myeloid lineage17;22;23. In addition to PU.1, CCAAT enhancer-binding 
protein-alpha (C/EBPα) is also important in specifying the granulocyte/myeloid lineage over the 
lymphoid24;25. The relative amounts of these two transcription factors are thought to regulate 
the fate of myeloid lineage cells into either monocyte or neutrophils26. High levels of PU.1 
activate further transcription factors such as early growth response 1, 2 (Egr-1,2)/NGFI-A-
binding protein 2 (Nab-2) which together go on to activate monocyte specific genes and repress 
neutrophil development. In contrast C/EBPα activates the transcription factor growth factor 
Chapter 1: Introduction  Marianne Fairclough 
 9
independence 1 (Gfi-1) which has the opposite effect of repressing monocyte specific genes and 
activate neutrophil ones (reviewed16). In the review by Laslo et al16 they go on to propose that 
the primary cell fate determinates such as PU.1 and C/EBPα as well as the secondary cell 
determinates Egr/Gfi-1 work together in feed forward loops to promote transcription of lineage 
specific genes, so reinforcing cell fate decisions. 
 
1.2 Cross talk between cells 
Both while cell differentiation is taking place and afterwards, as cells are undertaking their roles 
within the body, how they interact with each other and ultimately ‘talk’ to one another is very 
important. The ‘cues’ that one cell releases can have major effects on not only the cells around 
it but cells distant from it as well. One way that cells interact with one other is by the release of 
cytokines, these can be proteins, peptides or glycoproteins that are regulators produced widely 
throughout the body and act as signalling molecules, allowing cross talk and communication. 
They can act in an autocrine (on the cell that produced them), paracrine (on cells nearby) or 
endocrine (on cells distant from them) fashion and are critical to the development and 
functioning of both the innate and adaptive immune response. Each cytokine will bind particular 
cell surface receptors which will initiate a cascade of signals into the cell triggering many 
different responses27.  
 
Cytokines and their receptors are grouped based on their structure. There are two main 
structural families, the hematopoietin family (Table 1.1), which includes many interleukins 
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involved in both adaptive and innate immunity, as well as growth hormones, and the tumor 
necrosis factor (TNF) family (Table 1.2), which also functions in both adaptive and innate 
immunity but includes many membrane bound members. Other families of cytokines include 
the interferons, the IL-10 family (Table 1.3), the IL-12 family (Table 1.4) and unassigned 
cytokines (Table 1.5). Originally the name interleukin was used as a standard nomenclature to 
identify those cytokines that were secreted by, and acted on leukocytes, however since then 
many more cytokines have been identified that have diverse origin, structure and effects and 
the interleukin nomenclature has become confusing27.  
Cytokine Alternative name Producer  cells Receptor's 
Epo Erythropoietin Kidney cells, hepatocytes EpoR 
IL-2 T cell growth factor T cells CD25(α), CD122(β), CD132(γc) 
IL-3 Multicolony CSF T cells thymic epithelial cells CD123, βc 
IL-4 BCGF-1 BSF-1 T cells, mast cells CD124, CD132(γc) 
IL-5 BCGF-2 T cells, mast cells CD125, βc 
IL-6 IFN-β2, BSF-2, BCDF T cells, macrophages, endothelial cells CD126, CD130 
IL-7   Non- T cells CD127, CD132(γc) 
IL-9   T cells IL-9R, CD132(γc) 
IL-11 AGIF  Stromal fibroblasts IL-11R, CD130 
IL-13 P600 T cells IL-13R, CD132(γc), CD24 
G-CSF Granulocyte stimulating factor  Fibroblasts and monocytes G-CSFR 
IL-15 T-cell growth factor Many non-T cells IL-15R, CD122 CD132(γc) 
IL-21   TH2 cells IL-21R, IL-2R (γc) 
GM-CSF Granulocyte-macrophage 
stimulating factor Macrophages, T cells CD116 βc 
OSM OM, oncastatin T cells, macrophages CD116 βc 
LIF Leukaemia inhibitory factor Bone marrow stroma, fibroblasts LIFR, CD130 
 
Table 1.1 Hematopoietin family of cytokines. Sixteen members of the hematopoietin family of 
cytokines are listed by their name. Alternative names are also indicated, as are the cells that 
produce them and their receptor, where available. Table adapted from Appendix III in27. 
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Cytokine Alternative name Producers Receptor's 
TNF-α Cachectin Macrophages, NK cells, T cells p55, p75, CD120a, CD120b 
TNF-β lymphotoxin, LT, LT-α T cells, B cells p55, p75, CD120a, CD120b 
LT-β   T cells, B cells LT-βR or HVEM 
CD40 ligand CD40-L T cells, mast cells CD40 
Fas Ligand FasL T cells CD95 (Fas) 
CD27 Ligand CD27L T cells CD27 
CD30 Ligand CD30L T cells CD30 
4-1BBL   T cells 4-1BB 
Trial   T cell, monocyte DR4, DR5, DCR1. DCR2, OPG 
OPG-L RANK-L Osteoblasts, T cells RANK, OPG 
APRIL     TAC1, BCMA 
LIGHT   Activated T cells   
TWEAK     TWEAKER 
Blys BAFF Monocytes, dendritic cells TAC1, BCMA 
 
Table 1.2 TNF family of cytokines. Fourteen members of the TNF family of cytokines are listed 
by their name. Alternative names are also indicated, as are the cells that produce them and 
their receptor, where available. Table adapted from Appendix III in27 
 
Cytokine Alternative name Producers Receptor's 
IL-10 Cytokine synthesis inhibitory factor 
T cells, macrophages, EBV-
transformed B cells IL-10Rα + IL-20Rβc 
IL-19   Monocytes IL-20Rα + IL-20Rβc 
IL-20   Monocytes IL-20Rα + IL-20Rβc, IL-22Rαc + IL-20Rβc 
IL-22 IL-TIF T cells, NK cells IL-22Rαc + IL-10Rβc 
IL-24 MDA7 Monocytes, T cells IL-22Rαc + IL-20Rβc, IL-20Rα + IL-20Rβc 
IL-26 AK155 T cells, NK cells IL-20Rα + IL-10Rβc 
IL-28A, B IFN-λ2,3   IL-28Rαc + IL-10Rβc 
IL-29 IFN-λ1   IL-28Rα + IL-10Rβc 
 
Table 1.3 IL-10 family of cytokines. Eight members of the IL-10 family of cytokines are listed by 
their name. Alternative names are also indicated, as are the cells that produce them and their 
receptor, where available. Table adapted from Appendix III in27 
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Cytokine Alternative name Producers Receptor's 
IL-12 NK-cell stimulatory factor Macrophages, dendritic cells IL-12Rβ1c + IL-12Rβ2 
IL-23   Dendritic cells IL-12Rβ1c + IL-23R 
IL-27   Monocytes, macrophages, dendritic 
cells WSX-1+CD130c 
 
Table 1.4 IL-12 family of cytokines. Three members of the IL-12 family of cytokines are listed by 
their name. Alternative names are also indicated, as are the cells that produce them and their 
receptor, where available. Table adapted from Appendix III in27. 
 
Cytokine Alternative name Producers Receptor's 
TGF-β 
  Chrondrocytes, monocytes, T cells TGF-βR 
IL-1α 
  Macrophages, epithelial cells CD121a and CD121b 
IL-1β   Macrophages, epithelial cells CD121a and CD121b 
IL-1 RA   Monocytes, macrophages, 
neutrophils, hepatocytes CD121a  
MIF   T cells, pituitary cells   
IL-16   T cells, mast cells eosinophils CD4 
IL-17 mCTLA-8 CD4 memory cells   
IL-18 IGIF, interferon-γ inducing factor 
Activated macrophages and kupffer 
cells IL-1R related protein 
IL-25   TH2 cells, mast cells   
 
Table 1.5 Unassigned cytokines. Nine unassigned cytokines are listed by their name. Alternative 
names are also indicated, as are the cells that produce them and their receptor, where 
available. Table adapted from Appendix III in27. 
 
Another group of cytokines, chemokines, or chemotactic cytokines, are low molecular weight 
(8-10kDa) polypeptides that are involved in the activation, recruitment and retention of 
leukocytes in both homeostatic and inflammatory conditions28. Homeostatic chemokines are 
expressed constitutively within lymphoid tissue and are involved in controlling migration in 
normal processes of tissue maintenance or development. However inflammatory chemokines 
are specifically up-regulated at sites of inflammation, often stimulated by pro-inflammatory 
cytokines such as interleukin 1 (IL-1). These chemokines are thought to be involved in recruiting 
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leukocytes, such as monocytes, neutrophils and other effector cells from the peripheral blood to 
site of infection or tissue damage, often to initiate an immune response or to promote wound 
healing29;30. Homeostatic and inflammatory chemokine groups are not mutually exclusive, same 
chemokines can be involved in both processes.  
 
Chemokine nomenclature is based on the locations of distinct cysteine residues that form 
disulphide bonds which are the key to holding their 3-dimensional shape. There are two major 
(CC and CXC) and two minor (C and CX3C) families based on these cysteine signature motifs, 
where X indicates any residue between the cysteines31.  
 
The CC chemokine (or ß-chemokines) subgroup has at least 27 different members reported in 
mammals (Table 1.6), usually containing four cysteines, although a small number have six32. This 
subfamily of chemokines is known to induce the migration of monocytes and other cell types 
such as NK cells and dendritic cells as well as inducing cellular migration by binding to, and 
activating, CC chemokine receptors. Ten CC chemokine receptors have been discovered to date 
and are called CCR1-1032.  
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Systematic 
name 
Other name Target cell Receptor 
CCL1 I-309 Neutrophil, T cells CCR8 
CCL2 MCP-1 T Cell, monocyte, basophil CCR2 
CCL3 MIP-1α Monocyte/macrophages, T cell, NK cell, basophil, Immature dendritic Cell, bone marrow cell CCR1, 5 
CCL4 MIP-1β Monocyte/macrophages, T cell, NK cell, basophil, Immature dendritic Cell, bone marrow cell CCR1, 5 
CCL5 RANTES Monocyte/macrophages, T cell, NK cell, basophil,  dendritic cell, eosinophil CCR1,3,5 
CCL6 MRP-2 Monocyte/macrophage, neutrophil CCR1 
CCL7 MCP-3 T cell, monocyte eosinophil, basophil, dendritic cell CCR2,3 
CCL8 MCP-2 T cell, monocyte eosinophil, basophil CCR2 
CCL9/10 MIP-1γ Dendritic cells, osteoclasts CCR1 
CCL11 Eotaxin Eosinophil CCR3 
CCL12 None Eosinophil, monocyte, T cell CCR2 
CCL13 MCP-4 T cell, monocyte, eosinophil, basophil, dendritic 
cell CCR2,3 
CCL14 HCC-1 Monocyte CCR1 
CCL15 MIP-5/HCC-2 T cell, monocyte, neutrophil, dendritic cell CCR1,3 
CCL16 HCC-4 Monocyte CCR1 
CCL17 TARC T cell, immature dendritic cell, NK cell CCR4 
CCL18 DC-CK1 Naive T cell, T cell Unknown 
CCL19 MIP-3β Naive T cell, mature dendritic cell, B cell CCR7 
CCL20 MIP-3α T cell, PBMC CCR6 
CCL21 6Ckine Naive T cell, B cell, CCR7 
CCL22 MDC Immature dendritic cell, NK cell, T cell thymocytes CCR4 
CCL23 MPIF-2 Monocyte, T cell Unknown 
CCL24 Eotaxin-2/MPIF-2 T cell, eosinophil, basophil CCR3 
CCL25 TECK Macrophage, thymocytes, dendritic cell CCR9 
CCL26 Eotaxin-3/MIP-4α Eosinophil, basophils CCR3 
CCL27 CTACK T cell CCR10 
CCL28 MEC T cell, eosinophil CCR10,3 
 
Table 1.6 CC subfamily of chemokines. All 27 members of the CC subfamily of chemokines are 
listed by their systematic name, other names are also indicated, as are the target cells these 
chemokines will affect and their receptor. Table adapted from Appendix IV in27. 
 
The CXC family is the second major chemokine subfamily, as its name suggests, the two N-
terminal cysteines of CXC chemokines (or α-chemokines) are separated by one amino acid, 
represented with an ‘X’. In mammals 16 different CXC chemokines have been described, divided 
into two categories, those with a specific amino acid sequence (or motif) of glutamic acid-
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leucine-arginine (or ELR for short) immediately before the first cysteine of the CXC motif (ELR-
positive), and those without an ELR motif (ELR-negative) (Table 1.7). ELR-positive CXC 
chemokines specifically induce the migration of neutrophils, and interact with chemokine 
receptors CXCR1 and CXCR2. CXC chemokines that lack the ELR motif tend to be 
chemoattractant for lymphocytes. CXC chemokines bind to CXC chemokine receptors, of which 
seven have been discovered to date, designated CXCR1-732. 
Systematic 
name 
Other name ELR+/- Target cell Receptor 
CXCL1 GROα + Neutrophil CXCR2 
CXCL2 GROβ + Neutrophil CXCR2 
CXCL3 GROγ + Neutrophil CXCR3 
CXCL4 PF4 - Fibroblast CXCR3 
CXCL5 ENA-78 + Neutrophil CXCR2 
CXCL6 GCP-2 + Neutrophil CXCR2 
CXCL7 LDGF-PBP + Fibroblast, neutrophil CXCR2 
CXCL8 IL-8 + Neutrophil, basophil, T cell CXCR1, 2 
CXCL9 Mig - Activated T cell CXCR3 
CXCL10 IP-10 - Activated T cell CXCR3 
CXCL11 i-TAC - Activated T cell CXCR3 
CXCL12 SDF-1α/β - CD34+ bone marrow cell, T cell, dendritic cell, B 
cell, activated CD4 T cell CXCR4 
CXCL13 BLC/BCA-1 - Naive B cells, activated CD4 T cells CXCR5 
CXCL14 BRAK + T cell, Monocytes Unknown 
CXCL15 Lungkine + Neutrophils CXCR2 
CXCL16 BUNZO/STRC33 - T cell, NK T cell CXCR6 
 
Table 1.7 CXC subfamily of chemokines. Members of the CXC subfamily of chemokines are 
listed by their systematic name, other names are also indicated, as are the target cells these 
chemokines will affect and their receptor. Table adapted from Appendix IV in27. 
 
The third group of chemokines is known as the C chemokines (or γ chemokines), and is unlike all 
other chemokines in that it has only two cysteines; one N-terminal cysteine and one cysteine 
downstream. Two chemokines have been described for this subgroup and they  are called XCL1 
(lymphotactin-α) and XCL2 (lymphotactin-ß)32 (Table 1.8). 
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Systematic 
name 
Other name Target cell Receptor 
XCL1 Lymphotactin-α T cell, NK cell XCR1 
XCL2 Lymphotactin-β Those expressing XCR1 XCR1 
 
Table 1.8 C subfamily of chemokines. Members of the C subfamily of chemokines are listed by 
their systematic name, other names are also indicated, as are the target cells these chemokines 
will affect and their receptor. Table adapted from Appendix IV in27. 
 
Finally, there is only 1 member to date of the fourth subgroup of chemokines, fractalkine (or 
CX3CL1). in which the two cysteines have three amino acids between them, termed the CX3C 
chemokine (or δ-chemokine)32 (Table 1.9). 
 
Systematic 
name other name Target cell Receptor 
CX3CL1 Fractalkine T cell, monocyte, neutrophil CX3CR1 
 
Table 1.9 CX3C subfamily of chemokines. The one member of the CX3C subfamily of chemokines 
is listed with its systematic name, its other name, the cells it can target and its receptor. Table 
adapted from Appendix IV in27. 
 
Chemokines interact with G-protein coupled receptors (GPCR) that have seven trans-membrane 
spanning α helix domains33-35. To date 20 chemokine receptors have been described for the 46 
human chemokines, with additional complexity via the potential formation of homodimers and 
heterodimers36. GPCR can be split into four categories based on the chemokines they interact 
with, CXCR bind CXC chemokines, CCR bind CC chemokines, CX3XR1 binds the sole CX3C 
chemokine and XCR1 the XC chemokines. As the name suggests GPCR are linked to G-proteins 
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that transmit cell signals following ligand binding. These can go on to promote many signaling 
cascades which are involved in chemotaxis, degranulation and release of superoxide anions37.  
 
1.3 Monocyte development 
The development of monocytes takes place in the bone marrow, and as discussed previously 
involves a complex crosstalk of transcription factors to ensure the development of first the 
granulocyte/myeloid precursor from the myeloid/lymphoid precursor, and then monocytes 
from the granulocyte/myeloid precursor38. After all this co-operation and cross-talk of 
transcription factors a differentiated monocyte can be released from the bone marrow into the 
peripheral blood39 by the interactions of chemokine receptors and their ligands. Monocyte 
emigration is highly affected by the level of inflammation within the body as well as the 
presence of a high fat diet40. The chemokine receptor CCR2 and its ligands CCL7 and CCL2 have 
been shown to be important in the emigration of monocytes from the bone marrow40. 
 
Once in the blood monocytes circulate for a few days, before entering the tissues and giving rise 
to a variety of tissue resident macrophages throughout the body39, as well as specialized cells 
such as dendritic cells41;42, osteoclasts43;44 and fibrocytes45-49. Monocytes make up 5-10% of the 
circulating leukocytes in the human body however they are extremely heterogeneous in their 
size, degree of granularity and nuclear morphology, which can sometimes lead to confusion in 
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their identification at the extremes of these50. These are important cells of the immune system 
that link inflammation and the innate part of the immune system, to the adaptive portion.  
 
Three subsets of monocytes have been defined, based on phenotype and chemokine 
expression. In the 1980s various groups described the existence of two monocyte populations in 
humans that differed in phenotype and functions (reviewed in40 and51). The dominant 
population consisted of larger, more active cells with both phagocytic and myeloperoxidase 
activity, as well as a higher super oxide release. The smaller monocytes had low peroxidase 
activity, but were able to release IL-1 and mediate antibody-dependent cytotoxicity40;51. 
Subsequently it was found that this larger population represented between 80-90% of all 
monocytes and could be identified by the expression of CD14 but not CD1652. They also 
expressed high levels of the chemokine receptor CCR2 but low levels of CX3CR1 and in response 
to LPS in vitro they released IL-1053-55. The smaller monocytes however were identified by their 
expression of CD16 and low levels of CD1456, expressing high levels of CX3CR1 and low levels of 
CCR253;55. These cells were termed proinflammatory52;57, as in response to LPS they released 
TNF-α and have been reported as being in higher numbers in the blood of patients with acute 
inflammation58 and infectious diseases59;60.  
 
More recently the small population of CD16+ monocytes has been suggested to consist of two 
distinct populations with different functions51. Monocytes which express both CD16 and CD14 
have been seen to express the Fc receptors CD64 and CD32, have phagocytic activity and are 
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responsible for the expression of both TNF-α and IL-1 in response to LPS61. However those 
CD16+ monocytes that have a very low level of CD14 are much less efficient at phagocytosis, do 
not express the Fc receptors or produce either TNF-α or IL-1 in response to LPS62. 
 
1.4 Monocyte derived progeny 
1.4.1 Macrophages and Dendritic cells 
Two major cell types that can differentiate from monocytes are macrophages and dendritic cells 
(DCs), however the exact origin and lineage relationships of these cells remains poorly 
understood. Both macrophages and dendritic cells are involved in the scavenging of dying cells, 
pathogens, and molecules through phagocytosis, endocytosis and the use of pattern recognition 
receptors63. Both can be termed antigen presenting cells (APC) and are widely dispersed 
throughout the body participating in the initial capture and processing of potential antigens 
(innate immunity) and then in the activation of specific T and B lymphocyte effector 
mechanisms (adaptive immunity)63. Although these two cell types have overlapping functions 
within the body, they are distinct. Macrophages are tissue-resident cells that take part in the 
innate immune response64, whereas dendritic cells are professional antigen presenting cells that 
trigger and help regulate the adaptive immune response65.  
 
Although initially it was thought that both macrophages and DCs differentiated entirely from 
monocytes that had circulated in the blood and then travelled into tissues it is now thought 
that, although this is still the case for some subtypes, it is not the case for all. Characteristics 
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such as half life, their replacement after bone marrow graft and whether inflammation has an 
effect on their differentiation or not allow macrophages and DCs to be split into three groups40. 
Group one includes cells which, following bone marrow transplantation, remain host derived 
unless the cells are specifically depleted by irradiation66;67. For example certain macrophages, 
such as microglia of the central nervous system, and epidermal DC’s, such as Langerhans cells 
remain host derived, suggesting that there may be some kind of self renewal taking place which 
is separate from bone marrow derived cells, such as the monocyte40. In 2007 Massberg et al 
reported work on haematopoietic stem cells and progenitor cells68 and showed that progenitor 
cells have the ability to circulate and then proliferate within extramedullary tissues so giving rise 
to tissue resident cells68. In the presence of Toll-like receptor (TLR) agonists the differentiation 
of these cells was increased, hence they can respond in both steady state and inflammatory 
conditions68.  
 
The second group consist of cells such as the conventional DCs (cDCs). These can be either 
CD8a+ of CD8a- and are located in all lymphoid organs. cDCs have a very short half life and 
renew in steady-state from bone marrow precursors, without a monocyte intermediate42;69-71. 
Finally the third group of cells is a short lived population which responds to inflammatory cues 
by differentiating from bone marrow derived monocytes into monocyte derived DCs and tissue 
resident macrophages39;40, which was initially thought to be the way that all macrophages and 
DCs differentiated.  
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Tissue resident macrophages are extremely heterogeneous, studies using monoclonal 
antibodies have shown that these cells express different phenotypes dependent on their 
location, perhaps suggesting specialisation for their particular microenvironments. For example 
alveolar macrophages found in the lungs express a high number of pattern recognition 
receptors and scavenger receptors72;73 which are involved in clearing microorganisms, viruses 
and environmental particles; whereas macrophages isolated from the lamina propria in the gut 
have a high phagocytic and bactericidal activity but produce few pro-inflammatory cytokines74. 
Tingible body macrophages in the germinal centres of tonsils have been shown to clear 
apoptotic lymphocytes generated during the development of an immune response75 and rarely 
come into contact with external pathogens. In response to inflammatory and immune 
stimulation additional monocytes can also be recruited in increased numbers to local sites, 
where local cues such as macrophage colony stimulating factor (M-CSF) cause macrophage 
differentiation, however they have been shown to display different phenotypes from the 
originally resident macrophages64. 
 
The surface receptors seen on macrophages are extremely versatile and can be involved in 
regulating a range of functions including differentiation, growth and survival, adhesion, 
migration, phagocytosis, activation, and cytotoxicity64. These receptors also allow them to 
recognize a wide range of endogenous and exogenous ligands and respond appropriately, 
whether it be in the role of homeostasis or as host defense in innate immunity64. 
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Monocyte derived DCs in vitro exist in two functionally and phenotypically distinct states, 
immature and mature. Immature dendritic cells express relatively low levels of MHC class I and 
II proteins and co stimulatory molecules on their surface, although large amount of MHC class I 
and II are being made and sequestered intracellularly into lysosomes65. Immature dendritic cells 
are very adept at endocytosis and readily take up antigen, though are very inefficient at 
processing it and presenting it to T cells65. Once the dendritic cell has detected a microbial 
product or pro-inflammatory cytokines in vitro it matures, reducing its ability to take up antigen 
but becoming extremely efficient at presenting antigen to T cells. There is also a massive 
cytoplasmic reshuffle with MHC class II molecules being moved from intracellular compartments 
to the plasma membrane, along with an increased expression of co-stimulatory molecules for T 
cells65. The maturing dendritic cells can alter their chemokine receptor profile to help promote 
the movement of the cell from the tissue to home to the lymphoid organs, during which these 
cells extend long projections called dendrites, possibly to help with the interaction with T cells65. 
However when studied in vivo Nolte et al showed that inflammatory mediators originating from 
non-hematopoietic tissues are not sufficient, or necessarily required for DC activation76. They 
saw that radio-resistant cells throughout the body, which respond strongly to LPS by initiating 
local and systemic inflammatory responses, are not sufficient, or necessary to change DC 
localization, phenotype or T cell stimulatory function, despite the high levels of TNF and IL-1 
released76. 
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1.4.2 Osteoclasts 
Osteoclasts are a multinucleated cell type, formed by the fusion of mononuclear macrophages. 
They are the major cell type involved in re-absorption of bone and work in partnership with 
osteoblasts, which form bone, to regulate the size and mass of the skeleton. Unlike osteoblasts 
which are mesenchymally derived, osteoclasts are haematopoietic in origin77;78 differentiating 
from monocytes43. Once monocytes have received the macrophage signal, M-CSF, binding to its 
receptor, colony stimulating factor 1 receptor (c-Fms), they begin to differentiate into 
macrophages, but this is also a signal to early osteoclast precursors for survival and 
proliferation77. RANK (receptor activator of nuclear factor (NF)-kappaB,) is expressed on 
osteoclasts and their precursors and it was found that the interaction with its ligand, RANK-L is 
the signal for osteoclast generation. In-vivo RANK-L is expressed on stromal cells, osteoblasts 
and activated T lymphocytes77, however in-vitro RANK-L can be added as a soluble factor to a 
cell culture in the presence of M-CSF differentiated macrophages, to see the production of 
osteoclasts. Once differentiated osteoclasts become polarised towards bone, developing a 
ruffled edge which involves the complex infolding of the plasma membrane, thought to allow 
the formation of microtubules that transport the acidifying vesicles to the bone surface77. 
Although no surface markers specifically identify osteoclasts their massive multinucleated 
morphology does, as does the presence of tartrate-resistant acid phosphatase or TRAP, known 
to be highly expressed by osteoclasts, as well as the osteoclast specific protease cathepsin K79. 
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Osteoclasts have been recently shown to only differentiate from the CD16- fraction of 
monocytes, when both the CD16+ and CD16- fractions of monocytes were examined to look at 
their ability to differentiate into osteoclasts. The CD16- fraction formed ten times as many 
osteoclasts as the CD16+ fraction and following various tests it was found that although the 
CD16+ fraction of cells do respond to M-CSF and RANK-L treatment, by differentiating into 
osteoclasts, they do not respond to the same extent as the CD16- fraction, possibly due to the 
reduced level of αvβ3 integrin on their surface, which is vital for osteoclast differentiation and 
activation44. This was shown when osteoclasts could not differentiate in vitro from macrophages 
of integrin β3 deficient mice80;81 due to the lack of activation of ERK (extracellular signal-
regulated kinase) and c-Fos, both of which are essential for osteoclastogenesis82;83. Therefore 
although osteoclasts differentiate from monocytes, they only differentiate from the larger 
CD14+ CD16- population. 
 
1.5 Fibrocytes 
1.5.1 Overview of Fibrocytes 
It was reported as long ago as 1892 that blood mononuclear cells were capable of transforming 
into connective tissue following studies in tadpoles. This observation was then confirmed by 
Maximov in 1928, however both reports were criticised as sceptics suggested that the results 
seen were due to contaminating fibroblasts entering the blood sample and expanding in culture 
(reviewed in Postlethwaite et al 200484). Experimental studies in 1969 used cannulation and 
diffusion chamber techniques to demonstrate that collagen-producing cells were not 
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contaminates dislodged from the blood vessel wall, but were derived from circulating blood 
elements (reviewed in Postlethwaite et al 200484). It was not until work undertaken during the 
1990’s however that the sceptics were quietened as connective tissue cells were observed to 
develop from blood mononuclear cells by a number of different groups85-87. 
 
Fibroblast-like cells that have developed from peripheral blood are referred to as many different 
things in the literature and are all reported to have slightly different characteristics. However, 
most groups are in agreement that these cells require the presence of CD14+ cells (monocytes), 
either alone or within PBMC to differentiate. Following in vitro culture for anywhere between 3 
days and 3 weeks, depending on conditions, long thin spindle shaped cells develop that 
phenotypically look very much like mesenchymally-derived fibroblasts45-47;85;86.  
 
It has been suggested that these cells are extremely important in wound healing87, in 1994 
Bucala et al reported the presence of fibroblast-like cells, or as they referred to them 
‘fibrocytes’ in a model of wound healing in mice87. The term fibrocyte combines the Greek 
‘kytos’ meaning cell and ‘fibro’ which is from the Latin meaning fiber88. Bucala’s group surgically 
implanted wound chambers into mice subcutaneously, 24 hours later a rapid influx of peripheral 
blood cells were seen and the unexpected development of a large number of adherent spindle 
shaped cells that resembled fibroblasts. Fibroblasts do migrate slowly from adjacent connective 
tissue to sites of healing however following the entry of a large number of circulating 
inflammatory cells into the wound site, and the presence of a large number of these fibroblast-
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like cells they suggested that there was a connection between them. Bucala et al did some 
preliminary studies on these cells in vitro and found that they had similar markers to fibroblasts, 
such as collagen I and III, vimentin, fibronectin and that they were negative to non-specific 
esterases, found on monocytes and granulocytes87. Further studies confirmed the presence of 
fibroblast-like cells in cultures of peripheral blood and that, in addition to expressing the 
fibroblast markers mentioned above, they also expressed leukocyte associated cells surface 
markers such as the common leukocyte antigen CD45, the pan myeloid antigen CD13, and the 
haematopoietic stem cell marker CD34, listed in table 1.1087. However it was found that these 
cells did not express epithelial and endothelial markers, monocytes/macrophage specific 
markers, CD14 and CD16, or proteins produced by dendritic cells and precursers87 (Table 1.1). 
Further work since 1994 has shown that fibrocytes can also produce both extracellular matrix 
(ECM) components as well as ECM-modifying enzymnes45;47;87;89, primarily matrix 
metalloproteinase-9 (MMP-9)90. 
 
Marker Role Cell subpopulations seen on 
Vimentin Intermediate Filament Fibroblasts 
Fibronectin Pericellular Matrix Mesenchymal cells, lymphoid cells 
Collagen I Extracellular matrix Fibroblasts 
Collagen III Extracellular matrix Fibroblasts 
CD11b Adhesion molecule Monocytes, granulocytes, NK cells 
CD13 Aminopeptidase N Myeloid and dendritic cells 
CD18 Integrin β2 Lymphoid and myeloid cells 
CD34 Precursor antigen Haematopoietic progenitors embryonic fibroblasts 
CD45 Leukocytes Common Antigen Leukocytes 
CD71 Transferrin receptor Macrophages, activated cells 
 
Table 1.10 Markers positively expressed on fibrocytes. Cell surface phenotype of human 
peripheral blood fibrocytes, positive expression seen on fibrocytes87  
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Marker Role Cell subpopulations seen on 
Esterase Lysosomal enzyme Monocytes and granulocytes 
TCR (αβ, γδ) Antigen receptor T cells 
Cytokeratin Matrix protein Epithelial cells 
Von Willebrand Coagulation factor Endothelial cells and platelets 
Desmin Intermediate filament Muscle cells 
α-Actin Cytoskeletal protein Smooth muscle cells 
Laminin Matrix protein Blood vessels, muscle cells, nerve etc 
CD3 TCR-associated antigen T cells 
CD4 Class II recognition Helper/inducer cells 
CD8 Class I recognition Cytotoxic/suppressor T cells 
CD10 Endopeptidase (CALLA) B cell populations 
CD11a LFA-1 antigen Lymphoid and myeloid cells 
CD14 LBP receptor Monocytes/macrophages 
CD16 FcγRIII (Ig receptor) Monocytes, granulocytes, NK cells 
CD19 B-cell antigen B cells 
CD25 IL-2 receptor Activated macrophages/T-/B- cells 
CD33 Pan-myeloid antigen Myeloid and monocytic precursors 
CD38 T10 antigen Precursor cells, activated T-/B-cells 
CD44 Lymphocytes homing receptor Leukocytes and erythrocytes 
CD54 ICAM-1 Monocytes and lymphocytes 
CD56 NCAM NK and T-cell subpopulations 
 
Table 1.11 Markers negatively expressed on fibrocytes. Cell surface phenotype of human 
peripheral blood fibrocytes, negative surface expression seen on fibrocytes87  
 
In 1997 it was reported that fibrocytes were potent antigen presenting cells capable of priming 
naïve T cells91. Using monoclonal antibodies it was determined that fibrocytes expressed the full 
complement of surface proteins that have been shown in other cell types to be necessary for 
antigen presentation, and following in vitro functional experiments concluded that they are 
almost as potent as dendritic cells at presenting antigen to naïve T cells91. This data indicated 
that fibrocytes may play a critical role in the initiation of antigen specific immunity. This coupled 
with the observation that fibrocytes induce an angiogenic phenotype in cultured endothelial 
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cells, promoting angiogenesis in vivo in mice90 could help to account for the persistent 
inflammatory state seen in some disease states.  
 
1.5.2 Fibrocyte differentiation 
In 1991 a group observed that neo-fibroblasts, (their term for peripheral blood derived 
fibroblast-like cells) that developed from monocytes in vitro would only do so after the loss of T 
lymphocytes. They suggested that T lymphocytes, stimulated by the cytokine interleukin-2 (IL 2) 
inhibit the transformation of monocytes into fibroblasts in culture85;86. In 2001 Bucala’s group 
reported a differentiation pathway of fibrocytes and their potential mechanism of migrating to 
wound sites. They determined that a peripheral blood population consisting of predominately 
CD14+ but not CD14- cells gives rise to fibrocytes in vitro. However in contrast to the 
observations of Labat et al ten years previously, Bucala’s group reported that fibrocytes would 
only differentiate in the presence of T cells and that cell-cell contact, not just conditioned 
medium, was necessary for their differentiation45. Yang et al found that direct contact between 
the CD14- and CD14+ fraction was not required for the differentiation of CD14+ cells into 
fibrocytes, however CD14- conditioned medium was46. Therefore there were many 
discrepancies between the different groups in relation to fibrocyte differentiation. 
 
Fibroblast-like cells had been reported to be seen in humans in 1991 by Labat et al85;86 in 
different diseased states. They found monocytes in patients suffering from 
osteomyelosclerosis85, Engelmann’s disease85 and cystic fibrosis86 could spontaneously 
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transform into neo-fibroblastic structures in vitro, that phenotypically looked very similar to the 
fibrocytes reported by Bucala et al87. Both osteomyelosclerosis and Engelmann’s disease are 
characterised by excessive osteoblastic bone formation and they report that long term 
mononucleated blood cell cultures appeared to contain fibroblastoid cells embedded in a matrix 
surrounded by macrophages85. They then studied the spleens of these patients and found that 
after 50 days of culture large adherent macrophages gave rise to fibroblast-like cells that kept 
some macrophage markers for a time, such as LeuM3 and CD68, before losing them85. In the 
same year this group reported that monocytes isolated from blood from patients with cystic 
fibrosis also spontaneously transformed into neo-fibroblasts in vitro. In contrast to the findings 
of Bucala et al 3 years later they reported that “neo-fibroblasts” that developed from 
monocytes did stain positively for non specific esterase activity initially, but that this was no 
longer seen in more differentiated neo-fibroblasts. Immuno-fluorescence staining by this group 
showed that the fibroblast marker 5B5 was not only seen on their neo-fibroblasts that had 
differentiated from monocytes but was also seen on macrophages, indicating the potential of 
these macrophages to synthesize collagen. In the case of both papers they discuss the relevance 
of these cells in these disease states, all of which are characterised by fibrosis, in the bones of 
osteomyelosclerosis and Engelmann’s disease; and in the pancreas, lungs and liver of cystic 
fibrosis patients. This group observed that these cells can develop from ‘normal’ patients 
however note that this was at a much lower rate than from their diseased patients86. This led 
them to suggest the hypothesis that under normal circumstances these cells are mainly resident 
in the bone marrow, but circulate within the blood during pathological situations85.  
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Both Yang and Hartlapp et al observed a positive correlation between the levels of serum 
transforming growth factor-β1 (TGF-β1) and the number of fibrocytes seen in cultures of 
PBMC46;90. However whereas Hartlapp et al was using healthy controls Yang et al observed this 
in peripheral blood from burns patients. Work on the number of fibrocytes seen in burns 
patients concluded that the development of fibrocytes was up-regulated systemically as a 
higher number of cells differentiated from the peripheral blood of burns patients than from 
healthy controls46. As TGF-β1 is known to be important in tissue repair and fibrosis then its 
effects on fibrocytes are not surprising92.  
 
1.5.3 Inhibition of fibrocyte generation 
The mechanisms that inhibit the differentiation of fibrocytes from CD14+ peripheral blood 
monocytes are of extreme importance, as unchecked fibrocyte differentiation could lead to an 
enhanced and sustained fibrosis at sites of inflammation. Pilling et al identified that serum 
amyloid P (SAP), found in serum, inhibits the differentiation of fibrocytes47. SAP is pentraxin 
protein which is produced by the liver and secreted into the blood where it circulates as a stable 
pentamer93;94. SAP appears to have an important role in the resolution phase of inflammation as 
it can cause opsonisation and engulfment of bacteria by binding to the surface sugar residues95. 
It can also bind free DNA and chromatin generated by apoptotic cells, preventing secondary 
immune responses96;97. 
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SAP can bind to all three classical FCγ receptors, FCγRI (CD64), FCγRII (CD32) and FCγRIII (CD16), 
although it has a preference to FCγRI and FCγRII. This means that when SAP coats a bacteria it 
can then react with phagocytic cells, such as macrophages, causing opsonisation98;99. All three 
receptors also bind to the Fc portion of immunoglobulin G (IgG) and are found on the surface of 
a variety of haematopoietic cells. The most high affinity receptor is FCγRI (CD64), it binds 
monomeric IgG and is found on peripheral blood monocytes100. Whereas both FCγRII (CD32) 
and FCγRIII (CD16) are low affinity receptors that will only bind aggregated IgG, FCγRII is 
expressed on monocytes and B cells and FCγRIII on natural killer cells and subpopulations of 
monocytes51;101;102. 
 
The inhibition of fibrocyte differentiation by SAP was found to be due to the interaction of SAP 
with the FCγ receptors, signalling intracellularly through Syk and Sre related tyrosine kinases48. 
Aggregated or cross-linked IgG but not monomeric was also found to be able to inhibit fibrocyte 
differentiation through the same mechanism. Only the Fc portion of IgG could inhibit fibrocyte 
differentiation through the signalling of the FCγ receptors though, the F(ab’)2 fragments were 
found to have no effect48. These results suggest that monocytes can differentiate into fibrocytes 
in situations where SAP and aggregated IgG levels are low. 
 
The potential importance of SAP in fibrocyte differentiation is illustrated in patients with 
scleroderma, a disease consisting of a pathological thickening and hardening of the skin caused 
by swelling and thickening of fibrous tissue. Normally men have much higher levels of SAP in 
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their serum than women and interestingly 80% of scleroderma patients are women. It was 
observed that sera from patients with scleroderma were less able to inhibit fibrocyte 
differentiation than that from healthy controls and that scleroderma patients also had lower 
levels of the SAP protein. Perhaps suggesting that changes in circulating levels of SAP may have 
an important role in fibrosis47. 
 
1.6 Fibrocytes and Fibrotic diseases 
Fibrocytes have been reported to express stromal markers such as fibronectin, collagen I and 
collagen III47;87, as well as extracellular matrix (ECM) components and ECM-modifying 
enzymnes45;47;87;89 therefore it is not surprising that their role in fibrotic diseases is under 
investigation. Fibrosis is the abnormal and excessive production of ECM proteins by fibroblasts 
or fibroblast-like cells, often accompanied by inflammation and so therefore can include an 
excessive of leukocytes, which can lead to the maintenance of high cytokine levels and the 
inhibition of ECM degrading enzymes. Fibrosis is also associated with repeated episodes of 
injury, creating positive-feedback loops, which increase ECM protein deposition and ultimately 
alters the tissue or organ physiologically, often inflicting functional constraints103.  
 
Fibrotic tissue is often described as containing myofibroblasts; these are fibroblasts that have 
differentiated following tissue injury into contractile and secretary myofibroblasts. These 
myofibroblasts are important in wound healing but when contraction and ECM protein 
deposition becomes excessive they can severely damage tissue, such as in fibrotic diseases104. 
Chapter 1: Introduction  Marianne Fairclough 
 33
Stimulation of fibroblasts by transforming growth factor β (TGF-β) is thought to have an 
important role in producing these myofibroblasts105 and α-smooth muscle actin (α-SMA), a 
contractile protein incorporated into stress filaments, is often used as a marker. Once 
developed, myofibroblasts sustain a contractile force over a long period of time, which is 
generated by the tension exerted by stress fibres in the surrounding extracellular matrix106, 
contributing to the damaging effect they have on organs and tissues when there is an excessive 
of them in fibrosis. 
 
1.6.1 Fibrocytes and Th-2 cytokines 
The pro-fibrotic cytokines involved in fibrosis are described as TH-2 cytokines, as they are known 
to be produced by the subset of CD4+ T helper 2 (TH-2) cells. They include the cytokines IL-4 and 
IL-13 which stimulate collagen production and deposition by fibroblasts107, as well as promoting 
the activation and differentiation of fibroblasts into myofibroblasts108. They have also been 
associated with the involvement of the fibrotic inflammatory environment in a number of 
disease states, such as asthma, cardiac fibrosis, hepatic fibrosis, early rheumatoid arthritis, 
scleroderma and various lung fibrosing pathologies107;109-112.  
 
As both fibrocytes and TH-2 cytokines are associated with fibrosis
107;109;111 the relationship 
between them was investigated by Shao et al in 2008 and found that the TH-2 cytokines IL-4 and 
IL-13 interacted directly with monocytes to promote fibrocyte differentiation103. Whereas the 
TH-1 cytokines, known to regulate TH-2 cytokines by exerting reciprocal inhibitory effects, such 
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as IL-12 and interferon-γ (IFN-γ) acted in the opposite direction and prevented differentiation of 
fibrocytes103 (Figure 1.4). The TH-1 and TH-2 cytokines were found to be able to counteract each 
other’s effects, showing no change in the rate of fibrocyte differentiation compared to a media 
control. The addition of SAP however inhibited the effect of the TH-2 cytokines
103 (Figure 1.5). 
 
 
Figure 1.4 Effect of cytokines on fibrocyte differentiation. Part of figure 1 from32. PBMCs at 
2.5x105 cells per ml were cultured in serum-free fibrocyte media for 5 days with the indicated 
concentrations of cytokines. Cells were then air-dried, fixed and stained and fibrocytes 
enumerated by morphology. As the number of fibrocytes differentiating from PBMCs varies 
between individuals, the effect of IL-4, IL-12, IL-13 and IFN-γ on the differentiation of fibrocytes 
from different donors was analysed. For each donor, counts were normalized to the no-cytokine 
control to obtain a percent of control. Results are expressed as the mean ±SEM of percent of 
control (n=6 donors). Statistical significance in comparison with the no-cytokine control was 
determined by ANOVA; *, P < 0.0532. 
 
Chapter 1: Introduction  Marianne Fairclough 
 35
 
Figure 1.5 SAP inhibits IL-4 or IL-13 induced fibrocyte differentiation. Part of figure 8 from32. 
PBMCs were cultured in serum-free fibrocyte media for 5 days with increasing concentrations of 
SAP in the presence or absence of 3ng/ml IL-4 or IL-13. Compared with PBMCs cultured with 
increasing concentrations of SAP alone, at SAP concentrations of 1µg/ml, IL-4 or IL-13 had no 
effect on the number of fibrocytes. Results are expressed as the mean ±SEM of the number of 
fibrocytes per 2.5x105 cells (n=6 separate donors)32. 
 
This group went on to suggest that in many chronic inflammatory conditions the presence of 
both the TH-2 cytokines, IL-4 and IL-13 and the TH-1 cytokines, IL-12 and IFN-γ may promote 
fibrocyte differentiation, depending on the ratio between them possibly leading to fibrosis. 
However the presence of SAP in an inflammatory site may prevent this, although currently little 
is known about the activity or quantity of SAP in an inflammatory site it is promising as a 
potential therapy for fibrosis103.  
 
1.6. 2 Treating animal models of fibrosis with SAP  
As the plasma protein SAP has been suggested to have potential as a therapy for fibrosis animal 
models of fibrotic disease have been treated with it111-113. In a mouse model of ischemic 
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cardiomyopathy the presence of fibroblasts and fibrosis was reported to be markedly reduced 
following treatment with SAP111. What they termed ‘blood-borne fibroblast precursors’, 
expressing both collagen I and CD45, were found to be recruited to the heart, by CCL2, when a 
myocardial infarction was induced. This murine model of closed-chest myocardial infarction and 
reperfusion allowed for the examination of chemokine induction after the dissipation of surgical 
trauma114. When SAP was administered to mice at the time of myocardial infarction induction 
these ‘blood-borne fibroblast precursors’ were not recruited and fibrosis was markedly reduced, 
although CCL2 was still released and inflammation still occurred111. Further work found that the 
mechanism that SAP uses to reduce this fibrosis is again due to its interaction with FCγ 
receptors113.  
 
As well as in vivo mouse work this group also looked at the migratory capacity of fibrocytes in 
the presence of SAP. Previously they have shown that monocytes are attracted to the site of 
injury by MCP-1 (CCL2). They set up an in-vitro trans-endothelial migration study using 
transwells with a layer of human umbilical vein endothelial cells (HUVECs) on the filter. PBMC 
were plated out for 3-4 days before being allowed to migrate through the HUVECs in response 
MCP-1, following this fibrocytes differentiated in the bottom chamber within a few days. 
Interestingly if SAP was added to the top of the transwell at the beginning monocytes migrated 
but fibrocyte differentiation did not occur in the bottom, however if SAP was put in the bottom 
of the transwell fibrocyte differentiation was seen following monocyte migration113. This 
implied that although preventing fibrocyte differentiation SAP does not prevent migration of the 
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monocytes. However, either something to do with the act of migration, or even developmental 
status of cells meant that the addition of SAP later, i.e. in the bottom of the transwell does not 
have the same effect113. These observations provide further evidence of the importance of 
fibrocytes in fibrosis and this paper goes on to suggest that monocytes are required to migrate 
through endothelial cells to be able to mature into fibrocytes rapidly113.  
 
Fibrocytes have also been reported to be the precursors for bronchial myofibroblasts in 
asthma115. Fibroblast-like cells, having a similar surface antigen expression profile as reported by 
Bucala et al in fibrocytes, were detected in the bronchial mucosa of patients with allergic 
asthma. Their numbers were seen to increase during an asthmatic reaction induced by allergen 
exposure, however there was no direct evidence that these cells seen in the bronchial mucosa 
were recruited from the peripheral blood115. In 2004 however, Phillips et al published that a 
population of CD45+ collagen I+ fibrocytes migrate in response to CXCL12 and traffic to the lungs 
in a murine model of bleomycin-induced pulmonary fibrosis116. They also saw that the 
increasing level of collagen deposition in the lungs correlated with the recruitment of these cells 
and therefore hypothesised that circulating fibrocytes contribute to the pathogenesis of 
pulmonary fibrosis116.  
 
Bleomycin was actually developed as a chemotherapeutic drug for testicular cancer, however a 
side effect of it in ~10% of patients is lung fibrosis117. The treatment of bleomycin in rodents has 
become the most widely used model of lung fibrosis118. It causes an accumulation of leukocytes, 
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especially macrophages, producing inflammation, and activates fibroblasts and fibroblast-like 
cells to produce collagen, events similar to those seen in human lung fibrosis118-120. 
 
In 2007 Pilling et al reported that bleomycin treated rats and mice treated with SAP had a 
decreased level of lung fibrosis compared to the untreated112. In rats the inflammation was 
reduced with less leukocytes, fibrocytes and activated fibrocytes and peripheral blood oxygen 
content was maintained112. The ability of SAP to reduce bleomycin-induced pulmonary fibrosis 
suggests that fibrosis is maintained by fibrocytes, as their differentiation has been shown to be 
inhibited by the presence of SAP47. However it may also be acting by reducing the numbers of 
mature fibrocytes as well as their precursors. The noted reduction in leukocyte recruitment 
following SAP treatment may also be linked to an inhibition of fibrocytes as they are known to 
release cytokines that promote leukocyte migration89, less fibrocytes, means less recruitment. 
Of course the effect of SAP could be completely unrelated to fibrocytes, SAP binds apoptotic 
material, the presence of it may have caused a rapid removal of the apoptotic material by the 
resident macrophages, so reducing leukocyte recruitment and reducing fibrosis112;121. As the 
literature does suggest the role of fibrocytes in pulmonary fibrosis115;116;122, and SAP is known to 
inhibit fibrocytes differentiation both in vitro47 and in vivo111 it has reasonable to assume that 
SAP is reducing fibrosis by acting on fibrocytes in this model rather than the rapid removal of 
apoptotic material, although this may also be taking place at the same time. 
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1.6.3 Mechanisms by which fibrocytes populate peripheral organs 
Since 2004 when Philips et al published that fibrocytes migrated through the peripheral blood in 
response to CXCL12116 a number of groups have shown, in mouse models, that this is not the 
primary mechanism that fibrocytes populate the peripheral organs49;111;123. The in vivo 
differentiation of fibrocytes, from circulating precursors, occurs mainly at the tissue sites and 
not in the peripheral blood. As discussed already Haudek et al saw a reduction in fibrocyte 
number and reduced fibrosis in a mouse model of ischemic cardiomyopathy when SAP was 
given as a treatment and suggested that SAP was interfering with the development of fibrocytes 
from the monocyte precursors taken up during the inflammatory response111, (as is seen in 
vitro
47), rather than affecting fibrocyte recruitment to the site.  
 
Frid et al used neonatal animal models of hypoxia induced pulmonary vascular remodelling to 
look at the role of fibrocytes in chronic pulmonary hypertension123. Circulating monocytes of 
chronically hypoxic rats were selectively labelled in vivo and were later identified in the 
remodelled layer of the pulmonary arteries expressing the marker CD45 and producing collagen, 
suggesting these cells differentiated in the layer from the monocyte precursors taken up from 
the circulation123, rather than themselves being recruited from the circulation. 
 
Thirdly Varoce et al looked at which circulating cells were involved in the vascular remodelling in 
an ovine model of carotid artery intimal hyperplasia, induced by vascular graft implantation. 
Circulating leukocytes were labelled and a subpopulation of them infiltrated the intima in vivo 
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to then go on to take on a fibrocyte phenotype, of CD45+ and Vimentin+49. Again suggesting 
fibrocyte differentiation was at the site of injury rather than these cells being recruited. 
 
In a pulmonary model of fibrosis, induced by intratracheal instillation of fluorescein 
isothiocyanate (FITC), minced lung explants and bronchoalveolar lavage (BAL) cultures saw the 
emergence of fibrocytes after 10 to 14 days in a serum-free culture medium124, however 
whether these are due to differentiation or were already present is unknown. However these 
fibrocytes were lost when the same experiment was performed on CCR2-/- mice. CCR2-/- have 
previously been shown to be protected from fibrosis induced by FITC injury, despite 
inflammatory cells still being recruited125. Bone marrow from CCR2+/+ mice transplanted into 
lethally irradiated CCR2-/- mice restored the level of fibrocytes seen within the lung explants and 
BAL cultures. These results suggest a pivotal role of CCR2 in accumulation of fibrocytes in sites 
of fibrosis124. The observations can be transferred to humans as well as the recruitment of 
monocytes is also dependent on the chemokine CCR240. 
 
Continuing work by Moore et al has reported that one of CCR2s ligands, CCL12, has an 
important role in fibrosis in regards to fibrocytes126. Neutralising CCL12 by antibody treatment 
protected mice from FITC induced pulmonary fibrosis, whereas neutralising the other CCR2 
ligands such as CCL2 and CCL7 was less effective. They suggest therefore that CCL12 is the ligand 
involved in fibrocyte accumulation at sites of fibrosis126. Interestingly the human homolog for 
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murine CCL12 is actually human CCL2, which has been shown to be important in human 
systemic sclerosis127, cystic fibrosis128 and cardiac fibrosis129. 
 
In a mouse model of renal fibrosis, where unilateral ureteral obstruction was performed, a 
considerable number of fibrocytes expressing both CD45 and collagen I were seen in the 
interstitium, these fibrocytes were also positive for CCR7130. The blockade of CCR7’s ligand 
CCL21 by anti-CCL21 antibodies reduced renal fibrosis, which was confirmed in CCR7-/- mice130.  
 
Although evidence now suggests that fibrocytes differentiate at the site of inflammation49;111;123 
in the tissue, rather than be traffic there from the circulatory system, Phillips et al’s observation 
of the importance of the interaction of the chemokine CXCL12 and its receptor CXCR4 in the role 
of fibrocytes in bleomycin induced model of lung fibrosis is extremely important. One of the 
subpopulations of monocytes thought to be able to differentiate into fibrocytes, identified by 
CD14+ CD16-, expresses both CXCR4 and CCR750, both of which have both been implicated in the 
accumulation of fibrocytes in mouse models of fibrotic diseases116;130 and so may be involved in 
their recruitment into sites which then go on to include fibrocytes. .  
 
1.6.4 Fibrocytes and Human fibrosis 
In the last decade the role of fibrocytes in fibrosis has been heavily reported on. Fibrocytes have 
been discussed as being involved in the pathogenesis of human lung fibrosis115;116;124;126;131;132, 
as well as renal fibrosis130;133 and liver fibrosis134;135. They have also been suggested as having a 
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role in the fibrosis seen in systemic sclerosis136 and in the fibrocellular membranes seen in 
proliferative vitreoretinopathy in the eyes137.   
 
In 2007 Mehrad et al reported on fibrocytes in human fibrotic interstitial lung disease131. The 
role of CXCL12 expression on fibrocytes associated with mouse lung fibrosis was suggested by 
Phillips et al116 in 2004 and Mehrad took this further by looking at the level of the CXCL12 
chemokine in lung tissue from patients suffering from fibrotic usual interstitial pneumonia (UIP) 
or non-specific interstitial pneumonia (NSIP). They found that it significantly higher in UIP and 
NSIP patients than healthy controls. They described circulating fibrocytes as Collagen I+, CD45+ 
cells in peripheral blood and found that UIP and NSIP had significantly more of these than 
healthy controls as well as significantly more circulatory CXCL12131. They concluded from this 
the importance of fibrocytes in human lung fibrosis and suggested the possibility that the 
mechanism surrounding this chemokine and fibrocytes could be used in some way as a 
therapeutic target for treatment of these diseases.  
 
There is a growing literature linking fibrocytes, or haematopoietic derived fibroblast-like cells, to 
fibrosis, and what was once a field dominated by the mesenchymal derived fibroblasts is 
accepting that the role of inflammatory cells and fibrocytes may be much more important than 
first thought. In fact a systemic fibrotic disease characterised by the thickening or hardening of 
the skin of the extremities in people with significant renal insufficiency is thought to be 
mediated by fibrocytes138. Nephrogenic systemic fibrosis or NFS was first reported in 1997, 
Chapter 1: Introduction  Marianne Fairclough 
 43
although is only ever seen in patients who suffer from renal dysfunction139, it is not related to 
the severity of the renal dysfunction, whether the patient has received a transplant or been on 
dialysis; and neither the cause or duration of the underlying renal disease is directly related to 
the severity of NFS138. They define the fibrocytes in this work by a spindle shaped morphology 
and the co-expression of CD34 and procollagen I. Skin biopsies from patients suffering from NFS 
contained cells of this description140 which have not previously been described in the skin141. 
Other factors suggest a systemic factor being the cause, such as the symmetry of the lesions, 
the rapid development of the lesions, indicating recruitment from the circulatory system rather 
than mitosis; the presence of the fibrosis in otherwise unaffected organs and an active case of 
NSF resembles a wound healing site, with resolved cases of NSF being indistinguishable from a 
healed wound138;140. The cause of NSF is still unclear and further investigation into what links 
renal dysfunction to the onset of this disease is required, however the fact that it appears to be 
a systemic disease due to the role of fibrocyte; and the subsequent treatments found to help 
have implications in the treatment of all fibrotic diseases138.  
 
1.7 Fibrocytes and wound healing 
Wounds result from an abrupt, physical disruption of the normal architecture of tissue; they can 
be due to trauma, burns or inflammatory processes and require immediate attention by the 
body’s immune system to prevent infection and tissue invasion; and to restore normal tissue 
integrity. Inflammatory cells and stromal cells such as myofibroblasts and fibrocytes are needed 
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to ensure correct wound healing; it is when this act of wound healing becomes excessive that 
fibrosis occurs.  
 
When fibrocytes were termed by Bucala et al in 1994 it was whilst looking at a wound healing 
model in mice, as they wanted to study the acute cellular responses of wound repair87. The 
mouse model they used involved wound chambers, short lengths of sponge filled, silastic 
tubing, implanted surgically in the subcutaneous tissues of a mouse’s back. Following 
implantation wound fluid was aspirated periodically and a massive influx of inflammatory cells 
was seen within 24hrs, consisting of neutrophils, monocytes and lymphocyte populations. When 
these chambers were eventually removed, and looked at under light microscopy they observed 
a large number of adherent, spindle shaped cells that were fibroblast-like. Although it was 
possible that it could be infiltrating fibroblasts from the surrounding area they considered it too 
much of a coincidence that a large number of peripheral blood cells had entered the wound 
chamber immediately before the emergence of these cells spindle shaped cells87. They went on 
to do in-vitro analysis of cultured peripheral blood cells identified CD45+ collagen I+ cells that 
they termed fibrocytes.  
 
More recently the role fibrocytes in wound healing has been researched in other mouse models 
and has provided evidence that fibrocytes contribute to the myofibroblast population seen in 
wounded skin; and that they originate from the bone marrow142;143. Myofibroblasts are vital in 
the healing process and secrete extra cellular matrix proteins involved in tissue repair as well as 
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α-SMA, a contractile protein. In 2005 Mori et al identified a substantial number of the α-SMA 
positive cells, in the skin of wounded mice, that also expressed the surface markers CD13 and 
CD45, suggesting they had differentiated from a haematopoietic origin and not from 
mesenchymal-derived tissue fibroblasts142. This group also isolated cells of a fibrocyte 
phenotype at different time points from the wounded tissue and found that these cells became 
α-SMA between 4 and 7 days post-wounding, indicating fibrocytes were differentiating into 
myofibroblasts at the tissue site. When looking at this differentiation in vitro this group 
observed that myofibroblast differentiation from fibrocytes was accelerated by the addition of 
TGF-β1
142, which is known to be involved in the differentiation of fibroblasts into 
myofibroblasts105. 
 
Due to the observed role of fibrocytes in sites of wound healing45;46;87;89;124;144 conditions of poor 
wound healing have been investigated to determine whether an inability to support fibrocyte 
differentiation or the inhibition of fibrocyte differentiation was responsible. Diabetic patients 
have poor wound healing abilities therefore PBMC were cultured with increasing amounts of 
glucose and 10µg/ml of insulin or increasing amounts of insulin, in a serum-free environment. In 
the absence of either glucose or insulin it was observed that all the cells died, and no fibrocytes 
were seen. At low levels of glucose (0.004-0.025g/L) fibrocyte differentiation was poor but 
occurred, at intermediate levels (0.1-2g/L) the same level of fibrocyte differentiation was seen 
as previously observed47; and with high levels of glucose (greater than 8g/L) an increased 
number of fibrocytes were seen. The effect of glucose on fibrocytes was further increased with 
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the addition of pyruvate and increasing levels of insulin138. Therefore whether the body can 
produce fibrocytes and to what extent could be highly important in their wound healing 
capacity.  
 
1.7.1 Fibrocytes and burn injury 
When an individual suffers from extensive burns hypertrophic scars and keloids represent two 
different forms of aberrant wound healing that are often seen145. Collagen fibrils arranged in a 
nodular structure are seen in hypertrophic scars, and keloids contain thick collagen fibres, made 
up of numerous fibrils packed together145. An inflammatory infiltrate is seen in both forms of 
scarring, however is more pronounced in the hypertrophic form and is composed of T cells, 
monocytes and dendritic-like cells. The nodules of the hypertrophic scars also have enhanced 
expression of TGF-β1 as well as α-SMA positive myofibroblasts
145. 
 
In 2002 Yang et al reported that burns patients were more efficient at producing fibrocytes than 
healthy controls46, they also found a positive correlation between levels of serum TGF-β1 and 
the percentage fibrocytes developed in those patients46. This group later went on to identify 
spindle shaped cells co-expressing leukocyte specific protein-1 (LSP-1; known to be on 
fibrocytes144) and pro-collagen I in post burn hypertrophic scars suggesting that fibrocytes are 
involved post-burn hypertrophic scars.  
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In 2006 Wang et al looked at the effect fibrocytes have on fibroblasts in burns patients146. They 
reported that conditioned medium from fibrocytes could up-regulate the production of collagen 
from fibroblasts, induce proliferation and cause differentiation from dermal fibroblasts to 
myofibroblasts. They also report that the degree in which the fibrocyte can do this is directly 
correlated to the size of the patient’s burn. However they do not see this ability in fibrocytes 
from healthy controls146.  
 
1.8 Fibrocytes as mesenchymal stromal cells 
There is some literature which refers to cells with fibroblast-like morphology that have been 
derived from CD14+ monocytes and have the capacity to differentiate into several mesenchymal 
type cell lineages. Kuwama et al reported these cells in 2003 and referred to them as ‘monocyte 
derived mesenchymal progenitors’ (MOMPs)147. They cultured CD14+ cells from peripheral 
blood for 7-10 days then collected these cells for use in various assays where they reportedly 
differentiated osteoblasts, skeletal myoblasts, chrondrocytes and adipocytes by varying the type 
of growth medium147. They verified these cell types by genes and protein expressions147. In the 
same year Zhao et al reported a subset of cells that act as a pluripotent stem cells derived from 
peripheral blood monocytes148. Phenotypically these cells represented fibroblasts but express 
the haematopoietic markers CD14, CD34 and CD45. By the addition of various cytokines and 
growth factors they induced various cells types to differentiate from these cells in vitro, T 
lymphocytes, epithelial, neuronal, endothelial and hepatocytes. They verified these cell types by 
immunostaining and, in the case of the T lymphocytes, a cytotoxicity assay148.  
Chapter 1: Introduction  Marianne Fairclough 
 48
 
Although the ‘stem’ cells described above appear to have the same expression profile and 
morphological characteristics as fibrocytes the literature as a whole does not agree that tissue-
resident mesenchymal stem cell/multipotent mesenchymal stromal cells and fibrocytes are the 
same cell149;150. Although there is a lot of confusion in the literature over the nature of these 
tissue-resident mesenchymal stem cell/multipotent mesenchymal stromal cells, as the 
terminology to describe them has not been standardised, it is agreed they are not the same as 
fibrocytes. Two of the defining surface markers of fibrocytes are the expression of CD34 and 
CD4547;87, as these markers depict a haematopoietic origin and separates them from fibroblasts. 
One of the criteria’s for these tissue-resident mesenchymal stem cell/multipotent mesenchymal 
stromal cells which is agreed on is that they do not express CD34 or CD45145;149;150. In culture 
they also have different morphological characteristics, although both spindle shaped and 
fibroblast-like fibrocytes are described as having a slightly plump body, with two elongated thin 
ends, whereas the tissue-resident mesenchymal stem cell/multipotent mesenchymal stromal 
cells are described as much more stretched out in shape, pale in colour and do not have sharp 
ends.  
 
1.9 Overview of fibroblasts 
Fibroblasts are a type of stromal cell that are found ubiquitously throughout the body, providing 
mechanical strength to tissues by supporting the extra cellular matrix151. They are identified by 
their morphology, ability to adhere to plastic, production of extra cellular matrix and lack of 
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epithelial, vascular and leukocyte lineage markers152. Although initially thought to have a mainly 
structural role throughout the body, in the synthesis and remodelling of extra cellular matrix, 
they have more recently been reported as being involved in maintaining the homeostasis of 
adjacent cell types, such as epithelial and endothelial cells, by both producing and responding to 
growth factors153. Fibroblasts have also found to produce cytokines and chemokines, playing a 
key role in the development of an immune response152; as well as being implicated in the 
development and duration of an inflammatory response, and the resolution154;155. Fibroblasts 
were thought to be the same cell throughout the body, however they have been found to be 
phenotypically different from one tissue type to another, and it has been suggested that they 
are not a homogeneous population even within single tissues, but exist as subsets of cells, in a 
similar way that macrophages and dendritic cells do156. In 2002 Chang et al reported that when 
analysing the transcriptome of human fibroblasts from different anatomical locations within the 
body samples from the same anatomical location clustered more closely together, in 
hierarchical clustering analysis, than samples from the same individual, suggesting that 
fibroblasts from different locations in the body should be considered distinct differentiated cell 
types157.  
 
Fibroblasts are believed to originate from three distinct origins, primary mesenchyme, local 
epithelial-mesenchymal transition (EMT) and bone marrow derived precursors84. Whilst 
mesenchymal cells are believed to be the major contributor of tissue fibroblasts the EMT 
hypothesis is described as a way that mesenchymal derived epithelial cells are reshaped into 
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fibroblasts following epithelial stress, such as inflammation or tissue injury152. It has also been 
suggested that bone marrow derived circulating precursors can develop into fibroblasts, namely 
the fibrocyte84;111;116;158;159, however whether fibrocytes become fibroblasts, or are just similar 
morphologically is still an issue for debate. 
 
1.10 Transcriptome analysis 
With the exception of certain cells of haematopoietic origin, every cell in the body has exactly the same 
DNA within its nucleus. The factors that make cells develop down different differentiation paths is the 
way that this DNA is transcribed and translated into proteins; so a cell can be described as the sum of all 
the genes it expresses, which is collectively termed the transcriptome. Which mRNA species are 
transcribed from the DNA is modulated by DNA-binding regulatory proteins, for example the mRNA 
transcribed to cause a neuronal cell to develop will be very different to that transcribed in the 
development of, for example, a hepatocyte. 
 
Transcriptome analysis or gene expression profiling has been applied to various malignant and 
immune disorders such as leukaemia, lymphoma, systemic lupus erythematosus and 
rheumatoid arthritis, as well as many others160-164. This approach has helped to identify 
important diagnostic and prognostic markers as well as potential therapeutic targets. Gene 
expression profiling has also been used to look at the relationships between subsets of 
peripheral blood cells to establish, or confirm potential lineages165-169. Work reported in 2005 by 
two separate groups looked at different subsets of T lymphocytes, naïve, central and effector 
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memory; and both came to very similar conclusions of their lineage relationships by using 
cluster analysis165;166.  
 
1.11 Justification of this project 
Much of the early literature on fibrocytes refers to these cells as circulating cells of the 
peripheral blood45;46;87-91;115;116;142;170, however in the methods section of these reports they 
culture PBMC in medium, wash off the non-adherent cells after 1 or 2 days then wait for 7-10 
days to see fibrocytes. As fibrocytes have been reported to differentiate from CD14+ cells45;47-
49;85;86 it is more logical that, like some subtypes of macrophages for example, these cells 
differentiate from monocytes at the sites they are needed. This has been supported by work in 
mouse models of fibrosis49;111;123, which were discussed earlier.  
 
There is also a large discrepancy running through all the fibrocyte literature, in some reports in-
vitro derived fibrocytes are generated in a serum-free media and in others a serum-containing 
media. Although marker expression between the cells generated in the two media types are the 
same47;87;145 there are some differences seen. Serum-free derived fibrocytes express high levels 
of prolyl 4-hydroxylase, the enzyme required for the synthesis of new collagen48, whereas those 
generated in serum-containing media are reported as having low levels of prolyl 4-hydroxylase 
activity in comparison to mature fibroblasts146. Also SAP, a plasma protein found in serum, 
inhibits fibrocyte differentiation in serum-free media in vitro47 and in vivo111. SAP is present in 
the serum of the serum-containing fibrocyte media, although fibrocytes in this media take 
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longer to differentiate than serum-free fibrocytes they do differentiate, therefore the SAP is 
having no or very little effect on their differentiation. Therefore the question arises, are these 
fibrocytes seen to differentiate in serum-free and serum-containing media the same cell? Or are 
they two different, although clearly related cell types, despite having the same surface marker 
express profile and morphology. 
 
A large portion of the literature describes fibrocytes as differentiating from monocytes. 
Monocytes found in peripheral blood are actually made up of 3 subpopulations, identified in 
humans by their expression of the surface markers CD14 and CD16. The subpopulation 
CD14+CD16- constitutes approximately 80-90% of monocytes with the remaining 10-20% made 
up of CD14+CD16+ and CD14loCD16+ populations. Another monocyte derived cell type, 
osteoclasts, has been reported to only differentiate from the CD16- fraction of monocytes44 
(CD14+CD16-) and these observations lead us to suggest that the differences seen between the 
two types of fibrocytes in the literature may be due to them differentiating from different 
subpopulations of monocytes, therefore the differential potential of different subsets of 
monocytes into fibrocytes could be very interesting. 
 
To define the connection between these two types of fibrocytes seen in the literature 
understanding what defines a fibrocyte is vital. As the identity of a cell can be defined as the 
sum of the genes it expresses then comparing the transcriptome of these cells to each other by 
transcriptome analysis may provide the clearest answer to this question. Transcriptome analysis 
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also allows fibrocytes to be compared to other monocyte-derived progeny, such as 
macrophages, and mesenchymal derived fibroblasts, allowing for speculation on the lineage 
relationships between both the types of fibrocytes, and these other cell types.  
 
As both serum-free and serum-containing derived fibrocytes are morphologically and 
phenotypically very similar, if not almost identical, then if they are different cell types based on 
functional characteristics and transcriptome analysis their roles within the body will still be 
highly related. Due to the surface marker expression of these cells their roles in wound healing 
will both be important, however as they prefer different environments they could potentially be 
involved at different time points of the healing process. We could hypothesis that the serum-
containing derived fibrocytes are involved at the beginning of inflammatory response, helping 
to initiate the wound healing response and the serum-free fibrocytes near the end when the 
environment becomes more suitable for them.  
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1.12 Aims of this project 
• To determine the ideal procedure for quantifying fibrocyte differentiation.  
•  To optimise culture conditions for differentiating fibrocytes in both serum-free and 
serum-containing fibrocyte medium, and determine whether that the cells used in this 
thesis have the same marker expression as those described in the literature.  
 
• To determine which monocyte subpopulation/s fibrocytes differentiate from and 
whether serum-free and serum-containing fibrocytes differentiate from different 
subpopulations. 
 
• To compare serum-free and serum-containing generated fibrocytes by both in vitro and 
transcriptional protocols to determine if they are the same cell generated by two 
different methods or two different, although related, cell types that potentially could be 
involved in different time points of a wound healing response.  
 
• To compare serum-free and serum-containing fibrocytes with in vitro derived donor 
matched macrophages and fibroblast cell lines to determine potential lineage 
relationships. 
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2.0 METHODS AND MATERIALS 
2.1 Abbreviations 
avi  Audio video interleave 
BLAST  Basic Local Alignment Search Tool 
BSA  Bovine serum albumin 
cDNA   Complementary de-oxy ribonucleic acid 
CO2  Carbon dioxide 
DC  Dendritic cell 
DiOC6  Dihexaoxacarbocyanine iodide 
DMEM  Dulbecco’s modified essential medium 
DNA  De-oxy ribonucleic acid 
dATP  Deoxyadenosine triphosphate 
dCTP  Deoxycytidine triphosphate 
dGTP  Deoxyguanosine triphosphate 
dNTP  Deoxynucleotide triphosphate 
dTTP  Deoxythymidine triphosphate 
DTT  Dithio threitol 
EDTA  Ethylenediaminetetraacetic acid 
FACS  Fluorescence-activated cell sorter 
FCS  Foetal calf serum 
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GAL  Generic array logic 
GEPAS  Gene expression pattern analysis suite 
GPS  L-glutamine, benzylpenicillin, streptomycin 
HI-FCS  heat-inactivated foetal calf serum 
IL  Interleukin 
IMDM  Iscove’s modified Dulbecco’s Medium 
ITS+3  insulin, transferrin and selenite 
MACS  Magnet assisted cell selection 
NEAA  Non-essential amino acids 
P.A.L.M. Photoactivated localization microscope 
PAM  Prediction analysis of microarrays 
PBMC  Peripheral blood mononuclear cells 
PBS  Phosphate buffered saline 
PCA  Principal component analysis  
PCR  Polymerase chain reaction 
RNA  Ribonucleic acid 
rpm  Revolutions per minute 
RPMI 1640 Rosswell Park Memorial Institute medium 1640 
SAM  statistical analysis of microarrays 
SAP  Serum amyloid P 
SOP   Sodium Pyruvate 
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WinMDI Windows Multiple Document Interface Flow Cytometry Application program 
w/v  Weight/volume 
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2.2 Cell preparation 
Fibrocyte cell culture was carried out using one of two medium recipes. Serum-free fibrocyte 
medium consisted of Rosswell Park Memorial Institute medium 1640 (RPMI 1640; Sigma), 
supplemented with 1% GPS (1.64mM L-glutamine, 40U/ml benzylpenicillin, 0.4mg/ml 
streptomycin; Sigma), 1% HEPES buffer (Sigma), 1% ITS+3 liquid media supplement (containing 
insulin, transferrin, sodium selenite, linoleic acid, oleic acid and bovine serum albumin; Sigma) 
1% non-essential amino acids (NEAA; Sigma) and 1% sodium pyruvate (SOP; Sigma)47. The 
serum-containing fibrocyte medium consisted of Dulbecco’s modified eagle medium (DMEM; 
Sigma) supplemented with 1% GPS and 20% foetal calf serum (FCS; Biosera)87. Macrophage 
medium consisted of Iscove’s modified Dulbecco’s medium (IMDM; Sigma) 1% GPS, 10% human 
serum (Biosera) and 50ng/ml macrophage-colony stimulating factor (M-CSF; Peprotech). Non-
sterile solutions were filtered through 0.22µm filters and the majority of tissue culture plastics, 
tubes and filters were purchased from Sarstedt Ltd. 24-well plates used were purchased from 
BD biosciences, as were the glass chamber slides.  
 
2.3 Differentiating fibrocytes 
To differentiate fibrocytes from PBMC or CD14+ selected cells they were resuspended at the 
required density in either serum-free or serum-containing fibrocyte medium and plated out into 
either 8-well glass chamber slides (500µl), 24-well (2mls) or 96-well (200µl) plastic plates. 
Differentiation took approximately 3-7 days in the serum-free fibrocyte medium or 10-14 days 
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in the serum-containing fibrocyte medium. At day 4 the non-adherent cells were washed out of 
PBMC cultures and the medium replaced.  
 
2.4 Differentiating Macrophages 
To differentiate macrophages from PBMC they were resuspended at 1x106cell/ml, the required 
density in macrophage medium, and plated out into either 8 well glass chamber slides (500µl), 
24 well (2mls) or 96 well (200µl) plastic plates and macrophages left to differentiate. At day 4 
the non-adherent cells were washed out and the media replaced. Differentiation took 
approximately 7 days. 
 
2.5 Viable cell counts using a haemocytometer 
Cell suspensions were diluted 1:1 with 0.4% trypan blue (Sigma) and incubated for 1 minute at room 
temperature. 8µl was then inserted beneath a coverslip on an improved Neubauer counting chamber 
(haemocytometer) (Weber Scientific, UK Materials), the number of cells were counted within a 5x5 
square of the counting chamber and multiplied by two for the trypan blue dilution, then by 104 to provide 
an estimate of cells per ml. Multiple squares were counted to provide an average count. Dead cells were 
stained blue by the trypan blue and therefore excluded from the count. 
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2.6 Cell counts using an eye piece micrometer 
An eye piece micrometer (Olympus) consisting of a grid, 10mm by 10mm, with 1mm 
graduations, was used to count fibrocytes and macrophages on the microscope (Olympus CX2). 
When counting cell cultures at least three separate fields of view were counted. To calibrate the 
eyepiece micrometer a stage micrometer was purchased, 1mm long with 0.01mm divisions 
(Pyser-SGI Limited). Once the eye piece micrometer had been calibrated the total number of 
cells in each population could be estimated from the total number of cells counted. For each 
objective on the microscope the multiplication factor required to estimate the total number of 
fibrocytes present was calculated.  
 
At 10x magnification the area of 100 squares of the micrometer was 1.1025mm2, the area of a 
glass well was 70mm2 therefore 70/1.1.025 = 63.492, the factor by which the average cell 
number from the 3 fields of view was multiplied by to estimate the total cell number. For 20x 
magnification the area of 100 squares of the micrometer was 0.2756mm2, the area of a glass 
well was 70mm2 therefore 70/0.2756 = 253.97.  
 
All graphs to do with fibrocyte counting data throughout the thesis were made using GraphPad 
Prism version 3.00 software. When statistical analysis was performed on fibrocyte counting data 
the analysis package GraphPad Prism, version 3.00, was also used. 
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2.7 Separation of peripheral blood mononuclear cells 
Peripheral blood was donated by healthy controls, following informed consent, heparinised and 
diluted 1:1 with RPMI 1% GPS, 1% HEPES. Peripheral blood mononuclear cells (PBMC) were then 
separated from the blood using ficoll density centrifugation (Ficoll-PaqueTM Plus, Amersham 
Biosciences). 15ml of diluted peripheral blood was layered over 8mls of ficoll and centrifuged at 
225g for 30 minutes at 20oC. The PBMC were then removed using a Pasteur pipette and washed 
five times in RPMI 1% GPS, 1% HEPES, centrifuging at 300g for 8mins. The heparin used during 
sample collection was preservative free and obtained from CD Pharmaceutical Ltd. All cell 
culture was performed in category 2 tissue culture flow cabinets. 
 
2.8 CD14+ selection using Magnetic beads 
PBMC were isolated as specified above and suspended at 80μl per 107cells in MACS buffer 
(phosphate buffered saline (PBS) supplemented with 0.5% bovine serum albumin (BSA; Sigma)) 
and 2mM EDTA, (pH 7.2, Sigma). 20μl of CD14+ MACS beads (Milteny Biotec) per 107 PBMC were 
added and left at 4oC for 15 minutes. Unattached beads were washed away by the addition of 
10mls of MACS buffer and centrifugation at 300g for 8 minutes, twice. After choosing the 
relevant separation column, dependent on cell number, this was primed with MACS buffer on a 
magnet before the cell suspension added to the top in a volume dependent on the size of the 
column. The column was then washed three times with MACS buffer and the CD14- cells 
collected.  The column was removed from the magnet and washed again with MACS buffer to 
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collect the CD14+ fraction of cells. The CD14+ cells were counted using a haemocytometer and 
spun down to be resuspended in the required medium. A sample of cells was removed to be 
stained with antibodies and so that the purity of the CD14+ selection could be checked using 
flow cytometry. 
 
2.9 Flow cytometry to check CD14+ purity 
Analysis of the purity of CD14+ cell selection of PBMC was carried out on a Beckman Coulter 
Epics XL bench-top flow cytometer (Beckman Coulter). The cytometer calibration was 
standardised using Flow-set fluorospheres (Beckman Coulter) and data was analysed using the 
Windows Multiple Document Interface Flow Cytometry Application program (WinMDI Version 
2.8). For analysis, a live gate was set around viable cells based on their forward scatter versus 
side scatter profile. 
 
2.10 Cell Surface epitope staining for flow cytometry 
To check the purity of the CD14+ microbead selection staining was performed on 1x105 cells, or 
as many as could be spared from the CD14+ and CD14- cell fractions. Each sample was put in a 
96-well flexi plate and spun at 4oC for 5min at 300g before being resuspended in 50μl of an 
antibody mix made up using PBS 2% BSA. Protein level matched irrelevant isotype control 
samples were also prepared. Samples were left for 20 minutes at 4oC before 200μl of PBS 2% 
BSA was added and the plate centrifuged at 300g for 5min at 4oC and resuspended in 100μl PBS 
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2% BSA. Antibody stained samples were stored at 4oC until analysis on the flow cytometer. List 
of antibodies used is shown in table 2.1.  
 
Antibody Name Conjugated to Dilution Manufacturer 
Anti-human CD14 FITC 1/50 Immunotools 
Anti-mouse IgG1 FITC 1/50 Immunotools 
 
Table 2.1 List of antibodies used for flow cytometry. Antibodies used to test the purity of a 
CD14+ cell selection using magnetic microbeads.  
 
When determining the purity of the CD14+ population a live cell gate was drawn on a dot plot of 
forward scatter versus side scatter and the percentage of cells CD14+ determined. The CD14+ 
cell fraction indicates the purity of the selected sample. Figure 2.1 is an example of the analysis 
of a purity check with the CD14+ cell fraction being 96% CD14+, and the CD14- cell fraction being 
5.66% CD14+. Therefore, in the case of this selection the purification was quite high and some 
CD14+ cells have not been selected by the beads.  
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Figure 2.1 Purity check of a CD14+ selection using MACS beads. The live cells are gated on using 
forward versus side scatter and the percentage of cells that are CD14+ looked at using single 
colour histograms. The isotype control is indicated with the open histograms and the CD14+ 
staining by the closed red histograms. 
 
2.11 Growing Fibroblast cell lines 
The fibroblast cell lines used were previously set up within the group by Dr Andrew Filer and 
originated from samples of tissue removed from an affected rheumatoid arthritis joint with 
informed consent from the patient. Complete fibroblast medium was prepared, RPMI 1640, 
supplemented with 1% GPS, 10% FCS, 1% NEAA and 1% SOP. Aliquots of frozen fibroblasts were 
bought up from liquid nitrogen storage at -150oC and defrosted quickly by placing in a 37oC 
water bath, defrosted cells were then added to 24mls of warmed complete fibroblast medium 
and centrifuged at 300g for 8 minutes. Cells were washed twice more before being counted, on 
a haemocytometer, using trypan blue exclusion dye and, depending on the number of viable 
cells, resuspended in an appropriate volume of complete fibroblast medium before being put 
into a suitable vessel. The cells were plated out at high densities to ensure that the fibroblasts 
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could to support each other as they went through the lag phase of growth from storage in liquid 
nitrogen. The cells were left to adhere overnight and the medium refreshed the following day to 
remove dead cells. 
 
When feeding the fibroblast cultures the conditioned medium was collected and 66% of the 
final volume of medium replaced with fresh complete fibroblast medium. The collected medium 
was centrifuged at 300g for 5 minutes to remove cell debris and added back to the cell cultures 
as conditioned fibroblast medium to make the volume up to 100%. 
 
When fibroblast cultures were 100% confluent, or the cells required for use in experiments, the 
cells were removed from the plate with 2x trypsin EDTA (Sigma) prepared from 10x stock 
solution using sterile PBS. The conditioned fibroblast medium was removed from the cells, and 
once centrifuged mixed with fresh complete fibroblast medium in a ratio of 1:2. The cells were 
washed in sterile PBS, as the FCS in the medium would inactivate the trypsin EDTA, enough 2x 
trypsin EDTA was added to cover the monolayer of cells and they were incubated at 37oC for 5 
minutes or less. Detachment of the cells was checked microscopically and complete fibroblast 
medium added to the cultures to inactivate the trypsin EDTA. The cells were centrifuged at 300g 
for 8 minutes and the supernatant discarded twice before being resuspended in an appropriate 
volume of 33% fibroblast conditioned medium and 66% complete fibroblast medium and 
transferred to an appropriate vessel for use.  
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2.12 Photographing fibrocytes and macrophages 
Cultures of differentiated fibrocytes were photographed on day 11, and differentiated 
macrophages on day 7. The microscope used was a Zeiss Axiovert 200 with a Hamamatssu 
digital camera (C4742-95), the images were captured by Simple PCI version 5.0 computer 
software.  
 
2.13 Testing different detachment solutions on fibrocytes 
Fibrocytes were differentiated in 24-well plates from PBMC in serum-free fibrocyte medium and 
the efficiency of various detachment agents tested. In preparation the fibrocyte medium was 
removed and every well washed in PBS. Photographs of each well were taken pre-treatment 
and the number of fibrocytes calculated by taking the mean fibrocyte number, based on three 
fields of view of each well. The PBS was removed and the various detachment agents added and 
incubated at either 37oC or 4oC, dependent on treatment. After 40 minutes of treatment, with 
the wells being checked approximately every 10 minutes, 1ml of RPMI/ 1%GPS/ 1% HEPES was 
added to each well to deactivate the agents. The detachment agent plus media were removed 
and replaced with PBS to allow post-treatment photographs to be taken and the number of 
fibrocyte to be again counted using an eye piece graticle.  
 
Trypsin EDTA was prepared as in protocol in section 2.11 however was used at both 2x and 10x 
(stock) concentration. The detachment agent Accutase (PAA) was also used on a separate well, 
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500μl was added and the well incubated at 37oC for 40 minutes. Finally three concentrations of 
EDTA were tested, 0.5M, 0.05M and 0.005M EDTA (Sigma). The EDTA was diluted in PBS to the 
required concentration and 500µl added of each concentration to three separate wells. The 
wells were treated and incubated at 4oC for 40 minutes. The percentage fibrocytes detached 
was calculated by dividing the number of fibrocytes pre-treatment by the number of fibrocytes 
in the same well post-treatment, and multiplying by one hundred.  
 
2.14 Use of Puramatrix HydrogelTM in tissue culture 
PuramatrixTM hydrogel consists of standard amino acids (1% w/v) and 99% water and under 
physiological conditions the peptide component self assembles into a 3D hydrogel with a fibrous 
structure. To create the 3D hydrogel the stock PuramatrixTM was sonicated for 30 minutes and 
diluted with sterile water to the concentrations required. When using it for the first time a 
titration of concentrations was recommended to determine which was the optimal for the cells 
that were being cultured. Initially a titration between 1 and 0% w/v (1, 0.75, 0.5, 0.25 and 0% 
w/v) was used, but in later experiments it was determined that these concentrations were too 
high so the titration was scaled down to between 0.25 and 0% w/v (0.25, 0.2,0.15,0.1, 0.05 and 
0% w/v). The PuramatrixTM hydrogel was set up in 24 well plates, 250μl of each concentration 
was added to a different well and 500μl RPMI 1%GPS 1%HEPES carefully layered over the top. 
The plate was then kept at room temperature for an hour and the medium carefully replaced 
with fresh. Every 30 minutes for 90 minutes the medium was replaced and the plate kept at 
room temperature. The purpose of layering the medium over the gel was to exchange the water 
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used to make up the gel with the medium by osmosis, therefore the more washes the gel had 
the less water remained within the makeup of it. Fibroblasts were used to test the system and 
after 90 minutes were layered over the gel in 1.5mls of the appropriate medium and left to 
culture at 37oC with 5% CO2. Two control wells were included, one where the well went through 
the same procedure as those with hydrogel in i.e. 0% w/v, and one where fibroblasts were just 
plated out following no treatment. 
 
To dissolve the gel and so remove the adherent cells the media was removed from the cells and 
Dispase (BD Bioscience) added, 10 units/per cm2, which, in the case of a 24-well plate was 
200µl. The dispase was left to work for 2hrs at 37oC then the whole mixture pipetted to disperse 
the cell suspension and break up any remaining hydrogel. The action of the dispase was stopped 
by chelation of Ca++ and Mg++ using 5-10mM EDTA and the cell suspension washed several times 
at low speed before analysis. Dispase was also used on the well that contained no hydrogel to 
detach the fibroblasts. 
 
2.15 Identification of live cells with DiOC6 using flow cytometry 
Staining was performed on fibroblasts detached by dispase when testing the PuramatrixTM 
hydrogel. Fibroblasts recently detached from the hydrogel or control wells were transferred to a 
flexi plate and spun for 3 minutes at 4oC at 300g before the supernatant was flicked off and 
100µl PBS 2% BSA added. 100µl of DiOC6 was also added at a working concentration of 2nM. 
The cells were incubated in the DiOC6 for 15 minutes at 37oC before the wells were filled with 
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PBS 2% BSA and the flexi plate spun for 3 minutes at 4oC at 300g. The supernatant was then 
flicked off and the cells resuspended and washed again for 3 minutes at 4oC at 300g, before 
being finally resuspend in 100μl of PBS 2% BSA. Prior to running on the flow cytometer the 
stained cells were added to 300μl PBS. Analysis of fibroblasts detached by dispase when testing 
the PuramatrixTM hydrogel was carried out on a Beckman Coulter Epics XL bench-top flow 
cytometer (Beckman Coulter). The cytometer calibration was standardised using Flow-set 
fluorospheres (Beckman Coulter) and data was analysed using the WinMDI Version 2.8 package. 
DiOC6 was identified by the 488 laser on the flow cytometer; it is a mitochondrial membrane 
dye which will only bind to live cells with intact mitochondrial membrane. Therefore when 
analysing this data live cells were gated on using DiOC6 positivity.  
 
2.16 Cell surface epitope staining on slides 
Cultures of fibroblasts, serum-free fibrocytes, serum-containing fibrocytes and macrophages 
were set up in 8-well chamber slides, 12 wells for each cell type. Fibrocytes were taken at day 
11, macrophages at day 7 and fibroblasts at the point they were approximately 60% confluent. 
For staining of these cultures all medium was removed from each chamber slide and, using the 
tool provided, the top chambers removed, to leave just the glass slide with the adherent cells 
attached. The slide was then washed three times in PBS for 5 minutes before being left to dry 
and fixed in -20oC acetone (Sigma) for 15 minutes. At this point slides were stored at -20oC until 
staining.  
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Slides were removed from freezer and allowed to warm up to room temperature. Using a 
hydrophobic pen the wells were drawn around to prevent any cross contamination of 
antibodies. The cells were rehydrated in PBS/2% BSA for 5 minutes and blocking was performed 
with 10% serum (type dependent on secondary antibody to be used on that well) to prevent 
non-specific staining of the secondary antibody, and left for 20 minutes. The serum was 
removed and the slides gently washed in PBS with a stirring bar. Once excess liquid had been 
removed 50μl of the primary antibody mixes were added to the centre of each well, diluted in 
PBS/2% BSA. The slides were left overnight in a humidified incubator. The following day the 
antibodies were removed and the slides washed twice in PBS with a gentle stirring bar. Again, 
once excess liquid had been removed, the secondary antibody mix was added, diluted in PBS/ 
2% BSA, and left for one hour in a humidified incubator. After an hour the secondary antibodies 
were removed and the slides washed twice more, for 10 minutes, in PBS with a stirring bar. The 
outside of the wells was dried as much as possible and the slides dipped in the nuclear counter-
stain Hoechst (20µg/ml; Bis-benzimid H33258 Fluorochrome) for two minutes and rinsed once 
more in PBS to remove any remaining counter-stain. The slides were dried and to retard fading 
slides were mounted in 2.4% 1,4-Diazabicyclo[2.2.2]octane (DABCO; Aldrich) in glycerol (Fisher 
Scientific) pH 8.6. The slides were then stored at -20oC until analysed.  
 
The antibody stained slides were analysed on the Zeiss Axiovert 100M confocal microscope, and 
images collected using the Zeiss laser scanning microscope LSM 5.10, version 3.2 SP2, computer 
program. A well stained with an irrelevant matched isotype control was completed for every 
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antibody type and when analysing the slides the irrelevant’s were used to set the photo-
multipliers, so that the irrelevant appeared negative. Using these settings any staining seen with 
the matched antibodies was specific for that antibody and not unspecific. A list of the primary 
antibodies used is shown in table 2.2, and the secondary antibodies in table 2.3. 
 
Antibody 
Amount of 
antibody 
added 
Dilution 
used  Manufacturer 
Blocking 
serum 
Secondary antibody 
used 
Rabbit α human collagen I 50ng 1/100 Rockland  (600-401-103-0.1) Donkey 
Donkey α rabbit IgG 
Cy5 
Rabbit α human collagen III 200ng 1/25 Rockland  (600-401-105-0.1) Donkey 
Donkey α rabbit IgG 
Cy5 
Rabbit α human fibronectin   1/100 Sigma (F3648) Donkey Donkey α rabbit IgG Cy5 
Rabbit Immunoglobulin 
fraction 200ng 1/4000 Dako (X0903) Donkey 
Donkey α rabbit IgG 
Cy5 
Mouse α human CD68 
(IgG2b) 1µg 1/25 
BD Pharmingen 
(556059) Goat 
Goat α mouse IgG2b 
Alexa Flur 633 
Negative Control IgG2b 1µg 1/10 Dako (X0944) Goat Goat α mouse IgG2b Alexa Flur 633 
Mouse α human CD13 (IgG1) 2µg 1/25 Immunotools (21270131) Goat 
Goat α mouse IgG1 
Alexa Flur 633 
Mouse α human CD3 (IgG1) 750ng 1/20 Dako (M0835) Goat Goat α mouse IgG1 Alexa Flur 633 
Mouse α human CD45 (IgG1) 2µg 1/25 Immunotools (21270451) Goat 
Goat α mouse IgG1 
Alexa Flur 633 
Negative Control IgG1 2µg 1/5 Dako (X0931) Goat Goat α mouse IgG1 Alexa Flur 633 
Mouse α human Vimentin 
(IgG1) 2µg 1/100 Dako (M725) Goat 
Goat α mouse IgG1 
F(ab) FITC 
Negative Control IgG1 2µg 1/5 Dako (X0931) Goat Goat α mouse IgG1 F(ab) FITC 
 
Table 2.2 List of primary antibodies used in immunostaining. The primary antibodies used in 
immunostaining are listed, along with the amount used to stain, the dilution the antibody was 
used at, its manufacture, which serum was used to block and which conjugated secondary 
antibody was used.  
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Secondary antibodies Dilution used  Manufacturer 
Donkey α rabbit IgG Cy5 1/125 Jackson (711176152) 
Goat α mouse IgG2b Alexa Flur 633 1/100 Molecular probes A-(21146) 
Goat α mouse IgG1 Alexa Flur 633 1/100 Molecular probes A-(21126) 
Goat α mouse IgG1 F(ab) FITC 1/100 Southern Biotec (1032-02) 
 
Table 2.3 List of secondary antibodies used in immunostaining. The secondary antibodies used 
in immunostaining are listed, along with the dilution the antibody was used at and its 
manufacture. 
 
2.17 Time-lapse photography of fibrocytes and macrophages 
Serum-free fibrocytes, differentiated from PBMC, and serum-containing fibrocytes, 
differentiated from CD14+ selected cells were cultured in 8-well class chamber slides and used 
at day 11. The microscope used for time-lapse photography was the Zeiss Axiovert 200 with a 
Hamamatssu digital camera (C4742-95). The chamber slides were placed in a temporary 
incubator which attaches to a heated stage that fitted to the microscope. The CO2 supply was 
set at 5% CO2, and the heated stage set at 37
oC. To get the clearest time-lapse images the lid of 
the cultures was removed from the chamber slides, to prevent condensation, and sterile 
mineral oil layered over the media (all done in category 2 tissue culture hoods), which 
prevented evaporation. The computer program Simple PCI, version 5.0, controlled the 
microscope, and was set to take photographs of the culture every five minutes for at least 6 
hours. The images were saved in a datafile database which could then be used to create avi 
video files. The video files were set to run at 15 frames/second and each frame had a time 
stamp added to it, indicating the time from start.  
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The videos were then analysed on Image pro-Plus, version 4.5, where various readings could be 
taken. The package analysed the video frame by frame, and individual cells could be drawn 
around and the centre of the shape found. The centre of the shape was depicted as an XY co-
ordinate of the frame, this cell was then drawn around in the next frame and the new XY co-
ordinate recorded, using Pythagoras’ theorem the distance the cell had moved over time could 
be calculated. This process was repeated every three frames (so 15 minute intervals on the 
video) and using this, the average speed of each cell calculated. Ten cells were analysed for each 
video so that the average cell speed in each video could be found. As well as the speed of 
movement other readings of each cell could also be taken, once the cell has been drawn around 
the analysis package also provided the length and area of the shape. The length of the shape 
reading was used when looking at the effect serum had on serum-free fibrocytes. 
 
2.18 Cell sorting of monocyte populations to culture in different media 
Fluorescence-activated cell sorting (FACS) was performed using a Mo-Flo MultiLaser flow 
cytometer (Dako Cytomation) operated by Roger Bird. Cell sorting involved labelling cells with 
antibodies conjugated to different fluorochromes. Labelled cells can then be ran through a cell 
sorter and, as a single cell stream, pass through the beam of a blue argon laser, the laser excites 
the attached fluorochromes and the fluorochromes emits light within specific wave lengths, 
dependent on the fluorochrome, detectors identify cells expressing these fluorochromes by the 
wavelength of the emitted light. Based on the combinations of fluorochromes they have bound 
to their surface by antibodies cells can be identified and subsequently collected. On this 
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particular machine up to four different populations, expressing different combinations of 
fluorochromes, could be collected at one time, and any cells not expressing these combinations 
of fluorochromes were discarded.  
 
To prepare cells for cell sorting approximately 100x106 PBMC were isolated from 100mls of 
peripheral blood. Three wells of a 96-well plate were set up at 1x106 cells/ml in serum-free, 
serum-containing fibrocyte medium and macrophage medium as a PBMC control for culturing 
later. Of the remaining cells one aliquot of 2x106 cells and four aliquots of 1x106 cells were 
taken and stored at 4oC in 1.5ml microfuge tubes. Finally the remaining cells were labelled with 
antibodies against the surface markers CD14, CD16 and CD56, for antibody information see 
table 2.4. The antibody cocktails were made up in PBS/2%BSA. The large sample of cells was 
spun down at 300g for 8mins and resuspended in 1ml of antibody cocktail in a 1.5ml microfuge 
tube. The aliquot of 2x106 PBMC was resuspended in 800µl PBS/2% BSA and stored on ice as an 
unlabelled cell control. One of the smaller aliquots of 1x106 cells was labelled with matched 
irrelevant controls for each antibody, and the other three set up to compensate the cell sorter, 
all in 1.5ml microfuge tubes. Although the large population of cells were labelled with 
CD14/CD16/CD56 all three compensation tubes were made up using CD14 conjugated 
antibodies. Labelling with this marker provided a relatively large, bright population that gave 
plenty of events to compensate. All antibody/cell combinations were left for 30 minutes before 
an excess of PBS/2%BSA was added to fill the tube. The tubes were spun down 500g for 5 
minutes, then resuspended in PBS/2% BSA and spun again. The irrelevant and compensation 
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tubes were resuspended in 100µl PBS/2% BSA and filtered through separate 50μm filters (cup-
type, DakoCytomation) that had been pre-wet with 100μl of PBS/2% BSA. 200µl of unlabelled 
cells were also added to each of these filters to have labelled and unlabelled monocytes in the 
same sample. The filters were then washed twice with 100µl PBS/2% BSA to give a final volume 
of approximately 600µl.  The cells labelled with all three markers were resuspended in 1ml 
PBS/2%BSA, and also filtered through a 50μm filter. The filter had been pre-wet with 200μl of 
PBS/2%BSA and following the cells was washed 3 times with 200µl PBS/2% BSA to give a final 
volume of 1.8mls. All cells were filtered into polypropylene tubes with lids (Becton Dickinson) 
and stored on ice until sorting. 
 
The computer program used to control the sorting was Summit v4.3 from Dako. When sorting 
the PBMC a forward/side scatter gate was drawn around monocytes, to exclude nonviable cells 
and lymphocytes; using a dot-plot of CD14 verses CD56 the CD56- fraction of cells was also 
gated to exclude neutrophils. Both the forward/side scatter gate and CD56- gate were applied 
to a dot-plot of CD14 verses CD16 and the populations CD14+CD16-CD56-, CD14+CD16+ CD56- 
and CD14lo CD16+ CD56- were gated on so sorting of these populations could be performed.  
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Tube Antibodies Manufacturer Dilution 
Irrelevant 
Mouse IgG1 Control-FITC Immunotools (21335013) 1/100 
Mouse IgG1 Control-PE Immunotools (21335014) 1/100 
Mouse IgG2a Control-PE-Cy5 Immunotools (21335025) 1/100 
FITC compensation Mouse α human CD14-FITC  Immunotools (21270143) 1/20 
PE Compensation Mouse α human CD14-PE Immunotools (21270144) 1/200 
PE-Cy5 
Compensation Mouse α human CD14-PE-Cy5 
Immunotools 
(21330145) 1/100 
Cells to be sorted 
Mouse α human CD16-FITC 
(IgG1) 
Immunotools 
(21279163) 1/100 
Mouse α human CD56-PE 
(IgG1) Dako (R7251) 1/50 
Mouse α human CD14-PE-Cy5 
(IgG2a) 
Immunotools 
(21330145) 1/100 
 
Table 2.4 List of antibodies used in cell sorting of monocyte populations. For cell sorting of 
monocyte populations the tubes listed above were prepared with the indicated antibodies. The 
dilution the antibodies were used at and the manufacturer of the antibody is also listed. The 
fluorochromes the antibodies are conjugated to are also shown, fluorescein isothiocyanate 
(FITC), phycoerythrin (PE) and phycoerythrin linked to Cy5 (PE-Cy5). 
 
The purity of the sorted populations was checked by running a small number of sorted cells back 
through the machine. Depending on the number of cells collected in each population, the cells 
were plated out at 2x105cells/ml in serum-free fibrocyte, serum-containing fibrocyte and 
macrophage medium. At day 7 the number of macrophages in the macrophage medium was 
counted, based on a fried egg morphology. At day 11 the number of fibrocytes were counted in 
serum-free, serum-containing and macrophage medium.  
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2.19 Microarray analysis of fibrocytes, macrophages and fibroblasts 
2.19.1 Sample collection 
A large number of serum-free, serum-containing fibrocytes, macrophages and fibroblasts were 
required for transcriptome analysis using microarrays. To collect serum-free fibrocytes 
approximately fifty million PBMC were isolated, as previously described, and plated out in 24 
well plates at 1x106cell/ml, 2ml per well, in serum-free fibrocyte media. At day 4 the non-
adherent cells were washed out and the media replaced. To collect serum-containing fibrocytes 
approximately eighty million PBMC were isolated, and the CD14+ cells selected using magnetic 
bead selection, these were then plated out in serum-containing fibrocyte medium at 
2x105cell/ml in 24 well plates, 2ml per well. At day eleven fibrocytes differentiated in both 
media types were harvested. The media was washed out of each well and replaced with 1ml 
sterile PBS. The number of wells set up was divided into three equal sets and the number of 
fibrocytes calculated from three wells of each set. The PBS in each well was then removed and 
700µl of lysis buffer (RNeasy mini kit, Qiagen) used to lyse the cells in the wells in each set. For 
each fibrocyte culture three aliquots of lysed cells were produced and stored at -70oC for RNA 
extraction later. 
 
To collect macrophages for the transcriptome analysis approximately fifty million PBMC were 
isolated and plated out in 24-well plates at 1x106cell/ml, 2ml per well, in macrophage media. At 
day 4 the non-adherent cells were washed out and the media replaced; and at day seven the 
macrophages were harvested. As with the fibrocytes, on the day of harvesting the media was 
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washed out of each well and replaced with 1ml sterile PBS. The number of wells set up was 
divided into three equal sets and the number of macrophages calculated from three wells of 
each set. The PBS in each well was removed and 700µl of lysis buffer (RNeasy mini kit, Qiagen) 
used to lyse the cells in the wells in each set. For each macrophage culture there were three 
aliquots of lysed cells produced and stored at -70oC for RNA extraction later. 
 
To collect fibroblasts for transcriptome analysis a 75mm2 culture flask of fibroblasts was allowed 
to become 100% confluent, the cells detached using trypsin EDTA, as described earlier, and 
counted using a haemocytometer. The harvested fibroblasts were split into three equal aliquots, 
spun down and resuspended in 350µl lysis buffer (RNeasy mini kit, Qiagen), then stored at -70oC 
for RNA extraction later.  
 
As well as three aliquots of each culture giving technical replication, three separate cultures 
were set up for each cell type, giving biological replication. The biological replicates of serum-
free, serum-containing fibrocytes and macrophages were donor matched, so the same three 
donors were used for each in vitro derived cell. The fibroblasts used were established cell lines, 
so three different cell lines were used, but not donor matched to the in-vitro derived cells. 
Overall 36 samples of lysed cells were prepared, nine for each cell type, consisting of 3 biological 
replicates of 3 technical replicates. 
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2.19.2 Microarray preparation 
The microarrays used were custom printed spotted microarrays, containing oligos supplied by 
Operon. The 70-mer oligos consisted of 37,000 genes from the Human Genome Array Ready 
Oligo set (AROS) version 4.0 and, until use, were stored in a lyophilized form at -800C. Prior to 
use they were resuspended at a concentration of 40μM in 3x SSC (for recipe of SSC see section 
2.19.8) and left to resuspend overnight at 40C. The resuspended oligos were then spotted onto 
Ultra-GAPS coated slides following the protocol supplied using a Microgrid TAS II arrayer 
(BioRobotics) at 70% humidity. After spotting the arrays were stabilised and immobilised as per 
their instructions using a UV cross-linker. The arrays were then stored in a desiccated chamber 
at -800C. The microarrays were prepared by Liverpool Microarray Facility, Professor Andy 
Cossins. 
 
 2.19.3 RNA Extraction for microarray analysis 
Cell sample aliquots were defrosted at room temperature and the RNA extracted using the 
RNeasy mini kit from Qiagen as per manufacturer’s instructions. Following extraction the RNA 
was treated to remove any contaminating DNA (DNase I kit, Ambion). The RNA was then stored 
at -200C for future use. 
 
2.19.4 Reverse Transcription PCR 
For each sample two reverse transcription reactions were set up, consisting of 16μl RNA and 1μl 
oligo(dT)12-18 primer (Invitrogen). Each reaction was heated to 65
oC for 10 minutes before being 
cooled to 4oC for the next reagents to be added. A further reaction mix was prepared for each 
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sample, 8μl of first strand buffer, 4μl 0.1M DTT and 2μl Superscript II (200U/μl) (all from 
Superscript II RNase H Reverse Transcriptase kit, Invitrogen). Plus 2μl dATP (10mM), 2μl dCTP 
(10mM), 2μl dGTP (10mM) and 2μl dTTP (10mM) dNTPs (made up from 100mM PCR Grade 
dNTP Set; Invitrogen), and 1μl de-ionised water, the samples were then kept at 50oC for 2 hours. 
The newly formed cDNA was purified using the Nucleospin extraction kit (Macherey-nagel), as 
per manufacturer’s instructions, and the eluted cDNA stored at -20oC. 
 
2.19.5 Quantification of amount of cDNA in each sample 
To ensure that approximately the same amount of cDNA was hybridised to each microarray 
slide from each sample a quantitative real-time L27 gene PCR reaction was prepared. By 
calculating from the initial cell number lysed each real-time PCR reaction was prepared using 
the equivalent of 1000 cells worth of cDNA for each sample, and each reaction was set up in 
triplicate. The human reference sample (see next section for review) was used as a positive 
control for the reaction but also set up as a standard curve. The stock solution of the human 
reference sample was 106ng/µl, dilutions of 1, 1/2, 1/20, 1/50 and 1/100 were prepared and 
also run in triplicate. Each reaction mix consisted of 8.5µl of template, with de-ionised water 
used to make up the volume if required, 0.5µl of each of the forward, reverse primers and 
labelled probe, and 10µl of the real-time PCR mastermix (Applied Biosystem Taqman 2x PCR 
mastermix; Roche). Reactions were made up in a 96-well plate (Applied Biosystems), with six 
wells prepared as negative controls. The plate was loaded into the Stratagene MX3000P real-
time PCR machine, the program the samples were tested on was 50oC for 2 minutes, 95oC for 10 
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minutes, then 40 cycles of 95oC for 15 sec and 60oC for 1 minute. Following the reactions the 
results were analysed using the MxPro, Mx3005P version 3.20 software and using the relative 
amounts of samples compared to the standard curve readings calculated how much cDNA each 
sample contained.  
 
The primer and probe set for human L27 was designed using Primer Express version 1.0 (ABI). 
The primers and probe sequences were as follows – 
L27 sense: GCAAGAAGAAGATCGCCAAG 
L27 antisense: AAACCGCAGTTTCTGGAAGA 
TaqMan probe for L27: CCCTTGGACAAAACTGTCGT (VIC labelled). 
 
The TaqMan probe for L27 was VIC labelled and specificity for the target genes was checked by 
a BLAST search against Genbank sequences. 
 
2.19.6 Dye Labelling  
Before hybridising the isolated cDNA to the microarray slides it first needed to be labelled with 
Cy3-dCTP. To do this 1µg of cDNA, calculated for each sample from the L27 quantitative real-
time PCR and 20μl of random primer mix (Bioprime Labelling Kit, Invitrogen) were made up to 
43μl with deionised H2O. The human reference sample (Universal reference RNA; Stratgene) 
was also labelled as a positive control of both hybridisation, and of the slides by acting as an 
internal control in the microarray analysis, to show any inter-slide variation. The human 
reference sample was composed of the total RNA from ten different human cell lines, including 
adenocarcinoma (mammary gland), hepatoblastoma (liver), adenocarcinoma (cervix), histiocytic 
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lymphoma (macrophage; histocyte), embryonal carcinoma (testis), lymphoblastic leukaemia (T 
lymphoblast), glioblastoma (brain) and plasmacytoma (myeloma; B lymphocyte). It was 
produced in RNA form and was reverse transcribed as described above then stored in aliquots 
at -20oC at a stock concentration of 106ng/µl. For every cell sample to be labelled with Cy3-dCTP 
a reaction mix was also prepared for a reference sample to be labelled with Cy5-dCTP, using 
530ng of cDNA. Each reference/cell sample mix was heated to 95oC for 5 minutes before being 
cooled to 4oC. The following reagents were then added to each reaction, 1.2μl dATP (10mM), 
0.72μl dCTP (10mM), 1.2μl dGTP (10mM), 1.2μl dTTP (10mM) (all made up from 100mM dNTP 
Set PCR Grade, Invitrogen), 1µl 40U/μl Klenow enzyme (Bioprime Labelling Kit, Invitrogen), 1μl 
of either Cy3-dCTP (cell samples) or Cy5-dCTP (reference sample) dye (Amersham Biosciences), 
made up to 7μl with deionised H2O. The reaction was kept at 37
oC for 8 hours and the labelled 
cDNA purified with the nucleospin extraction kit and eluted in 70μl of elution buffer.  
 
2.19.7 Probe Quantification  
The labelled cDNA was measured for pmols of labelled product by use of a spectrophotometer 
(Pharmacia Biotech Ultrospec 2100 pro) at 550nm (Cy3-dCTP) or 650nm (Cy5-dCTP). The 
concentration of probe was then calculated using the equation below 
 
The labelled cDNA was then stored in the absence of light at 4oC for hybridisation to be 
performed later on the same day. 
0.15(Cy3) or 0.25 (Cy5) 
Absorbance 
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Aliquots of 100pmols of labelled cDNA for cell and reference samples were concentrated 
together using microcon concentration columns (Millipore) as per manufacturer’s instructions, 
eluting into 30µl H2O. 
 
2.19.8 Probe hybridisation  
Each probe (reference and cell sample together) was prepared for hybridisation by being 
denatured in a hybridisation solution consisting of 20μl formamide (Sigma), 20μl 20x SSC, 0.4μl 
20% SDS, 5μg PolyA DNA (Invitrogen), 8μg Cot1 DNA (Invitrogen) made up to 50μl with H2O for 
5 minutes at 95oC, then kept at 4oC until use.  
• 20x SSC- Dissolve 175.3g sodium chloride (NaCl; Fisher scientific), 88.2g sodium citrate 
(Fisher scientific) in 800mL water, pH adjusted to 7.0 with 10N sodium hydroxide (NaOH) 
and volume adjusted to 1L with water. 
• 10% SDS (Sodium dodecyl sulphate)- 100g electrophoresis grade SDS in 900ml water, 
heat to 68
o
C to assist in dissolution, pH adjusted to 7.2 by adding concentrated 
hydrochloric acid (HCL) and volume adjusted to 1L.  
 
2.19.9 Preparation of microarray slides 
Before hybridisation microarray slides had to be treated with both pre-soak solution and pre-
hybridisation solution. Pre-soak solution (Pronto!TM, microarray hybridisation kit; Corning) was 
prepared as per manufacturer’s instructions and the required number of slides incubated at 
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42oC for 20 minutes. Slides were washed three times in water and placed in pre-hybridisation 
solution at 42oC for 2 hours. Pre-hybridisation solution was made up of 12.5ml formamide 
(Sigma), 12.5ml 20x SSC, 0.25ml 20% SDS and 50μl 100mg/μl BSA (Sigma), made up to 50ml with 
water.  
 
After 2 hours the slides were washed in water and spun dry at 1500rpm for 15 minutes in a 
centrifuge at room temperature. Once dry the slides were added to a hybridisation chambers 
(Corning) and the preparation instructions for the chamber followed.  The labelled probe mix 
was then carefully applied to the surface of the slide and a Lifter Slip (VWR) slotted on the top. 
The hybridisation chamber was sealed, wrapped in a damp paper towel and tinfoil and left for 
16-20 hours in a hybridisation oven at 42oC. 
 
2.19.10 Post hybridisation washes 
Slides were removed from the hybridisation chambers and the cover-slips removed by being 
immersed in 2x SSC, 0.1% SDS at 42oC. The slides were washed using a AdvaWash machine, 
version 3.4 from Advalytix. The machine used 3 buffers, buffer 1, kept at 42oC, 2 x SSC + 0.1% 
SDS; buffer 2, at room temperature, 0.2 x SSC and buffer 3, at room temperature, 0.05 x SSC. 
The machine washed the slides for 10 minutes in wash buffer 1, 10 minutes in wash buffer 2, 15 
minutes in wash buffer 3, and two lots of wash buffer 3 for 4 minutes. Finally the slides were 
spun dry at 1500rpm for 15 minutes in a centrifuge at room temperature. 
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2.19.11 Slide scanning 
Microarray slides were scanned using a Scanarray GX+ scanner and analysed using Scanarray 
express version 3.03.0002 using variable PMT voltages. A prepared GAL file was used to 
annotate the slide images and the intensity data was extracted and exported as gpr files using 
the same software. These were uploaded into the Gene Expression Pattern Analysis Suite 
(GEPAS) (Bioinformatics Unit CNIO; http://gepas.bioinfo.cnio.es) software for normalization, 
which was performed using print-tip loess normalisation with background subtraction, initially 
within each slide and subsequently between slides.  
 
2.19.12 Analysis of microarrays 
 
For microarray analysis, normalised data was exported as a tab delimited file to the software 
application TIGR Multiexperiment Viewer (TMEV), version 2.0 (free for Academic Institutions at 
http://www.tigr.org/tdb/euk)171 and this was used to perform exploratory analysis (e.g. 
hierarchical clustering, and Principal component analysis (PCA)) as well as to identify 
differentially expressed genes (statistical analysis of microarrays (SAM)).  
 
Hierarchical cluster analysis of the samples was performed using Euclidean distance clustering. 
Sample classes, such as different cell types were colour coded on the dendrogram tree in order 
to make easier the biological interpretation. Principle component analysis was performed as an 
alternative data exploration technique on the samples using a incomplete approximation 
procedure. 
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Significant analysis of microarrays was performed on the normalised data using either a 
multiclass analysis (three way) or a two class unpaired analysis. These analyses were performed, 
using 100 permutations of the data original data to compute the FDR. More permutations 
would have been preferable but computer limitations meant 100 was the maximum possible. 
The false discovery rate used to define a differentially expressed gene may differ between 
analysis and it is indicated in the specific results chapters. However in most cases a 0.1% FDR 
was chosen. The genes found to be significantly differentially expressed were then set as the 
data source and hierarchical and principle component cluster analyses performed.  
 
Normalised data was exported to Prediction Analysis of Microarray (PAM), version 2.1 for 
identifying gene subsets predictive of different cell identities. This program is implemented as a 
plug-in within Microsoft Excel, files were set up with gene name and ID in the first two columns. 
A random selection of six samples of each cell type were used as a training set whereas three 
samples were used as the test set. Ten different iterations of PAM were performed with 
different random selection of training and test sets.  
 
PAM was performed setting the shrinkage threshold to allow maximum predictivity on the 
training set with a model size of at least 100 genes. Using these genes the cell type of the 
remaining samples (prediction set) were predicted. The top 100 genes in each of the ten gene 
lists were ranked by the number of times they appeared (i.e. used as a predictive gene); and 
those genes which had been used 8 times and above selected. The normalised data for each of 
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these genes was then extracted to be represented in a graph, or loaded into TMEV for 
hierarchical and principle component cluster analysis.  
 
To determine any potential biological meaning behind these gene lists the database for 
annotation, visualization and integrated discovery (DAVID), was used. This is a web-based tool 
(www.david.abcc.ncifcrf.gov http://www.david.abcc.ncifcrf.gov) that maps the genes contained 
in a given gene list to biological annotation databases such as GO. It then it identifies functional 
pathways which are over-represented in the input gene list172. It is extremely useful to 
formulate hypothesis on the role of these genes in biological systems.  
 
The ideal gene number to analyse with DAVID is between 200-2000 genes172 however the gene 
list we wanted to use was far too large for this so to reduce this a three-fold difference cut off 
was introduced, only those genes whose ratio to reference was three fold different or more 
between the two cell populations were used. The list of genes which remained was split into 
two, based on which cell type had the highest gene expression, using the mean log(2) ratio 
reading across the samples for each population. The two lists were inputted separately into 
DAVID and a cut off of an enrichment score of greater than 2 and a FDR of less than 5 was used 
when looking at the biological processes provided. 
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3.0 CULTURING AND QUANTIFYING FIBROCYTES 
3.1 Generating Fibrocytes 
As discussed in the introduction fibrocytes have been shown to differentiate from the CD14+ 
monocyte population within peripheral blood45-47 in vitro, however there are two methods used 
to generate these, in both the presence45;87 and absence47 of serum (Figure 3.1). There are also 
discrepancies within the literature on the optimum conditions for culture, therefore for the 
purpose of this thesis this chapter is to address the ideal culture conditions for generating 
fibrocytes, to allow for the questions raised in the overall aims to be answered.  
 
More specifically the aims of this chapter are to determine the most precise method to quantify 
fibrocyte differentiation and to determine the optimum culture conditions for both serum-free 
and serum-containing fibrocytes. To discuss various potential methods of isolating a pure 
sample of fibrocytes; and to determine that the cells being differentiated have the same 
expression profile as those described in the literature. 
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Figure 3.1 Culture conditions for generating fibrocytes. A schematic to represent the culture 
conditions described in the literature for generating fibrocytes in both serum-free and serum-
containing fibrocyte medium47;87. 
 
Using the serum-containing fibrocyte medium, according to the literature, fibrocytes 
differentiate in vitro after 10-12 days45;87;89-91. However in the case of the serum-free fibrocyte 
medium fibrocytes are seen to differentiate after just 3-5 days; this was shown to be due to the 
lack of serum amyloid P (SAP) which is found in serum47;48. For the purpose of this report the 
medium used by Pilling et al will be referred to as serum-free fibrocyte medium and the 
medium used by Bucala et al serum-containing fibrocyte medium. To demonstrate the fibroblast 
like morphology of fibrocytes figure 3.2 shows an example of fibrocytes differentiated in either 
serum-free (a) or serum-containing (b) fibrocyte medium photographed at day 12 of culture. 
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Figure 3.2 Photographs of Fibrocytes. Fibrocytes differentiated in serum-free fibrocyte medium 
from isolated PBMC plated out at 1x106cell/ml (a). Fibrocytes differentiated in serum-containing 
fibrocyte medium from positively selected CD14+ cells, plated out at 2x105cell/ml (b). Both were 
photographed on day 12 of culture. Scale bar indicates 100μm.  
 
3.2 Quantifying Fibrocytes 
Whilst doing preliminary work for this thesis it was found that serum-free derived fibrocytes 
were extremely adherent, which will be discussed later in this chapter, however to be able to 
establish the best conditions for in vitro fibrocyte generation a criteria for counting 
differentiated fibrocytes in situ had to be developed. The best phenotype for the identification 
of fibrocytes is their spindle shaped, fibroblast like morphology (Figure 3.2). Initially fibrocyte 
cultures were photographed periodically, using a Zeiss inverted microscope, and the number of 
cells in the photographs counted using the two categories, fibrocyte or non-fibrocyte. From this 
data the percentage of differentiated fibrocytes could be calculated. Subsequently an eye piece 
micrometer was purchased to allow for differentiated cells to be counted in situ on the 
microscope, without the need for photographs. When using the eye piece micrometer three 
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random fields of view were counted for each culture condition and the mean percentage and 
number of fibrocytes calculated for each well. Fibrocyte differentiation is extremely 
heterogeneous and when counting using the eye piece micrometer it became clear that just 
counting three random fields of view from one well was not sufficient to get an accurate picture 
of what was happening in the cultures. On one day the three fields of view randomly chosen 
may have a very low percentage/number of fibrocytes and on the next day the three fields of 
view, randomly chosen, could contain a high number of fibrocytes, making it appear that there 
has been a large increase over night, or vice versa. Therefore an experiment was performed to 
look at how many fields of view in how many replicate wells needed to be counted to get a 
precise fibrocyte count. Three wells of a glass 8-well chamber slide and a plastic 24-well plate 
were seeded with PBMC in serum-free fibrocyte medium at 1x106cells/ml and the non-adherent 
cells washed out at day four. On day eleven ten fields of view were counted in each well and the 
percentage and number of serum-free fibrocytes calculated (Figure 3.3). 
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Figure 3.3 Percentage and number of serum-free fibrocytes differentiated on two different 
substrates. Fibrocytes were differentiated in serum-free fibrocyte medium from PBMC on a 
glass 8 well chamber slide and plastic 24 well plate. Using the eye piece micrometer cells were 
counted in ten fields of view of 3 replicate wells (A, B and C) for both substrates. The percentage 
fibrocytes (a.) and number of fibrocytes (b.) in PBMC culture of glass chamber slide with the 
mean shown. The percentage fibrocytes (c.) and number of fibrocytes (d.) in PBMC culture of 
plastic plate with the mean shown. 
 
The percentage fibrocytes seen in the 3 wells of the glass chamber slide ranged between 50 and 
85% fibrocytes, however the number of fibrocytes seen had a much larger range, which may 
have been due to the heterogenic way these cells differentiate, with some fields of view having 
many more fibrocytes than others. The percentage fibrocytes seen in the plastic plate was lower 
than that seen in the glass chamber slide, which may indicate the cells substrate preferences of 
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glass over plastic. However, as for the glass chamber slides, the range in the number of 
fibrocytes calculated in the plastic wells was much higher than the range of percentage 
fibrocytes, again probably due to the heterogeneity of the culture. 
 
Using the fibrocyte percentage and number data calculated from the ten fields of view the 
percentage coefficient of variation was chosen to determine the level of variation seen within 
the different fields of view. This helped to determine the number of fields of view and replicate 
wells that need to be counted to get precise counting results. The percentage coefficient of 
variation was calculated looking at single wells (A, B or C), two wells (A+B, A+C or B+C) or all 
three wells (A+B+C), with an increasing number of fields of view included. These analyses were 
all performed for percentage and number of fibrocytes in glass chamber slides and plastic plates 
(Figure 3.4). 
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Figure 3.4 Determination of the ideal number of fields of view and replicate wells required for 
precise counting results. Percentage coefficient of variation of an increasing number of fields of 
view and increasing number of wells for fibrocytes differentiated in serum-free fibrocyte 
medium from PBMC. Using the eye piece micrometer cells were counted in ten fields of view of 
3 replicate wells (A, B and C) for both substrates and the data analysed as above. The 
percentage coefficient of variation of percentage fibrocytes (a.) and number of fibrocytes (b.) 
differentiated from PBMC in glass chamber slide. The percentage coefficient of variation of 
percentage fibrocytes (c.) and number of fibrocytes (d.) differentiated from PBMC in plastic 
plate. 
 
Due to the heterogeneity of the cultures the variation between the different fields of view and 
wells was always going to be high, in some cases the percentage coefficient of variation was in 
the 60’s (Figure 3.4). However the purpose of these experiments was to calculate at what point 
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the percentage coefficient became stable and no longer changed so that no matter how many 
fields of view or wells were counted it never actually got any lower, and therefore indicated the 
level of variation within the cultures, not of the counting. 
 
When just looking at the percentage coefficient of variation of increasing fields of view in three 
wells (Figure 3.5) three fields of view appeared to be the point where the variation became 
stable, more than three fields of view did not lower the level of variation seen and three fields 
of view for three wells for each condition is technically feasible. Therefore counting three fields 
of view from three replicate wells was decided to be the most precise way to quantify fibrocyte 
cultures. 
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Figure 3.5 Determination of the ideal number of fields of view when counting three wells to 
get precise counting results. Percentage coefficient of variation of an increasing number of 
fields of view counted in three wells of fibrocytes differentiated in serum-free fibrocyte medium 
from PBMC. Using the eye piece micrometer cells were counted in up to ten fields of view of 3 
different wells (A, B and C) for both substrates and the data analysed as above. The percentage 
coefficient of variation of percentage fibrocytes (a.) and number of fibrocytes (b.) differentiated 
from PBMC in glass chamber slide. The percentage coefficient of variation of percentage 
fibrocytes (c.) and number of fibrocytes (d.) differentiated from PBMC in plastic plate. 
 
To test that three fields of view from three wells was a suitable method ten permutations of 
three fields of view from the ten counted for each well were chosen by using a random number 
generator. These were put together with three random fields of view from the other two wells 
Chapter 3: Culturing and quantifying fibrocytes Marianne Fairclough 
 97
and the percentage coefficient of variation calculated for both the percentage and the number 
of fibrocytes seen. Figure 3.6 illustrates the range of the percentage coefficients of variation 
seen for these ten permutations. Although the fibrocyte percentage and number percentage 
coefficient of variations are very different on the glass chamber slide, the 10 permutations 
cluster closely together indicating that although the degree of variation is high within the plate, 
counting three fields of view of three wells is enough to ensure the counts are precise.  
 
 
 
Figure 3.6 Testing precision of counting three fields of view from three replicate wells. 
Percentage coefficient of variation of fibrocytes differentiated in serum-free medium from PBMC 
for ten replicates of 3 randomly chosen fields of view from 3 wells. For (a.) glass wells and (b.) 
plastic wells. 
 
3.3 Optimising culture conditions of both serum-free and serum-
containing fibrocytes 
As with many other cultured cells the concentration at which PBMC are plated out can influence 
the percentage, and number of fibrocytes seen to differentiate, due to cell density effects171;172. 
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To determine the optimal seeding density for the generation of serum-free derived fibrocytes, 
PBMC were isolated and seeded at 1x107/1x106/1x105cells per ml into glass chamber slides in 
serum-free fibrocyte medium (Figure 3.7). The number of fibrocytes was calculated on days 4, 7, 
11 and 14. 
 
Figure 3.7 Number of differentiated fibrocytes for different seeding concentrations of PBMC. 
PBMC were plated out at the indicted concentrations in glass 8 well chamber slides in serum-
free fibrocyte medium. At days 4, 7, 11 and 14 the number of fibrocytes was calculated. Error 
bars indicate standard deviation about the mean of the three fields of view counted for each 
condition from one experiment. Experiment representative of n=3. 
 
The ideal seeding concentration was found to be 1x106cells/ml as it gave the most serum-free 
fibrocytes at every time point counted. Whenever PBMC were plated out in serum-containing 
fibrocyte medium however very few fibrocytes differentiated in our hands, therefore it was 
decided that the majority of work on them would be performed on cells that had differentiated 
from CD14+ selected cells. 
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When counting the number of fibrocytes in culture, following set up from PBMC, it was difficult 
to see the differentiating adherent cells underneath the non-adherent cells, therefore the non-
adherent cells were removed. To ensure these were being washed out at the ideal time point a 
time course was performed. It was important to ensure that the non-adherent cells were not 
being washed out at a time point at which the monocytes were still adhering, to ensure minimal 
loss in monocyte number and maximum fibrocyte differentiation. Non-adherent cells were 
washed out at 1hr, 24hr, 48hr and 96hrs after PBMC were plated out in serum-free fibrocyte 
medium at 1x106cells/ml. The number of fibrocytes were calculated on days 4, 7, 11 and 14 and 
at every time point the number of fibrocytes were counted the optimum wash out time was 
96hrs (Figure 3.8). 
 
Figure 3.8 Optimum time point to wash out non-adherent cells to ensure minimal monocyte 
loss. PBMC were plated out at 1x106cell/ml in glass chamber slides in serum-free fibrocyte 
medium. At 1hr, 24hr, 48hr and 96hr time points the non-adherent cells were washed out and 
at days 4, 7, 11 and 14 the number of fibrocytes was calculated. Error bars indicate standard 
deviation about the mean of the three fields of view counted for each condition from one 
experiment. Experiment is representative of n=3. 
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Fibrocytes have been reported to differentiate from CD14+ monocytes45;47-49;85;86 and as usable 
numbers of serum-containing fibrocytes repeatedly failed to differentiate from PBMC the 
optimum seeding concentration for CD14+ selected cells in each media type was also 
determined. CD14+ cells were selected using magnetic bead selection, (described in the 
methods section, 2.8) and only purities of 95% and above were used. To ensure the correct 
seeding density of the CD14+ selected cells a titration was set up including 
1x104/1x105/2x105/5x105cells per ml plated into glass chamber slides in both serum-free and 
serum-containing fibrocyte media (Figure 3.9). The number of fibrocytes were calculated at days 
7, 11 and 14 for each condition. 
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Figure 3.9 Number of differentiated fibrocytes for different seeding concentrations of CD14+ 
selected cells. CD14+ selected cells were plated out at the indicted concentrations in glass 8 well 
chamber slides in serum-free and serum-containing fibrocyte medium. At days 7, 11 and 14 the 
number of fibrocytes was calculated. Error bars indicate standard deviation about the mean of 
the three fields of view counted for each condition. Experiment is representative of n=3. 
 
In both media types the optimum seeding concentration was 2x105cells/ml, although in the 
serum-containing fibrocyte medium, at the earlier time points, 5x105cells/ml appeared to be 
better, however this dropped off very quickly, whereas the number of fibrocytes in the lower 
concentration continued to increase. Therefore 2x105cells/ml was chosen as the optimum cell 
concentration for plating out the CD14+ selected cells in both media. 
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3.4 Harvesting Fibrocytes 
3.4.1 Testing different detachment solutions on serum-free fibrocyte cultures 
Although it has been reported that fibrocytes will detach from plastic following treatment with 
ice cold 0.05M EDTA46;87;90;91 preliminary experiments in our group did not find this to be the 
case. Fibrocyte cell culture conditions do not produce a homogeneous population therefore 
being able to detach the cells from the plastic to subsequently analyse the effect of treatments, 
or to sort them to gain a pure cell population was required. Consequently an experiment was 
designed to investigate the effect of different detachment solutions on fibrocyte cultures. The 
different detachment solutions tested included, 0.005M EDTA, 0.05M EDTA, 0.5M EDTA (Sigma, 
at 4oC), Accutase (PAA) and Trypsin EDTA (Sigma). Manufactures’ protocols were followed for 
Trypsin EDTA (2x) and Accutase. However a higher concentration of Trypsin EDTA was also used 
(10x).  
 
PBMC were set up in serum-free fibrocyte media and on day 11, prior to treatment, each 
culture was counted to determine the number of differentiated fibrocytes and the cultures 
photographed. Following forty minutes of treatment all wells had some detached cells in 
suspension, however it was impossible to tell what they were, and both fibrocytes and non-
fibrocytes still remained attached to the bottom of the well. To deactivate each detachment 
agent 1ml of RPMI/1%GPS/1% HEPES was added to each well, the wells then washed with PBS, 
and the number of attached fibrocytes counted again before cultures re-photographed. 
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Figure 3.10 shows the results determined by counting the number of fibrocytes before and after 
treatment. The number of fibrocytes that detached is represented as a percentage of the 
number of fibrocytes pre-treatment. With every treatment less than 60% of the serum-free 
fibrocytes seen in culture detached following 40 minutes of treatment. The detachment agent 
which worked the most efficiently was 10x Trypsin EDTA, however it still only detached 55% of 
the fibrocytes, the remaining 45% that remained could represent a distinct population of 
fibrocytes which are more adherent, therefore a representative population of fibrocytes could 
not be collected. The other detachment agents detached less than 40% of the serum-free 
fibrocytes (Figure 3.10), this is also illustrated in the photographs in figures 3.11 and 3.12, pre 
and post treatment. Although there are perhaps less non-fibrocytes following treatment there 
are still fibrocytes clearly in the post treatment photographs, indicating that none of these 
detachment populations are suitable.  
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Figure 3.10 Percentage of serum-free fibrocyte detachment The number of serum-free 
fibrocytes was determined pre and post treatment. The number of fibrocytes detached by 
treatment is shown as a percentage of the number of cells counted pre-treatment. Data 
representative of n=2 experiments. 
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Figure 3.11 Photographs of fibrocyte cultures pre and post treatment with commercially 
available detachment agents. At day 11 three cultures of serum-free derived fibrocytes were 
photographed before treatment with either Trypsin EDTA (Sigma- concentrations 10x and 2x) or 
Accutase (PAA) and after 40 minutes of treatment. Scale bar represents 100µm. 
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Figure 3.12 Photographs of fibrocyte cultures pre- and post treatment with ice cold EDTA. At 
day 11 three cultures of serum-free derived fibrocytes were photographed before treatment 
with either 0.5/0.05/0.005M EDTA (Sigma- at 4oC) and after 40 minutes of treatment. Scale bar 
represents 100µm. 
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3.4.2 Culturing cells on PuramatrixTM Hydrogel 
Differentiating fibrocytes on PuramatrixTM Hydrogel from BDTM Biosciences was another option 
for obtaining a pure culture of fibrocytes in suspension. This hydrogel was a synthetic matrix 
designed to create defined three dimensional micro-environments for cell culture experiments. 
The peptide hydrogel consisted of standard amino acids (1% w/v) and 99% water and under 
physiological conditions the peptide components self assembled into a 3D hydrogel with a 
fibrous structure. The theory behind using this gel was that once fibrocytes had differentiated 
on the gel it could then be dissolved with dispase, a detachment agent able to dissolve the 
PuramatrixTM gel, allowing the collection and sorting of the detached fibrocytes into a pure 
culture.  
 
Figure 3.13 A schematic of how Puramatrix
TM
 hydrogel detaches adherent cells. After making 
the hydrogel the cells would be differentiated on it, then the PuramatrixTM hydrogel dissolved, 
using dispase, and in the process detaching the cells, so allowing collection of normally adherent 
cells for cell sorting into a pure culture.  
 
Initially the optimal percentage of amino acids (gel concentration) needed to be determined as 
the manufacturers advised that different cell types required slightly different percentage w/v’s. 
For ease of tissue culture dermal fibroblasts were used when optimising the PuramatrixTM gel. A 
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titration of gel concentrations was performed in a 24-well plate, with final concentrations of 1, 
0.75, 0.5, 0.25 and 0% w/v, made up using the stock hydrogel and water. As a control one well 
had no hydrogel added, just water. Then over a series of washes the water content of the gel 
was replaced by fibroblast medium and the gel allowed to solidify. 2x104 dermal fibroblasts 
were seeded into each well, as well as a sixth untouched well. After 7 days the cells were 
observed under the microscope and dispase used to dissolve the gel and detach the cells. To 
identify live cells anything detached by the dispase was stained with DiOC6, a lipophillic dye 
selective for polarised mitochondria and therefore will only stain live cells.  
 
When looking at the cells on the PuramatrixTM, very few fibroblasts had proliferated and some 
had not even stretched out into their distinctive morphological characteristic. However the two 
wells that contained no hydrogel had a confluent culture of fibroblasts all stretched out. This 
suggested that every concentration of hydrogel that was tested was unsuitable for fibroblast 
culture and therefore unlikely to be suitable for fibrocyte culture. Figure 3.14 confirmed this, 
the DiOC6 labelled detached cells were ran on the flow cytometer in a fibroblast specific 
program. When just looking at the forward scatter versus side scatter plots of the samples 
obtained from 1, 0.5 and 0% gel (w/v) a lot more debris could be seen down the left hand side, 
i.e. debris and dead cells in the samples that were cultured on PuramatrixTM gel (1 and 0.5%) 
compared to the no hydrogel well (0%), there were also a lot fewer events in the fibroblast gate 
(R1). When the DiOC6hi samples were back gated onto the forward scatter versus side scatter 
plots the actual percentage of live cells was again much less in the samples that had been 
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cultured on PuramatrixTM gel compared to the 0% control, confirming that these concentrations 
of PuramatrixTM gel are not suitable for fibroblast cultures. 
 
 
Figure 3.14 DiOC6 staining of dermal fibroblasts cultured on PuramatrixTM. Identification of live 
cells by DiOC6 staining of detached dermal fibroblasts cultured on PuramatrixTM gel at different 
concentrations. Dermal fibroblasts were plated out at 2x104 on increasing concentrations of 
PuramatrixTM hydrogel before being detached using dispase treatment. The detached cell 
samples were labelled with DiOC6 and looked at on the flow cytometer to determine the 
proportion of live fibroblasts versus total cells detached. 
 
This experiment was then repeated using much lower concentrations of PuramatrixTM hydrogel, 
0.25, 0.20, 0.15, 0.10, 0.05 and 0% w/v. Those fibroblasts on the lower concentration hydrogel 
were seen to proliferate and spread out, however they did not appear to proliferate as well as 
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the 0% controls. At this point we attempted to differentiate serum-free fibrocytes on the 
hydrogel. They were also seen to differentiate at the lower concentrations of gel, however 
when dispase was used to dissolve the matrix and detach the cells they did not detach, 
suggesting that they were able to differentiate at the lower concentrations of hydrogel because 
they went through the hydrogel and actually attached to the plastic of the well, at which point 
dispase could not detach them. Therefore although suitable for fibroblast culture PuramatrixTM  
was found to be unsuitable for the isolation of differentiating fibrocytes.  
 
3.4.3 Differentiating serum-free fibrocytes on coated plates 
Various options for improving differentiation efficiency and detachment of serum-free 
fibrocytes were suggested by different company representatives, including various coatings and 
temperature sensitive plates.  
 
Plates with various coatings were trialled to see if differentiation efficiency improved and/or if 
detachment efficiency increased. Serum-free fibrocytes did differentiate on plates coated with 
collagen I, collagen IV, laminin, poly-D-lysine and fibronectin however there were a lot less 
differentiated cells than uncoated plastic plates or glass slides (data not shown), therefore the 
use of these plates was not pursued.  
 
Temperature sensitive plates were also trialled, these were plates which were coated with a 
substrate that was solid at 37oC but when removed from the incubator for any length of time at 
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20oC the substrate would detach, allowing for collection of adherent cells. In theory the idea 
was good however the serum-free fibrocytes would not differentiate on the temperature 
sensitive substrate (Data not shown). 
 
3.5 Marker expression of serum-free and serum-containing fibrocytes 
To ensure that the cells being used to answer questions in this thesis express the same markers 
as those described within the literature both serum-free and serum-containing fibrocyte 
cultures were antibody stained for markers of which expression is reported. Fibrocytes are 
known to express both stromal and haematopoietic markers47;87; the stromal markers looked at 
here were fibronectin, collagen I, collagen III and vimentin (Figure 3.15) and the haematopoietic 
markers CD45, CD13 and CD68 (Figure 3.16). As positive and negative controls for both sets of 
markers donor matched macrophages and a fibroblast cell line were also stained. CD3 was used 
as a negative marker for all cell types. Matched irrelevant controls are shown in figure 3.17.  
 
Serum-free fibrocytes were differentiated from PBMC and serum-containing fibrocytes 
differentiated from CD14+ selected cells on glass chamber slides. At day 11, in both cases, the 
cultures were fixed for staining. Macrophages were differentiated from PBMC in specific 
macrophage media (see materials and methods) on glass chamber slides and fixed for staining 
on day 7. Fibroblast cell lines were plated out on glass chamber slides at either passage 4 or 5 
and fixed 48hrs later, allowing for a suitable confluency. 
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Figure 3.15 Images of stromal markers on serum-free, serum-containing fibrocytes, 
macrophages and a fibroblast cell line. Serum-free fibrocytes were differentiated from PBMC 
and serum-containing fibrocytes differentiated from CD14+ selected cells on glass chamber 
slides, at day 11 fixed for staining. Macrophages were differentiated form PBMC on glass 
chamber slides and fixed for staining on day 7. Fibroblast cell lines were plated out on glass 
chamber slides at approximately passage 4 and fixed 48hrs later, allowing for a suitable 
confluency. Matched irrelevant control for Fibronectin, Collagen I and Collagen III is rabbit IgG 
and matched irrelevant control for vimentin is IgG1 b (Figure 3.17). Images shown represent one 
donor from n = 3 for in vitro derived cells and one cell line from n = 3 for fibroblast cell lines. 
Scale bar indicates 50µm. 
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Figure 3.16 Images of haematopoietic markers on serum-free, serum-containing fibrocytes, 
macrophages and a fibroblast cell line. Serum-free fibrocytes were differentiated from PBMC 
and serum-containing fibrocytes differentiated from CD14+ selected cells on glass chamber 
slides, at day 11 fixed for staining. Macrophages were differentiated form PBMC on glass 
chamber slides and fixed for staining on day 7. Fibroblast cell lines were plated out on glass 
chamber slides at approximately passage 4 and fixed 48hrs later, allowing for a suitable 
confluency. Matched irrelevant control for CD45, CD13 and CD3 is IgG1 a and matched 
irrelevant control for CD68 is IgG2b (Figure 3.17). Images shown represent one donor from n = 3 
for in vitro derived cells and one cell line from n = 3 for fibroblast cell lines. Scale bar indicates 
50µm. 
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Figure 3.17 Images of irrelevant matched controls on serum-free, serum-containing fibrocytes, 
macrophages and a fibroblast cell line. Serum-free fibrocytes were differentiated from PBMC 
and serum-containing fibrocytes differentiated from CD14+ selected cells on glass chamber 
slides, at day 11 fixed for staining. Macrophages were differentiated form PBMC on glass 
chamber slides and fixed for staining on day 7. Fibroblast cell lines were plated out on glass 
chamber slides at approximately passage 4 and fixed 48hrs later, allowing for a suitable 
confluency. Images shown represent one donor from n = 3 for in vitro derived cells and one cell 
line from n = 3 for fibroblast cell lines. Scale bar indicates 50µm 
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Table 3.1 Summary of staining results on serum-free, serum-containing fibrocytes, 
macrophages and fibroblast cell lines. Summary of figures 3.15 and 3.16. The symbol + 
indicates positive staining and – negative staining.  
 
A summary of the staining results is shown in table 3.1. The staining indicated that serum-free 
and serum-containing fibrocytes have the same marker expression profile, positive for both 
stromal and haematopoietic markers, matching what is reported in the literature47;87. 
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Interestingly the fibronectin staining in both types of fibrocytes was much more peri-nuclear 
than in the fibroblasts, where it was seen along the whole length of the cell.  
 
3.6 Discussion of chapter 
Fibrocytes can be generated by two different protocols, in the absence47 or presence87 of 
serum, data in this chapter shows that both culture medium generate cells of a fibroblast-like 
morphology with the same marker expression profile as described in the literature47;87 (Figures 
3.2, 3.15-3.17 and Table 3.1). To quantify fibrocyte differentiation in culture, counting the 
number of differentiated cells in 3 fields of view and across 3 separate wells of a culture plate 
was found to be the most precise way of getting quantifiable results, due to the heterogeneous 
nature of fibrocyte differentiation (Figure 3.3 – 3.6). In 2003 Pilling et al enumerated fibrocyte 
differentiation by identifying them by their elongated morphology and the presence of an oval 
nucleus in 5 different fields of view of a 96-well plate47. In 2006 and 2008 the same group used 
the same method but with duplicate wells rather than single wells, with each culture being 
counted by at least two independent observers48;103. Therefore using cell counts based on cell 
morphology is a protocol deemed suitable for fibrocyte quantification within the literature and 
although multiple observers were not used here  multiple wells were to try and provide 
precision. 
 
The optimum culture conditions for differentiating fibrocytes vary within the literature, with 
reports using a starting concentration of PBMC that varies between 2.5x105cells/ml47;48;103, 
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1x106cells/ml46;89;91, 2x106cells/ml146 and 1x107cells/ml90. Some reports do not wash out the 
non-adherent cells at all47;48;103;116, whereas others wash them out at 24hrs87;89-91, 48hrs45 or 
72hrs46;146. Therefore it was vital for the optimal culture conditions for this laboratory to be 
determined. For serum-free fibrocytes these were found to be at a concentration of 1x106 
PBMC/ml of media in either plastic or glass wells (Figure 3.7). To enable quantifiable counting 
the ideal time to wash off non-adherent cells was also found to be at day 4 or 96hrs from the 
time the cultures were set up (Figure 3.8). This was seen at every time point following set up, 
suggesting that until 96hrs either the differentiating monocytes were not quite adherent 
enough to cope with the washing or, and more likely, something within the non-adherent 
fraction of PBMC, or released by it, is required to get optimum fibrocyte differentiation. Various 
factors have been discussed as being important for fibrocyte differentiation, the pro-fibrotic 
cytokines IL4 and IL13 have been shown to promote fibrocyte differntiation103. Previous to them 
the presence of T cells was shown to be important for their differentiation in vitro. However it is 
still unclear whether direct cell-cell contact between T cells and fibrocyte precursors is required 
or whether it is just soluble factors released by these cells45;46. Also this effect of T cells on 
fibrocyte differentiation is still seen in the presence of blocking anti-cytokine antibodies for the 
profibrotic cytokines IL4 and IL13138, suggesting there is another factor, or factors involved.  
 
The number of differentiated serum-containing fibrocytes from PBMC cultures was found to be 
extremely low in our hands, therefore the optimum cell density for both types of fibrocytes was 
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established from CD14+ selected cells and found to be 2x105 CD14+ cells/ml media for both 
serum-free and serum-containing generated fibrocytes (Figure 3.9). 
 
Neither serum-free nor serum-containing fibrocytes differentiate as pure populations, there 
were always cells without a spindle shaped morphology present in the cultures, therefore 
attempts were made to detach serum-free derived fibrocytes so that a pure population could be 
obtained. A pure sample of each population would allow for more precise comparisons between 
them to be made as there would be no question of non-fibrocytes biasing the results. A 
detached pure population would also allow for techniques such as flow cytometry to be used. 
Within the literature ice-cold 0.05% EDTA diluted in PBS was found to be sufficient to detach 
fibrocytes45;46;89;91;146;173, however this was not the case for cells differentiated in our hands as 
neither 0.5M, 0.05M or 0.005M were able to detach the serum-free derived fibrocytes (Figures 
3.10 and 3.12). Although one report does detach fibrocytes using the commercial product 
Accutase116, we unfortunately found no commercially available detachment agents able to do 
so; Trypsin EDTA, Accutase and Dispase were all tested (Figures 3.10 and 3.11 ). We also found 
that the efficiency of serum-free fibrocyte differentiation was not improved by using plates 
coated with collagen I, collagen IV, laminin, poly-D-lysine or fibronectin, despite fibronectin 
coated plates being used in the literature89;91. Fibrocytes were found to not differentiate on 
PuramatrixTM hydrogel or temperature sensitive plates. No protocols tested enabled a pure 
fibrocyte culture to be isolated, therefore the effects of any treatment on fibrocyte 
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differentiation were quantified by counting the number of differentiated fibrocytes in culture 
based on morphology. 
 
The cases in the literature where fibrocytes were detached using either EDTA or Accutase had 
differentiated their fibrocytes in serum-containing conditions45;46;89;91;116;144. Fibrocytes 
differentiated in serum-free conditions were not detached but quantified in situ by counting 
differentiated fibrocytes47;48;103. In this thesis the detachment agents were being tested on the 
serum-free derived fibrocytes, therefore our inability to detach them is not unseen within the 
literature. Although the literature suggests that detachment agents may have worked on the 
serum-containing fibrocytes this was not pursued as a detached population of fibrocytes 
derived under both methods were required for comparison, if a representative population of 
serum-free fibrocytes could not be detached there was no requirement for serum-containing 
derived fibrocytes to be detached. 
 
The experiments within this chapter determined the optimum culture conditions for our 
laboratory to differentiate serum-free and serum-containing derived fibrocytes and methods of 
quantification. All further experiments within this thesis are based on these. 
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4.0 COMPARING SERUM-FREE AND SERUM-
CONTAINING FIBROCYTES 
4.1 Generation of fibrocytes from PBMC and CD14+ selected cells 
Both serum-free and serum-containing fibrocytes are reviewed in the literature as being the 
same cell type, due to their similar morphology and expression profile in immunostaining47;87, 
however there are some differences also mentioned. Serum-containing fibrocytes take 10-14 
days to appear in vitro whereas serum-free are seen after just 3-5 days47;87. Also, serum-free 
fibrocyte differentiation is inhibited by the presence of the plasma protein SAP found in 
serum47, whereas serum-containing fibrocytes, as the name suggests, are differentiated in the 
presence of serum87. It has also been observed that serum-free fibrocytes express high levels of 
prolyl 4-hydroxylase, the enzyme required for the synthesis of new collagen48, whereas those 
generated in serum-containing media show low levels of prolyl 4-hydroxylase activity145;146, 
however both of these observations have been made separately and have not been directly 
compared.  
 
The aim of this chapter is to compare the generation and motility of serum-free and serum-
containing fibrocytes and to look at the effect serum has on serum-free derived fibrocytes. Due 
to our own observations, and the differences seen between the two types of fibrocytes 
described in the literature, the percentage and number of fibrocytes generated in both media 
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types were investigated in both PBMC and CD14+ selected cultures. PBMC were isolated and 
plated out at 1x106cells/ml in both serum-free and serum-containing fibrocyte media and on 
day 4 (96 hours), the non-adherent cells washed out and the media replaced. CD14+ cells were 
positively selected using magnetic beads selection (see materials and methods) from PBMC and 
plated out at 2x105cells/ml in both serum-free and serum-containing fibrocyte media. The 
number of fibrocytes were calculated at day 11 from triplicate wells (Figure 4.1). 
 
Figure 4.1 Number of fibrocytes differentiated in serum-free and serum-containing fibrocyte 
media from either PBMC or CD14
+
 selected cells. a. The number of fibrocytes differentiated in 
serum-free and serum-containing fibrocyte medium from isolated PBMC, plated out at 
1x106cell/ml and counted at day 11, mean is indicated (n = 16). b. The number of fibrocytes 
differentiated in serum-free and serum-containing fibrocyte medium from positively selected 
CD14+ cells, plated out at 2x105cell/ml and counted on day 11, mean is indicated (n = 6). 
Wilcoxon signed rank nonparametric test of significance performed on each.  
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When using the Wilcoxon signed rank nonparametric statistical test to compare the number of 
fibrocytes seen to differentiate in the two different media types the results were significantly 
different for fibrocytes differentiated from both PBMC and CD14+ selected cells. Significantly 
more fibrocytes were seen to differentiate in serum-free fibrocyte media compared to serum-
containing media when differentiated from PBMC. However in contrast significantly more 
fibrocytes differentiated in serum-containing fibrocyte media compared to serum-free when 
generated from CD14+ selected cells. This suggests that fibrocytes differentiated in the two 
types of media are not the same cell type, as they are acting differently under the same 
conditions.  
 
4.2 Donor Variability 
In the course of working on fibrocytes it has become obvious that there is a large donor to 
donor variation on the number of fibrocytes that will differentiate, which has been observed in 
both serum-free and serum-containing fibrocyte medium. PBMC isolated from some donors 
have the capacity to produce a high number of differentiated fibrocytes, whereas other donors 
produce a very low number. The donor variability of fibrocytes differentiated from PBMC in 
serum-free fibrocyte media is illustrated in figure 4.2. 
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Figure 4.2 Donor variability of serum-free derived fibrocytes. The number of fibrocytes 
differentiated in serum-free fibrocyte medium from isolated PBMC plated out at 1x106cell/ml 
and counted at day 11 for 24 donors. If an error bar is present it represents the mean and 
standard deviation for more than 1 culture from that donor. No error bar indicates n = 1 for that 
donor. Hashed bars indicate females and solid bars male; colour represents age range of donor. 
 
Cultures were set up at 1x106cells/ml in serum-free fibrocyte media and the number of 
fibrocytes calculated at day 11. Hashed bars depict females, and solid bars males; the colours 
indicate different age ranges. If an error bar is shown the bar on the graph represents the mean 
and standard deviation for multiple readings for that donor. No error bar indicates the results of 
an n=1. A large variability in the number of fibrocytes differentiating is seen within healthy 
donors that does not seem to correspond to age or sex.  
 
Figure 4.3 shows the donor variability for fibrocytes differentiated in serum-containing fibrocyte 
medium from CD14+ selected cells. As with the donor variability seen in serum-free derived 
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fibrocytes there is a large variation in the number of fibrocytes which will differentiate from 
different donors. This variability does not appear to be related to age or sex of the donor and no 
other quantified features within the donors appeared to account for it.  
 
 
Figure 4.3 Donor variability of serum-containing derived fibrocytes. The number of fibrocytes 
differentiated in serum-containing fibrocyte medium from positively selected CD14 cells plated 
out at 2x105cell/ml and counted at day 11 for 8 donors. If an error bar is present represents 
mean and standard deviation for more than 1 culture from that donor. No error bar indicates 
n=1 for that donor. Hashed bars indicate females and solid bars male; colour represents age 
range of donor. 
 
4.3 Motility of fibrocytes 
Observations made when looking at serum-free and serum-containing fibrocytes by time-lapse 
photography suggested that the serum-containing fibrocytes were more motile than the serum-
free fibrocytes. To analyse this three cultures of serum-free fibrocytes, differentiated from 
PBMC, and three cultures of serum-containing fibrocytes, differentiated from CD14+ selected 
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cells, were prepared and photographs taken of the cultures every five minutes for six hours, the 
resulting photographs were used to produce time-lapse videos. Three cultures of macrophages 
were also prepared and documented in the same way. A video analysis package was used to 
calculate the speed of 10 cells from each video in µm/hour. To do this the XY position of each of 
10 cells in the frame were recorded every three frames (every 15 minutes), and their movement 
was calculated from their change in location. Examples of the movement of three of the ten cell 
analysed in each of the serum-free fibrocyte cultures are shown in figure 4.4, and serum-
containing in figure 4.5. The movement in µm from their position at time 0hr is shown for 6 
hours. Examples of the movement of three of the ten cell analysed in each of the macrophages 
cultures are shown in figure 4.6. 
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Figure 4.4 Examples of motility of serum-free differentiated fibrocytes. Three time-lapse 
photography videos, each of 6 hours in length involving photographs taken every 5 minutes 
were made of three separate serum-free fibrocyte cultures. Videos were made at day 11 after 
culturing PBMC in serum-free fibrocyte medium, on glass chamber slides, at 1x106cells/ml, non-
adherent cells removed at 96 hours. The movement over 6 hours is shown in µm from their 
position at time 0hr for three of the ten cells analysed in each video. For videos see 
supplementary figures S1-S3. 
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Figure 4.5 Examples of motility of serum-containing differentiated fibrocytes. Three time-lapse 
photography videos, each of 6 hours in length involving photographs taken every 5 minutes 
were made of three separate serum-containing fibrocyte cultures. Videos were made at day 11 
after culturing CD14+ selected cells, on glass chamber slides, in serum-containing fibrocyte 
medium at 2x105cells/ml. The movement over 6 hours is shown in µm from their position at 
time 0hr for three of the ten cells analysed in each video. For videos see supplementary figures 
S4-S6. 
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Figure 4.6 Examples of motility of macrophages. Three time-lapse photography videos, each of 
6 hours in length involving photographs taken every 5 minutes were made of three separate 
macrophage cultures. Videos were made at day seven after culturing PBMC in macrophage 
medium on glass chamber slides, at 1x106cells/ml, non-adherent cells removed at 96 hours. The 
movement over 6 hours is shown in µm from their position at time 0hr for three of the ten cells 
analysed in each video. For videos see supplementary figures S7-S9. 
 
To calculate the level of motility of each time-lapse video the average speed of the 10 cells was 
calculated. Despite the initial suggestions that serum-containing fibrocytes were more motile 
than the serum-free fibrocytes figure 4.7 shows this is not the case. There is more variation in 
the level of motility seen in the serum-containing fibrocyte cultures, which may be why the 
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initial suggestion was made, however the mean speed is no different to that of the serum-free 
fibrocytes. Both types of fibrocytes were more motile than the macrophages however, although 
not significantly. 
 
Figure 4.7 Motility of serum-free, serum-containing fibrocytes and macrophages. Time-lapse 
photography videos, each of 6 hours in length involving photographs taken every 5 minutes 
were made of separate cultures of each of serum-free, serum-containing fibrocytes and 
macrophages, cultured on glass chamber slides. Videos were made at day seven for the 
macrophages and day 11 for the fibrocytes. The graph represents the average speed of 10 cells 
from each video.  
 
For videos see supplementary figures S1-S3 for serum-free fibrocytes, S4-S6 for serum-
containing fibrocytes and S7-S9 for macrophages, all found on the disc accompanied with this 
thesis.  
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4.3 Effect of serum-containing medium on serum-free derived 
fibrocytes 
The main difference in the generation of serum-free and serum-containing fibrocytes is the 
presence of serum in the media. If, as the literature suggests, these are the same cell type, just 
generated by different protocols then once differentiation has occurred the serum-free 
fibrocytes should survive in a serum-containing media and the serum-containing fibrocytes in a 
serum-free media.  
 
To investigate this serum-free fibrocytes and serum-containing fibrocytes were differentiated 
from PBMC in 96-well plates. Enough wells were set up for five conditions with three replicate 
wells of each to ensure as precise a fibrocyte count as possible for both media types. At day 4 all 
wells had their non-adherent cells washed out and the media replaced. At days 4, 7, 11 and 14 
the average number of fibrocytes in every set of triplicate wells were calculated, one set then 
had its media changed, either serum-free to serum-containing medium or serum-containing to 
serum-free medium. At days 5, 8, 12, 15 and 18 the average number of fibrocytes in every set of 
triplicate wells was again calculated to see any overnight changes from the change in media. 
One set remained in the initial medium throughout to act as a control.  
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Figure 4.8 Effect of switching medium on fibrocytes differentiated from PBMC. PBMC were set 
up in either serum-free or serum-containing fibrocyte media, at 1x106cell/ml. At day 4 the non-
adherent cells were washed out. On the day indicated (dashed line) the media was replaced 
with the opposite and the number of fibrocytes counted on days 4, 5, 7, 8, 11, 12, 14, 15 and 18. 
Cultures in serum-free fibrocyte media are indicated in red and serum-containing in blue. Mean 
and standard deviation shown for three wells of each condition (representative of n=3 
experiments). 
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The left hand side of figure 4.8 indicates that whichever time point serum-free fibrocyte media 
was switched to a serum-containing media the number of fibrocytes dropped to almost zero 
within 24 hours and did not recover for the duration of the experiment. However in the reverse, 
switching cultures in serum-containing fibrocyte media into serum-free media the same effect 
was not seen, the serum-containing fibrocytes appeared to be completely unaffected by the 
change of media. These effects were also observed when the cultures were set up from CD14+ 
selected cells in both media types, figure 4.9.  
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Figure 4.9 Effect of switching medium on fibrocytes differentiated from CD14
+
 cells. CD14+ 
selected cells were set up in either serum-free or serum-containing fibrocyte media, at 
2x105cell/ml. On the day indicated (dashed line) the media was replaced with the opposite and 
the number of fibrocytes counted on days 4, 5, 7, 8, 11, 12, 14, 15 and 18. Cultures in serum-
free fibrocyte media are indicated in red and serum-containing in blue. Mean and standard 
deviation shown for three wells of each condition (representative of n=3 experiments). 
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As well as the lack of serum, serum-free and serum-containing medium also differ in the types 
of media they are made up in, RPMI 1640 in the case of serum-free medium and DMEM in the 
case of serum-containing medium. To establish if it is the type of media, or the presence of 
serum in the serum-containing fibrocyte media that is causing this loss of fibrocyte morphology 
in serum-free derived fibrocytes various combinations of the two medium were made up. A 
serum-free media was made using DMEM as a base, and a serum-containing fibrocyte medium 
using RPMI 1640 as a base. PBMC were plated out at 1x106cells/ml in serum-free fibrocyte 
media and the non-adherent cells washed out at day 4. At day 11 one set of three wells were 
left untouched, one changed to serum-free fibrocyte media and one to serum-free DMEM 
media, all of which were counted on days 11, 12, 14 and 18 and the number of fibrocytes 
remained steady, with the change in media having little or no effect. However those wells which 
were switched into either serum-containing fibrocyte media or serum-containing RPMI 1640 
saw a loss in fibrocyte morphology within 24 hours which did not recover for the duration of the 
experiment (Figure 4.10). This suggested that it is the addition of serum to serum-free cultures 
and not, either the effect of changing the media, or the base the media is made up in (RPMI 
1640 or DMEM) which is causing this loss in fibrocyte morphology. In the same experimental 
setting FCS and human serum were added to different serum-free fibrocyte cultures and, again, 
the number of fibrocytes dropped within 24 hours and did not recover for the duration of the 
experiment either, validating our observation that the loss of cells with a fibrocyte morphology 
is due to the presence of serum (figure 4.10). 
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Figure 4.10 Control experiment to ensure change in fibrocyte morphology is due to addition of 
serum. PBMC were cultured for 11 days in serum-free fibrocyte medium then treated with 
various control conditions. The number of fibrocytes were counted before and after treatment. 
Mean and standard deviation shown for three wells of each condition (representative of n=3). 
 
To observe the effect serum-containing fibrocyte media has on serum-free fibrocytes a culture 
of serum-free fibrocytes had its media changed to serum-containing media immediately before 
being videoed using time lapse photography, with photographs taken every five minutes for 4 
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hours (supplementary figure S10). Figure 4.11 illustrates, using video stills, that the loss in 
fibrocyte morphology following treatment with serum-containing fibrocyte medium occurs 
within 4 hours, and that this loss is due to the cells rolling up. 
 
Figure 4.11. Fibrocytes differentiated in serum-free fibrocytes medium were changed to 
serum-containing fibrocyte medium and videoed. a. Still of video at 0hr. b. 2hr. c. 4hrs with 
four cells highlighted. Following the change in medium all the cells have shrunk by 2hrs and 
completely rolled up by 4hrs (representative of n=3). See supplementary figure S10 for video. 
 
4.4 Treating serum-free derived fibrocytes with serum 
As both FCS and human serum appeared to have the same effect on the number of serum-free 
derived fibrocytes in culture following serum-containing media treatment this was also looked 
at using time lapse photography. PBMC were plated out in serum-free fibrocyte media and non-
adherent cells washed out at day 4. At day 11 serum was added straight to the cultures, for a 
final concentration of 20%, as used in the serum-containing fibrocyte media. FCS and human 
serum were tested, both untreated and heat inactivated (56oC for 30 minutes). The effect of the 
serum was observed using time lapse microscopy and the serum added immediately before 
photographs began to be taken. Photographs were taken every five minutes for two and half 
hours and in all conditions FCS, human serum, untreated or heat inactivated, a loss of fibrocyte 
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morphology was seen within the two and half hour time frame. Figure 4.12 shows stills from a 
time-lapse video, every 30 minutes for a serum-free fibrocyte culture treated with FCS at time 0 
hours. Four cells are indicated and by two and half hours (150 minutes) all have rounded up. See 
supplementary figure S11 for video.  
 
Figure 4.12 Effect of FCS on serum-free fibrocytes. PBMC cultured in serum-free fibrocyte 
media treated with FCS, for a final concentration of 20%. Photographs taken every 5 minutes for 
2½ hours. Stills shown for every 30 minutes and the same four cells indicated in every still (n=1). 
Scale bar indicates 100µm. See supplementary figure S11 for video. 
 
Figures 4.13, 4.14 and 4.15 show stills of serum-free fibrocytes treated with heat-inactivated 
FCS, human serum and heat-inactivated human serum respectively. The cells were treated 
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immediately before photographs were taken and four cells followed throughout the two and 
half hour time frames. 
 
 
Figure 4.13 Effect of heat-inactivated FCS on serum-free fibrocytes. PBMC cultured in serum-
free fibrocyte media treated with heat-inactivated FCS, for a final concentration of 20%. 
Photographs taken every 5 minutes for 2½ hours. Stills shown for every 30 minutes and the 
same four cells indicated in every still (n=1). Scale bar indicates 100µm. See supplementary 
figure S12 for video. 
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Figure 4.14 Effect of human serum on serum-free fibrocytes. PBMC cultured in serum-free 
fibrocyte media treated with human serum, for a final concentration of 20%. Photographs taken 
every 5 minutes for 2½ hours. Stills shown for every 30 minutes and the same four cells 
indicated in every still (n=1). Scale bar indicates 100µm. See supplementary figure S13 for video. 
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Figure 4.15 Effect of heat-inactivated human serum on serum-free fibrocytes. PBMC cultured 
in serum-free fibrocyte media treated with heat-inactivated human serum, for a final 
concentration of 20%. Photographs taken every 5 minutes for 2½ hours. Stills shown for every 
30 minutes and the same four cells indicated in every still (n=1). Scale bar indicates 100µm. See 
supplementary figure S14 for video. 
 
The length of the four cells indicated in figures 4.12 - 4.15 were measured, using the Image pro-
plus analysis package, every three frames (15 minutes). The lengths of four cells in an untreated 
serum-free fibrocyte control video were also measured. Figure 4.16 shows the length of each of 
these cells over time following treatment with serum at day 11. As illustrated by figures 4.12 - 
4.15, figure 4.16 shows that all cells had rolled up within 150 minutes (two and half hours) by 
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the fact that their lengths reduced quickly following treatment. Whereas the length of the cells 
in the control video, with no treatment, changed very little over time.  
 
 
Figure 4.16 Change in length of serum-free fibrocytes treated with serum over time. PBMC 
cultured in serum-free fibrocyte media either (a) untreated or treated with (b) FCS, (c) human 
serum, (d) heat-inactivated FCS or (f) heat-inactivated human serum, for a final concentration of 
20% (n=1). Photographs taken every 5 minutes for 2½ hours. Length of four cells recorded every 
15 minutes for 150 minutes for each treatment. 
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The effect that serum has on fibrocyte morphology can also be titrated out, in figure 4.17 the 
number of fibrocytes seen following treatment with FCS as a percentage of the number of 
fibrocytes before treatment is shown. Serum free fibrocytes were differentiated from PBMC, 
non-adherent cells washed out at day 4 and the number of cells calculated on day 11 for each 
set of three wells. FCS was then added to four of the five sets of wells for final concentrations of 
1%, 5%, 10% and 20%. Twenty four hours later the number of fibrocytes were counted again 
and the percentage difference calculated. Although any serum caused a loss in fibrocyte 
morphology we can see the effect increases with the amount of serum added until 
approximately 10%. Therefore whatever protein constituent of serum is having an effect has so 
gradually, and perhaps needs a certain level to cause a complete loss in fibrocyte morphology. 
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Figure 4.17 Number of serum-free fibrocytes following a titration of serum. PBMC cultured in 
serum-free fibrocyte media and at day 4 non-adherent cells washed out. At day 11 all sets of 
three wells were counted. FCS was then added for final concentrations of 1, 5, 10 or 20%, three 
wells per condition. 24 hours later number of fibrocyte counted again and percentage 
difference compared to before treatment calculated, n = 1. 
 
4.5 Effect of serum-containing media on marker expression of serum-
free fibrocytes 
We have previously demonstrated that the loss of fibrocyte morphology following the 
treatment of serum-free fibrocytes with serum is due to them rolling up, however the cells do 
not appear to detach and die as an increase in debris within the culture was not observed, 
neither was a reduction in the number of attached cells, just the number of spindle shaped 
ones. Therefore the question arises of whether the rolled up cells remain fibrocytes, expressing 
both haematopoietic and stromal markers, or whether they are de-differentiating when rolling 
up. To address this serum-free fibrocytes were cultured from PBMC in eight wells of two 8 well 
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chamber slides, the non-adherent cells washed off at day 4 and at day 11 all the wells of one 
chamber slide had their medium changed to serum-free fibrocyte media and the other to 
serum-containing fibrocyte medium. Figure 4.18 shows the average number of fibrocyte per 
well, for the eight wells which had their media changed from serum-free medium to either 
serum-free or serum-containing, before and after treatment.  
 
 
Figure 4.18 Effect of changing media of serum-free generated fibrocyte to either serum-free or 
serum-containing fibrocyte medium. PBMC were cultured in two 8 well chamber slides in 
serum-free fibrocyte media. At day 11 the number of fibrocytes were calculated in every well 
and the mean fibrocyte number calculated for each chamber slide. All wells of one chamber 
slide had their media changed to serum-free fibrocyte medium and all wells of the other 
chamber slide to serum-containing fibrocyte medium. 24 hours later the mean number of 
fibrocytes per well on each slide was calculated again. Mean and standard deviation of the 
number of fibrocytes in all eight wells for each treatment shown. *Mann-Whitney non-
parametric significance test performed on data from each chamber slide.  
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Those wells which had their media changed from serum-free to serum-free media had 
approximately the same number of fibrocytes in 24 hours later. However those wells which had 
their media changed from serum-free to serum-containing media had significantly less 
fibrocytes following treatment, using the Mann-Whitney non-parametric test of significance. At 
day 12 all media was removed from all wells and the cultures washed and fixed for 
immunostaining. Each condition was stained for the markers vimentin, fibronectin, CD68, CD45 
and matched irrelevant controls as described in methods and materials. Figure 4.19 
demonstrates that, when looking at just these markers, fibrocytes which have rolled up have 
the same expression profile as spindle shaped fibrocytes.  
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Figure 4.19 Effect of changing media of serum-free generated fibrocyte to either serum-free or 
serum-containing fibrocyte medium. PBMC were cultured in two 8 well chamber slides in 
serum-free fibrocyte media. At day 11 all wells of one chamber slide had their media changed to 
serum-free fibrocyte medium and all wells of the other to serum-containing fibrocyte medium. 
24 hours later the cultures were washed and fixed for staining. The markers vimentin, 
fibronectin, CD68 and CD45 were all looked at and all seen to be expressed in both conditions. 
Nuclei are shown in blue, vimentin staining in green and all the rest in red. Scale bar indicates 
50µm. 
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Fibrocytes which have rolled up morphologically look very similar to macrophages and most 
importantly figure 4.19 shows that these cells still express fibronectin, which macrophages do 
not express (Figure 3.15). Further work needs to be done, specifically looking at the expression 
profile of fibrocytes which have rolled at a longer time point than 24 hours to see if they keep 
this expression profile or lose it, however current observations suggest that although rolled up 
serum-free fibrocyte treated with serum are still fibrocytes, at least for the first 24 hours. 
 
4.6 Determining what part of serum is causing the loss of fibrocyte 
morphology 
As discussed in the introduction the plasma protein SAP inhibits the differentiation of fibrocytes 
in a serum-free environment47, due to it binding to the Fcγ receptors48. We can hypothesise 
therefore that the factor in serum which is causing fibrocytes to roll up following treatment with 
serum is also SAP. SAP is an extremely stable protein known to be able to withstand high 
temperatures; and is a very large at 235kDa174. Some preliminary experiments have been 
performed to look into this hypothesis. Serum-free fibrocytes were differentiated from PBMC, 
at day 4 the non-adherent cells washed out and at day 11 the number of fibrocytes calculated 
for each set of three wells. A set of three wells were either left untreated or were treated with 
FCS, either normal or heat-treated for 1 hour at 60oC, 80oC or 100oC. The number of fibrocytes 
were counted 24 hours later and all FCS treatment, whether heat-treated or not caused a loss in 
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fibrocyte morphology (Figure 4.20), suggesting that the constituent of protein causing this effect 
on serum-free fibrocytes is extremely heat stable.  
 
Figure 4.20 Effect of heat-treated FCS on serum-free generated fibrocyte. PBMC were cultured 
in serum-free fibrocyte media, at day 4 non-adherent cells were washed out. At day 11 all sets 
of three wells were counted and then each set either left untreated or treated with FCS which 
had either not been heat treated or had been treated to 60oC, 80oC and 100oC for one hour. 24 
hours later the number of fibrocyte were counted again and the percentage difference 
compared to before treatment calculated, n=1. 
 
To establish the approximate size of the protein having the effect we have observed on serum-
free fibrocytes FCS was fractionated using various filters. A high molecular weight aliquot was 
obtained containing proteins of > 100,000Da (portion we would expect SAP to be in). A medium 
weight aliquot of < 100,000Da, > 50,000Da and a low weight aliquot of < 50,000Da were also 
tested. Serum-free fibrocytes were differentiated from PBMC, at day 4 the non-adherent cells 
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washed out and at day 11 the number of fibrocytes calculated for each set of three wells. A set 
of triplicate wells were either left untreated, treated with un-fractionated serum or treated with 
the different molecular weight aliquots of serum listed above. As figure 4.21 shows only the un-
fractionated serum and high molecular weight aliquot caused a loss of cells with fibrocyte 
morphology, suggesting it is a high molecular weight molecule/particle which is causing this loss 
in fibrocyte morphology. 
 
Figure 4.21 Effect of fractionated FCS on serum-free generated fibrocyte. PBMC were cultured 
in serum-free fibrocyte media, at day 4 non-adherent cells were washed out. At day 11 all sets 
of three wells were counted and then each set either left untreated, treated with un-
fractionated FCS or treated with three aliquots of fractionated FCS, > 100,000Da, < 100,000Da 
but > 50,000Da or < 50,000Da. 24 hours later the number of fibrocyte were counted again and 
the percentage difference compared to before treatment calculated, n=1. 
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However when serum-free fibrocytes were treated with commercially available SAP at either 
1µg/ml or 0.5µg/ml on day 11 a loss of fibrocyte morphology was not seen (Figure 4.22), despite 
fibrocyte differentiation being inhibited by the SAP when added at day 0 (Figure 4.23). PBMC 
were cultured in serum-free fibrocyte media, and at day 4 the non-adherent cells washed out. 
The commercial SAP is stored in EDTA therefore as a control separate serum-free fibrocyte 
cultures were also treated with equivalent amounts of EDTA to ensure it was not having an 
effect. The number of serum-free fibrocytes after treatment with either 1µg/ml or 0.5µg/ml SAP 
or EDTA controls, as a percentage of before treatment, show that neither the SAP nor EDTA had 
any effect on fibrocyte morphology as all were over 85%. 
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Figure 4.22 Effect of SAP and EDTA equivalents on serum-free generated fibrocyte. PBMC 
were cultured in serum-free fibrocyte media, at day 4 non-adherent cells were washed out. At 
day 11 all sets of three wells were counted and then either treated with SAP at 1µg/ml or 
0.5µg/ml, or EDTA controls. 24 hours later the number of fibrocyte were counted again and the 
percentage difference compared to before treatment calculated, n = 1. 
 
However, in the same experiment a control was set up in which either 1µg/ml or 0.5µg/ml of 
SAP, or equivalent amounts of EDTA, were added to serum-free fibrocyte cultures at day 0. 
These showed the SAP inhibiting fibrocyte differentiation, whereas the EDTA did not, when 
looking at the number of fibrocytes in a treated well as day 11 as a percentage of the number of 
fibrocytes in an untreated well at day 11 (Figure 4.23). Suggesting that the commercial SAP is 
active but cannot cause a loss of fibrocyte morphology if given once fibrocytes have 
differentiated. However further work is required as these are all only n=1 experiments. 
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Figure 4.23 Effect of SAP and EDTA equivalents on PBMC cultured in serum-free fibrocyte 
medium. PBMC were plated out in serum-free fibrocyte media, 3 wells were treated with either 
SAP at 1µg/ml or 0.5µg/ml, EDTA controls or left untreated. At day 4 the non-adherent cells 
were washed out and at day 11 the number of fibrocytes in each set of three wells counted. The 
percentage difference between the treated and untreated wells were calculated, n=1. 
 
4.7 Discussion of chapter 
Although it is not mentioned within the literature this chapter demonstrates that the ability of 
different ‘normal’ donors to produce both serum-free and serum-containing fibrocytes is highly 
variable. PBMC and CD14+ cell samples from some donors produced many fibrocytes however 
others produce very few; this is seen consistently throughout the donors used in this thesis and 
does not appear to be influenced by age, or sex of the donor, although no statistical analysis of 
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this has been completed (Figure 4.2, 4.3). There may be other factors that are affecting these 
donors that have not been measured in this thesis however. For example one donor, who was 
noted as not producing many fibrocytes in vitro, is known to suffer very badly with hay fever, 
which may in turn be affecting the monocytes ability to differentiate into fibrocytes. However 
this is all speculation, and the extent of the allergen responses of other donors whose 
peripheral blood was unable to differentiate fibrocytes was not determined. 
 
Serum-free and serum-containing derived fibrocytes are described as being the same cell type. 
In this chapter significantly more serum-free derived fibrocytes were generated from PBMC 
than serum-containing; whereas significantly more serum-containing derived fibrocytes were 
generated than serum-free from CD14+ selected cells (Figure 4.1) when cell numbers were 
counted based on morphology. We could speculate that following CD14+ selection something is 
lacking in the serum-free culture, leading to less cell differentiation; this observation is 
supported by the literature as both T cells and the cytokines IL-4 and IL-13 have been reported 
as being important in fibrocyte differentiation45;46;103. In contrast more fibrocytes differentiated 
in serum-containing fibrocyte media following CD14+ selection compared to PBMC could 
suggest that something within the PBMC is inhibiting fibrocyte differentiation, and once 
removed many more fibrocytes are allowed to differentiate. This is supported by reports 
published by Labet et al in 1991 that suggested that T cells prevent fibrocyte differentiation, in 
contrast to the reports mentioned previously85;86. Of course another possibility is that the 
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positive selection for CD14+ cells is having a signalling effect on the precursor cells, causing this 
increased fibrocyte differentiation in serum-containing fibrocyte media.  
 
The monocyte population CD14+CD16- is reported to release IL10 due to the interaction of the 
receptor CD14 with its ligand LPS in vitro55. The release of IL10 is reported as down regulating 
TH1 specific cytokines
175, which have been shown to inhibit fibrocyte differentiation,103 
therefore perhaps the interaction of the CD14 microbeads with the CD14 receptor is signalling 
to produce this chain of events that promotes fibrocyte differentiation. However we only see 
this in the case of serum-containing derived fibrocytes, not the serum-free, which may indicate 
other factors, not present in the CD14+ fraction of PBMC are required to get the same level of 
serum-free derived fibrocyte differentiation. 
 
When looking at the motility of fibrocytes analysis has shown that neither is more motile than 
the other, although both slightly more than macrophages (Figure 4.7). Compared to other 
haematopoietic cell populations however all three cell types tested moved very little with the 
mean speed being less than 25µm/hour (figure 4.7). The speed of un-treated neutrophils is 
reported as being between 17 ± 11 µm/minute176 (1020 µm/hour) and 2000 ± 310 µm/hour177. 
The speed of un-treated granulocytes at 13.3 ± 2.8 µm/minute (816 µm/hour)178, and un-
treated monocytes at 1.8 ± 0.3µm/minute (108 µm/hour)178. In this thesis the distance moved 
by these cells is calculated by their change in XY position between frames of the time lapse 
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video. To calculate the XY position the outer edge of the cell is drawn around and the central XY 
point of the shape set as the position of the cell, figure 4.24. 
 
  
Figure 4.24 Schematic of how XY co-ordinate is calculated in motility analysis. The cell being 
analysed is drawn around in each frame and the XY point calculated as the centre of the shape 
drawn.  
 
This works very well on round cells, however fibrocytes are spindle shaped, so a shuffle of their 
cytoplasm and nucleus would register as a movement even when the actual position of the cell 
has not changed. Also, as the length of fibrocytes can be anywhere between 300 and 800µm 
(based on own calculations see figure 4.17), an average movement of 25µm/hour is barely 
moving at all. Consequently the technique used here to measure movement is not ideal for use 
on cells of this shape and a more tailored way of measuring fibrocyte motility would be required 
to continue this work. A wound healing assay for example may be better, in which a ‘wound’ is 
made in a cell monolayer and a time lapse photography used to follow the process of repairing 
the ‘wound’. Having the stimulus of a wound to heal may cause the fibrocytes to be more 
active, so move more and any differences between them could potentially be identified. 
Following the correct environmental cues, the migration of these cells could be much more 
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rapid as they have been reported to respond to the chemokines CCL2 and CCL12 in mouse 
models of lung fibrosis124;126, and CCL21 in a mouse model of renal fibrosis130.  
 
Of course it is completely plausible that fibrocytes are really not very motile at all under any 
circumstances, if they are differentiating from monocytes in the tissue, at the site they are 
required, as is suggested49;111;123, then they don’t need to be able to move very far, other than 
around the site itself. Plus their long thin shape is not advantages for movement either. 
However if they remain a type of fibrocyte even when rolled up, expressing both 
haematopoietic and stromal markers, as figure 4.9 suggests, they may be more motile in that 
state, however further work into whether the expression of fibrocyte markers is retained over 
time once cells have lost their ‘fibroblast-like’ morphology is required.  
 
From looking at the time lapse videos it does appear that serum-containing fibrocytes are 
searching the area around them more, for example putting out more projections and perhaps 
looking for stimulus to move, however the technique used here to test their motility cannot 
quantify this as the main body of the cell doesn’t tend to move.  
 
When serum-free derived fibrocytes, generated from either PBMC or CD14+ selected cells, were 
treated with a serum-containing fibrocyte media they were observed to roll up within four 
hours and not return to their original shape, at least not within two weeks (length of time 
observations were made) (Figure 4.8, 4.9, 4.11). This was found to be due to the presence of the 
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serum in the media and not the media itself (RPMI 1640 verses DMEM), or the act of changing 
the media (Figure 4.10). When serum was added directly to a serum-free fibrocyte culture the 
same effect was seen whether the serum was human or bovine in origin, untreated or heat 
inactivated, suggesting that the constituent of serum having the observed effect is a heat stable, 
conserved protein or particle (Figures 4.10, 4.12-4.16). Although treatment with serum caused 
serum-free fibrocytes to roll up and lose their spindle shaped morphology they continued to 
express both hematopoietic and stromal markers, suggesting they were actually still fibrocytes 
(Figure 4.19) as other monocyte derived progeny, such as macrophages, did not express these 
stromal markers. It has been suggested that the presence of IgG molecules and other serum 
proteins, such as SAP, during the initial immune response would prevent fibrocyte outgrowth, 
however during the resolution phase, when these molecules are cleared from the site the lower 
levels of these complexes would allow for the differentiation of fibrocytes and so aid in tissue 
regeneration and wound healing138. This would clearly fit with what happens to the serum-free 
fibrocytes, and why, in the presence of serum molecules they roll up, and perhaps even become 
dormant until the environmental cues are present for them to aid in active wound healing.  
 
Fibrocytes which were differentiated in a serum-containing fibrocyte media have been reported 
as expressing antigen presenting cell markers such as HLA-DR and co-stimulatory molecules, and 
were able to stimulate T cell responses equivalent to those stimulated by dendritic cells91. The 
fact that we have found that serum-free and serum-containing fibrocytes react differently to 
serum may suggest that serum-containing derived fibrocytes are involved in the initial immune 
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response and the initiation of the wound healing process, along with other functions. The 
serum-free fibrocytes would appear as a second wave to continue with the process and wound 
healing and tissue regeneration as the environment changes. If the differentiation of serum-
containing derived fibrocytes is affected by the interaction of the receptor CD14 with its ligand 
LPS, it could support their presence quite early on at a site of inflammation, when LPS is possibly 
present.  
 
The observations made during the motility studies that serum-containing fibrocytes appear to 
‘search’ the area, putting out more projections than the serum-free fibrocytes would also fit 
with this hypothesis. If these cells are involved to some extent in other processes of an 
inflammatory site, such as T cell stimulation they would perhaps need to be more aware of their 
surrounding area. Whereas if the serum-free fibrocytes are appearing when the environment is 
much calmer they perhaps don’t need quite so vigilant to change.  
 
Preliminary experiments suggest that the constituent of serum causing this loss of fibrocyte 
morphology is very heat stable (Figure 4.20), and greater than 100,000DA in size (Figure 4.21), 
the same characteristics as SAP. However commercially available SAP does not appear to have 
the same effect on serum-free fibrocytes as serum does. When commercial SAP was given to 
differentiated fibrocytes at day 11 it did not cause them to roll up (Figure 4.22), as the serum 
had, however when given at day 0 it did prevent fibrocyte differentiation in the first place 
(Figure 4.23). A similar effect was seen in in vitro mouse studies by Haudek et al in 2008113 
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whereby the addition of SAP, once fibrocyte differentiation had taken place, had no effect on 
the cells. These are still preliminary experiments and would need to be repeated using both 
commercially available SAP and donor derived SAP. As well as SAP depleted serum to confirm 
that it isn’t actually another constituent of serum which is causing this lose in fibrocyte 
morphology, rather than SAP. However the current data suggest that although SAP can inhibit 
fibrocyte differentiation, it may not be responsible for the change in morphology seen when the 
cell is a fully formed fibrocyte. 
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5.0 CULTURING FIBROCYTES FROM SORTED 
MONOCYTE POPULATIONS 
5.1 Introduction 
Monocytes are a population of circulating leukocytes important in the innate immune system 
involved in linking inflammation and the innate portion of the immune system to the adaptive 
part. As discussed in the introduction, three subsets of monocytes have been defined, based on 
phenotype and chemokine expression. The majority of human monocytes, 80-90%, are 
identified as being CD14+ CD16-52, however two smaller populations of human monocytes have 
also been reported as CD16+ CD14lo and CD16+ CD14+ 51. These three populations of monocytes 
are thought to have different roles within the immune system40;51;53-55 and it has been suggested 
that some of these monocyte populations are more adept than others at differentiating into 
different progeny. Studies into the differentiation of osteoclasts from monocytes have found 
that the CD16- fraction of monocytes formed ten times as many osteoclasts as the CD16+ 
fraction44. Fibrocytes are reported as differentiating from the CD14+ fraction of PBMC45-49 and 
previous results reported in this thesis suggest that monocyte derived serum-free and serum-
containing fibrocytes are different cell types. Therefore whether they differentiate from the 
same, or different monocyte subsets could be informative on further analysing the differences 
seen between them. The aims of this chapter are to determine which population of monocytes 
both types of fibrocytes differentiate from. 
Chapter 5: Culturing Fibrocytes from sorted monocyte populations Marianne Fairclough 
 161
 
5.2 Cell sorting monocyte subsets 
Monocyte populations were isolated using fluorescence-activated cell sorting, as discussed in 
the materials and methods. Briefly PBMC were isolated and labelled with antibodies against 
human CD14, CD16 and CD56 surface markers. These cells were then put through a cell sorter 
and, using logical gating, the three monocyte populations identified by surface marker 
expression. Figure 5.1 illustrates the logical gating used when cell sorting monocyte subsets. 
Firstly, using a forward verses side scatter plot, monocytes were identified by their size and 
granularity and selected. A plot showing the expression of CD14 and/or CD56 on the selected 
cells was then used to isolate only the CD56- fraction of these cells, CD56 is expressed on natural 
killer cells (NK cells), which can be a similar size and granularity to monocytes, by gating out any 
CD56+ cells any of these cells included in the forward/side scatter gate are now excluded. 
Finally, by using both of these gates, three populations of monocytes expressing combinations 
of both CD14 and CD16 could be identified. 
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Figure 5.1 Logical gating when sorting monocyte populations from PBMC. To sort monocyte 
populations PBMC were antibody stained with the surface makers CD14, CD16 and CD56, these 
cells were then put through a cell sorter. To identify the required cell populations firstly 
monocytes were gated on using forward and side scatter properties. The CD56/CD14 expression 
of cells within this gate were then looked at and a second gate made around the CD56 negative 
population. The expression of CD14/CD16 cells were looked on cells which fell within both of 
these gates. Gates were drawn around the three populations of monocytes, CD14+CD16-, 
CD14+CD16+ and CD14loCD16+, and cells expressing each of these sets of markers sorted into 
separate populations.  
 
Having identified the three populations of monocytes these were sorted into separate 
populations and the purity of each population checked. Figure 5.2 illustrates the purity of an 
example sort, here the sample of the larger population of monocytes, CD14+ CD16-, was 99% 
pure, with the other two populations, CD14lo CD16+ and CD14+ CD16+, 97% and 87% pure 
respectively. 
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Figure 5.2 Purity check of sorted monocyte populations. Once the three populations of 
monocytes have been sorted, CD14+CD16-, CD14+CD16+ and CD14loCD16+, a small number of the 
sorted cells were run back through the machine to check the purity. In the case of the sort 
shown in this figure the CD14+CD16- population was 99% pure, the CD14loCD16+ population 97% 
pure and the CD14+CD16+ population 87% pure. An example of n = 17.  
 
For this work seventeen separate sorts were performed, with fifteen different donors, the purity 
of the CD14+CD16- populations were ≥98%, the CD14loCD16+ ≥85% and the CD14+CD16+ ≥80%. 
The lower purities for the two smaller populations were due to the proportion of PBMC they 
actually constituted. Total monocytes consist of between 5 and 10% PBMC50, however the large 
majority are the CD14+CD16- population. For the sort shown in figures 5.1 and 5.2 the 
percentage of CD14+CD16- cells of the total events was 4.5%, and for both CD14loCD16+ and 
CD14+CD16+ populations it was 0.9%. Sorting cells of such small proportions of the total 
population can make it very difficult to get high purities. However, although all CD14loCD16+ 
populations were at least 85% pure the mean purity across the seventeen sorts was actually 
93%; and the mean purity for the CD14+CD16+ population 89%. 
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5.3 Differentiating fibrocytes and macrophages from sorted monocyte 
populations 
Once the three populations of monocytes had been sorted as many conditions as possible were 
set up to differentiate fibrocytes or macrophages. Ideally three wells for each population were 
set up in a 96 well flat bottomed plate in either serum-free, serum-containing fibrocyte medium 
or macrophage media. However this was not always possible due to cell number constraints so 
although cells were always set up at 2x105cells/ml, determined as the ideal cell concentration 
using CD14+ selected cells (Figure 3.9), not all conditions were always set up.  
 
As a control PBMC, taken before sorting, were also set up in each media type at 1x106cells/ml 
and at day 4 the non-adherent cells washed out of these cultures. Figure 5.3 shows photographs 
of each culture condition at day 11 for an example sort to demonstrate the differentiation of 
fibrocytes and macrophages from each population. 
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Figure 5.3 Photographs of differentiated fibrocytes and macrophages from sorted monocyte 
populations. Once the three populations of monocytes have been sorted, CD14+CD16-, 
CD14+CD16+ and CD14loCD16+, they were plated out at 2x105cell/ml in either serum-free, 
serum-containing fibrocyte media or macrophage media. As a control matched PBMC were also 
plated out and the non-adherent cells washed out at day 4. At day 11 an example of each 
culture was photographed. Scale bar indicated 100µm. Example of n = 17 shown. 
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Figure 5.3 demonstrates that each population of monocytes, as well as PBMC differentiated into 
macrophages, identified by their fried egg-like appearance. However the monocyte population 
CD14loCD16+ did not differentiate into fibrocytes in either the serum-free or serum-containing 
fibrocyte medium, whereas both CD14+CD16- and CD14+CD16+ populations did. For this 
particular donor serum-containing fibrocytes were also not seen to differentiate from PBMC, as 
discussed previously in chapter 4.  
 
As well as photographs at day 11 the number of fibrocytes or macrophages in each culture 
condition were calculated, based on cell morphology and as an average of triplicate wells, the 
results are seen in figure 5.4.  
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Figure 5.4 Number of fibrocytes and macrophages differentiated from sorted monocyte 
populations. Once the three populations of monocytes have been sorted, CD14+CD16-, 
CD14+CD16+ and CD14loCD16+, they were plated out at 2x105cell/ml in either serum-free, 
serum-containing fibrocyte media or macrophage media. At day 11 the number of fibrocytes 
and macrophages were counted based on morphology. Closed circles indicates fibrocytes, open 
circles macrophages (at least n=6 for each condition). Mann-Whitney, non-parametric, paired 
statistical test used.  
 
In figure 5.4 cells of a fibrocyte morphology are shown with closed circles and cells of a 
macrophage morphology shown as open circles. Cells differentiated in serum-free fibrocyte 
media are shown in red, serum-containing in blue and macrophage media in black. The 
observation that neither serum-free, or serum-containing fibrocytes differentiate from the 
CD14loCD16+ population of monocytes made when looking at the photographs in figure 5.3 were 
confirmed in the counting data from each culture. By using the Mann-Whitney non-parametric 
paired test for significance significantly more fibrocytes were seen to differentiate in both 
serum-free and serum-containing fibrocyte medium from both the CD14+CD16- and CD14+CD16+ 
populations of monocytes, compared to the CD14loCD16+ population. Despite all three 
populations giving comparable numbers of differentiated macrophages. Also to note is that very 
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few fibrocytes were seen to differentiate in macrophage medium, significantly less than the 
number of macrophages from each population.  
 
5.4 Discussion of chapter 
Three populations of monocyte can be purified from PBMC based on size, granularity, and the 
surface markers CD56, CD14 and CD16. Once sorted these monocyte populations were plated 
out in serum-free, serum-containing fibrocyte medium and macrophage medium, and at day 11 
the number of differentiated cells calculated. Significantly more fibrocytes were seen to 
differentiate from both the CD14+CD16- and CD14+CD16+ populations in both fibrocyte medium 
compared to the CD14loCD16+ population, despite all three populations being able to 
differentiate into macrophages (Figure 5.4), illustrated in figure 5.3. Although serum-free and 
serum-containing fibrocytes appear to be different cell types, based on the data discussed in 
chapter 4, they both differentiate from the same two subsets of monocytes (CD14+CD16-, CD14+ 
CD16+), and interestingly neither from the third (CD14lo CD16+). 
 
Although the origin of fibrocyte differentiation has not been examined in the literature in the 
same way as it is here, the population of monocytes that fibrocytes differentiate from is 
discussed as being the CD14+CD16- fraction47;48;145. Although a number of papers have shown 
that CD14+ cells are required for fibrocyte differentiation45;46;48 they do not necessarily show 
that fibrocytes do not differentiate from CD16+ cells which also express CD14, or to the extent 
that CD14+ expression is required, as the third monocyte population looked at in this chapter 
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actually has a low expression of CD14 rather than none at all. The population of monocytes that 
differentiates into fibrocytes is known to express the FCγ receptors FCγR1(CD64) and FCγRII 
(CD32), as the interaction of these receptors with a ligand inhibits fibrocyte differentiation48, 
both the CD14+CD16- and CD14+CD16+ populations have been described as expressing these 
receptors61. The data presented in this thesis supports these findings by showing that it is the 
level of CD14 that is the defining marker of fibrocyte precursors and that CD16 does not affect 
this process.  
 
As osteoclasts have also been described as differentiating from a particular subset of monocytes 
(CD16-)44 these data suggests that the differentiation potential of monocytes is different for the 
different subsets. Although all three subsets were able to differentiate into macrophages it may 
be that as the monocytes role within the immune system itself changes as does its ability to 
differentiate into different progeny, this has previously been suggested to explain the 
heterogeneity seen in monocyte populations. As the monocytes develop and mature in the 
blood they can be recruited to the tissue at various points in this maturation and the point they 
leave the blood and enter the tissues may actually define their ability to differentiate into 
different progeny179;180.  
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6.0 TRANSCRIPTOME ANALYSIS  
6.1 Introduction 
As discussed previously fibrocytes are haematopoietic cells with a spindle shaped, fibroblast-like 
morphology45;47;48;87;90;91;103. Two methods of differentiating these cells are both widely used 
within the literature, either in the absence47;48;103 or presence45;87;90;91 of serum. Data in this 
thesis so far suggests that, although very similar, fibrocytes differentiated by these two methods 
may represent different forms of the same cell type. .To look at this in more detail the mRNA 
profiles, or transcriptomes, for both serum-free and serum-containing fibrocytes were 
examined, comparing them to each other as well as another monocyte derived progeny, 
macrophages and in vitro derived fibroblast cell lines. 
 
6.2 Transcriptome analysis 
Transcriptome analysis is a form of analysis used to compare data at the population rather than 
the individual cell level. The majority of cells within the body start out with the same DNA, 
(exceptions being sperm and eggs and certain cells of the immune system) however it is the way 
this DNA is translated, and then transcribed into mRNA which determines the final 
differentiation state of a cell. Cells that receive the same biological cues will transcribe a similar 
set of genes and ultimately become very similar cells. The total gene set that these cells 
transcribe is called their transcriptome, therefore cells of the same population will have very 
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similar transcriptomes; and by comparing the transcriptomes of different cell populations 
important differences between them can be determined. Transcriptome analysis can also be 
used as a tool in research into diseases, with the potential to suggest therapeutic targets and 
diagnostic indicators. Work done by Ramilo et al in 2007 suggested that microarray analyses of 
patients peripheral blood leukocytes might assist in the differential diagnosis of infectious 
diseases160, as they found that leukocytes fighting diseases such as influenza A virus, gram-
negative (Escherichia coli) or gram-positive (Staphylococcus aureus and Streptococcus 
pneumoniae) bacteria had gene expression profiles which could be used to identify the 
infectious agent, therefore assisting in diagnosis160. Classification of certain types of cancer has 
also been improved by including transcriptome analysis as a tool. When looking at human acute 
leukaemia transcriptome analysis was found to easily discriminate between acute myeloid 
(AML) and acute lymphoblastic leukaemia (ALL)161, and work on large B-cell lymphoma (DLBCL), 
a clinically heterogeneous subtype of non-Hodgkin’s lymphoma, showed that by using 
transcriptome analysis previously undetected and clinically significant subtypes of cancer could 
be identified162. In 2009 transcriptome analysis of adrenocortical carcinomas identified 
differentially expressed genes associated with malignancy, survival and hormonal activity that 
will go on to be investigated as possible drug targets/diagnostic or prognostic markers181.  
 
DNA-binding regulatory proteins modulate which areas, or genes of the DNA are transcribed, or 
not, as they can act as both activators and repressors. There are only a finite number of these 
proteins that act all over the DNA, regulating the expression of a much larger number of genes, 
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allowing the cell to modify which genes are transcribed in response to exogenous stimuli. When 
the human and chimpanzee genomes were compared they were found to share 98.7% identity 
in genomic DNA sequences, however the two organisms are functionally diverse, illustrating 
how the way the DNA is translated has such a large effect on the final differentiation of 
individual cells and ultimately the development of an organism182. However, changes in the way 
an identical set of genes is regulated during differentiation will also have an effect on the total 
mRNA transcribed from the genome. These changes can be measured by microarray analysis 
and may help in determining lineage relationships between cell populations. By comparing the 
transcriptomes of fibrocytes to other monocyte derived progeny, such as macrophages, 
whether fibrocytes are a unique cell type, or just elongated macrophages, (which has also been 
discussed within the literature85;86) can be determined. By looking at the relationships of these 
two types of fibrocytes (serum-free and serum-containing) to macrophages, the question of 
whether there are two cell types or just one can also be examined. In some cases the literature 
suggests that fibrocytes are a possible precursor for fibroblasts124;145;183, this can be addressed 
by comparing these transcriptomes and looking at the lineage relationships between them. 
 
Transcriptome analysis of peripheral blood monocytes, and tissue resident macrophages and 
DCs from the lungs of mice has been preformed to look at the emigration and pulmonary 
differentiation of monocytes under non-inflammatory conditions184. They were able to identify 
differentially activated genetic programs in the circulating monocytes and their lung progeny. 
They found that lung DCs activated a diverse set of gene families, but largely preserved their 
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ability to emigrate, exhibiting a profile with high expression levels of integrin and 
chemokine/chemokine receptors. However, the macrophages down-regulated the same set of 
genes, but strongly up-regulated a distinct set of matrix metallopetidases, potentially involved 
in tissue invasion and remodelling184. This work demonstrates that despite differentiating from 
the same population the pulmonary DCs and macrophages are transcriptionally distinct under 
non-inflammatory conditions, and the differences between these cell types can be identified by 
using this tool. 
 
6.3 Aims of this chapter 
The aims of this transcriptome analysis study are to determine the transcriptional relationship 
of both serum-free and serum-containing fibrocytes to each other, and to in vitro derived, donor 
matched macrophages; and fibroblast cell lines. However the comparisons which are being 
performed will also have great importance in the levels of discrimination seen and this must be 
considered when interpreting the results. 
 
During the course of this analysis clustering of samples, based on their transcriptional 
characteristics will be used to look at the lineage relationships between the samples. The 
hierarchical cluster analysis uses Euclidean linkage to cluster samples based on their 
transcriptome, and illustrates their relationships in the form of a tree. Principal component 
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analysis also uses Euclidean linkage to cluster, however to illustrate the clusters it uses a three 
dimensional plot.  
 
As well as clustering based on the entire transcriptome a statistical analysis of microarrays 
(SAM) determines those genes that are significantly different between the populations . The list 
of significantly different genes can then be used to cluster the samples, and can potentially 
provide more accurate clustering. However the more genes found to be significantly different 
by SAM analysis does not necessarily mean the more variation there is between cell 
populations. Distantly related cells may be distinguishable by a small number of genes with 
large consistent differences, however cells that are more closely related may only be 
distinguishable by subtle small changes seen within large number of genes.  
 
Predictive analysis of microarrays (PAM) looks at the differences between cell populations, this 
is an alternative method of analysis to SAM and is a statistical technique for class prediction 
from gene expression data, using nearest shrunken centroids. It was described by Tibshirani et 
al in 2002 and is used to establish those genes that are the most reliable classifiers of two or 
more groups185. It uses part of the data (prediction set) to predict a list of genes that 
characterise those samples and then tests these predictive genes on the remaining samples 
(test set), to see if by just using those genes the sample type can be determined. The gene lists 
provided by both SAM and PAM analysis can be used to indicate potential gene populations, or 
individual genes, that are important in separating out the cell populations.  
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6.4 Preparing samples for transcriptome analysis 
As discussed in the materials and methods cultures of serum-free, serum-containing fibrocytes, 
macrophages and fibroblast cell lines were prepared. As neither fibrocytes nor macrophages 
differentiate as homogeneous populations, and are extremely adherent, these cells were 
differentiated and the cultures then lysed in the well. Both the number of fibrocytes and 
macrophages were counted to calculate the purity based on cell morphology. The same three 
donors were used for all of the in vitro derived cells, therefore providing three biological 
replicates. For each cell type from each donor three experimental replicates were prepared, in 
which cells had been set up to differentiate from the same donor on the same day, however 
from that point onwards were treated as three separate replicates. Three different fibroblast 
cell lines were used, derived from three different donors, although not donor matched to the 
macrophages and fibrocytes. For each cell line three aliquots were taken at passage 4 to be 
treated as three technical replicates for each of the biological replicates. Each prepared sample, 
the donor it originated from, the purity and calculated cell number are indicated in table 6.1. 
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Cell sample Donor Purity (%) Cell number 
T08.21 Serum free fibrocytes 1 (T08.21 S.F.F. 1) Donor 1 58.8 1.37x105 
T08.21 Serum free fibrocytes 2 (T08.21 S.F.F. 2) Donor 1 61.3 1.55x105 
T08.21 Serum free fibrocytes 3 (T08.21 S.F.F. 3) Donor 1 53.1 1.12x105 
T08.21 Macrophages 1 (T08.21 Mac 1) Donor 1 80.2 9.63x105 
T08.21 Macrophages 2 (T08.21 Mac 2) Donor 1 80.7 7.07x105 
T08.21 Macrophages 3 (T08.21 Mac 3) Donor 1 88.4 8.03x105 
T08.281 Serum containing fibrocytes 1 (T08.281 S.C.F. 1) Donor 1 43.9 2x105 
T08.281 Serum containing fibrocytes 2 (T08.281 S.C.F. 2) Donor 1 45 2x105 
T08.281 Serum containing fibrocytes 3 (T08.281 S.C.F. 3) Donor 1 42.2 2x105 
T08.120 Serum free fibrocytes 1 (T08.120 S.F.F. 1) Donor 2 50.2 0.8x105 
T08.120 Serum free fibrocytes 2 (T08.120 S.F.F. 2) Donor 2 53.3 1.0x105 
T08.120 Serum free fibrocytes 3 (T08.120 S.F.F. 3) Donor 2 47.9 0.9x105 
T08.120 Macrophages 1 (T08.120 Mac 1) Donor 2 74.2 1.9x106 
T08.120 Macrophages 2 (T08.120 Mac 2) Donor 2 79.2 1.7x106 
T08.120 Macrophages 3 (T08.120 Mac 3) Donor 2 71.2 1.4x106 
T08.285 Serum containing fibrocytes 1 (T08.285 S.C.F. 1) Donor 2 29.6 6x104 
T08.285 Serum containing fibrocytes 2 (T08.285 S.C.F. 2) Donor 2 29.2 6x104 
T08.285 Serum containing fibrocytes 3 (T08.285 S.C.F. 3) Donor 2 29.6 6x104 
T08.135 Serum free fibrocytes 1 (T08.135 S.F.F. 1) Donor 3  40.1 1.21x105 
T08.135 Serum free fibrocytes 2 (T08.135 S.F.F. 2) Donor 3  47.8 1.7x105 
T08.135 Serum free fibrocytes 3 (T08.135 S.F.F. 3) Donor 3 44.9 1.26x105 
T08.143 Macrophages 1 (T08.143 Mac 1) Donor 3 82.8 5.69x105 
T08.143 Macrophages 2 (T08.143 Mac 2) Donor 3 86.6 6.68x105 
T08.143 Macrophages 3 (T08.143 Mac 3) Donor 3 85.9 5.93x105 
T08.255 Serum containing fibrocytes 1 (T08.255 S.C.F. 1) Donor 3 8.7 3.8x104 
T08.255 Serum containing fibrocytes 2 (T08.255 S.C.F. 2) Donor 3 8 3.1x104 
T08.255 Serum containing fibrocytes 3 (T08.255 S.C.F. 3) Donor 3 8.4 3.5x104 
RASY19 1 Line 1 100 2x105 
RASY19 2 Line 1 100 2x105 
RASY19 3 Line 1 100 2x105 
RASY11 1 Line 2 100 6.7x105 
RASY11 2 Line 2 100 6.7x105 
RASY11 3 Line 2 100 6.7x105 
RASY08 1 Line 3 100 2.9x105 
RASY08 2 Line 3 100 2.9x105 
RASY08 3 Line 3 100 2.9x105 
 
Table 6.1 Prepared samples for transcriptome analysis. Four different cell types were prepared 
for transcriptome analysis, serum-free fibrocytes, serum-containing fibrocytes, macrophages 
and fibroblasts. The serum-free, serum-containing fibrocytes and macrophages were 
differentiated from three matched donors and lysed in the well. For each cell type for each 
donor three technical replicates were used. Three fibroblast cell lines were used, lysed at the 
same passage, with three technical replicates prepared for each one. The purity and cell number 
for each sample is shown, for the fibrocytes and macrophages this is based on cell morphology.  
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The mRNA was isolated from these samples and reverse transcribed into cDNA. To ensure 
approximately the same amount of cDNA from each sample was used on each of the 
microarrays, a real time L27 gene PCR was performed to determine the amount of cDNA in each 
sample. Based on the cell number calculations approximately 1000 cells worth of cDNA was put 
into each reaction, and each reaction was performed in triplicate. Not all samples could be 
tested at once, however every set of reactions included a titration of the human reference 
sample, where known amounts of cDNA were added, and a reaction blank. Figure 6.1 shows an 
example plot from one of the real time PCR for twelve samples, the mean of the triplicates for 
each sample are shown. All samples came up after 17 cycles, blanks either never came up at all 
or in the case of one set of reactions came up at cycle 39 (not shown here). On the graph the 
green line indicates the point in which the Ct readings of those samples were taken, during the 
log phase of the reaction. As the amount of cDNA put into the reference sample reaction was 
known, the amount of cDNA for each sample could be calculated from it, taking into account the 
dilution of the samples themselves as well. For each sample 1µg of cDNA was then labelled with 
fluorescent probe, mixed with labelled reference sample and hybridised to the microarrays. For 
a more in depth protocol see the materials and methods section.  
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Figure 6.1 Example of real time L27 gene PCR results for twelve samples. Approximately 1000 
cells worth of cDNA was loaded into triplicate reactions for each sample. Four batches were run 
as not all sample could be done at once, an example of one batch is shown. In each batch a 
titration of the human reference sample was included, and a known amount of cDNA used, as 
well as an experimental blank. Figure 6.1 show the mean of the triplicates for each sample. 
Green line represents the point at which the Ct readings for each sample, and the reference 
samples were taken.  
 
6.5 Normalising microarray data 
Once microarrays had been prepared with material hybridised to the slides they were scanned 
to measure the amount of fluorescence of the two labelled probes, the reference and cell 
samples for each of the 37632 spots on the array. The 37632 spots on each microarray are 
separated into 48 sub arrays, each containing 784 spots, see figure 6.2 (a). The reference sample 
reading is represented in red and the cell sample in green, when both shown, as in figure 6.2 (a), 
they appear yellow. However the two colours can be seen separately, figure 6.2 (b) shows the 
sub array identified by a white box in (a), with both the reference and cell samples shown. 
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Figure 6.2 (c) also shows a smaller area of the sub array to illustrate the consistency of individual 
spots. 
 
Figure 6.2 Example image of microarray containing 37632 spots and subarrays. A cell sample 
was labelled with fluorescent dye (Cy3), mixed with fluorescently labelled (Cy5) reference 
sample and hybridised to a microarray slide containing 37632 spots. a. The slide was scanned 
using a slide scanner and depicted as an image of spots, consisting of 48 sub arrays each 
containing 784 spots. b. Three images of the subarray highlighted in a. are shown. The image of 
just the Cy5 labelled reference sample (red), the Cy3 labelled cell sample (green) and the two 
images merged. c. Higher magnification of a section of the sub-array in a. with the same three 
images shown. 
 
Once the slide images had been annotated with the prepared generic array logic file (GAL) the 
intensity data of each colour was exported and normalised, (materials and methods). By using a 
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reference sample as well as the test sample on each slide any inter-slide variation could be 
removed during normalisation, as well as controlling for any variation in the amount of sample 
cDNA. Figure 6.4 shows box plots of the normalised intensities of each sample. Following 
normalisation a reading for each gene on the array was given in the form of a ratio between the 
level of the gene within the test sample and the level of that same gene within the reference 
sample. The level of the gene in the reference sample should be very similar across all the arrays 
therefore the ratio readings are suitable to be used to compare across the samples. 
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Figure 6.3 Box-plot of normalised intensities of each sample. Samples were loaded into Gene 
Expression Pattern Analysis Suite (GEPAS) (Bioinformatics Unit CNIO; 
http://gepas.bioinfo.cnio.es) software for normalization, which was performed using print-tip 
loess normalisation with background subtraction, initially within each slide and subsequently 
between slides. 
 
6.6 Relationship between experimental replicates 
As mentioned previously all experimental replicates were treated as separate samples from the 
earliest possible stage of the preparation process. Following normalisation of the microarray 
results the relationship between the three experimental replicates for the fibroblasts cell line 
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RASY11 were examined. Figure 6.4 (a) shows the log(2) ratio readings for 10000 genes of each 
RASY11 sample plotted against each other, and a positive correlation is seen between them all 
(10000 genes used due to limitations in software; software used was Prism version 3.0). 
Correlation was calculated using the Pearson correlation statistical test and the coefficient of 
determination, or r squared (r2) shown with each plot. The r2 value represents the fraction of 
the variance which is shared between the two samples, perfect positive correlation would be 
represented as r2=1, no correlation as r2=0 and perfect negative correlation as r2=-1. As the r2 
readings seen when looking at the RASY11 cell line range between 0.65 and 0.75 we can be 
confident that there is a large amount of positive correlation between them. To show this is due 
to the samples being experimental replicates and not to do with either the reference sample, or 
processing, the correlation of RASY11 1 sample with an example of each of the other three cell 
populations being investigated was also examined. By just looking at the plots alone (figure 6.4 
(b)) less correlation is seen, the r2 readings support this as all are below 0.28, indicating there is 
some slight correlation, due to the fact that all these samples originate from humans, however 
the correlation is much less then that seen between the experimental replicates of RASY11. In 
all cases P<0.0001, indicating that the r2 values seen are significantly relevant. We can therefore 
be confident in our experimental replication. 
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Figure 6.4 Correlation between experimental replicates and other samples. a. To examine the 
experimental replication between the three RASY11 samples the same 10000 genes from each 
sample were plotted against each of the other two replicates and the level of correlation 
between them examined. The coefficient of determination, or r squared (r2) value is shown for 
each combination and a high level of positive correlation was seen. b. To determine that the 
level of correlation seen in a. was not related to either the presence of the reference sample, or 
the processing of the samples the RASY11 1 sample was compared to T08.255 serum-containing 
fibrocyte 1 (T08.255 S.C.F. 1), T08.120 serum-free fibrocytes 1 (T08.120 S.F.F.1) and T08.120 
macrophages 1 (T08.120 Mac 1). Some positive correlation was seen but not to the same level as 
seen between the experimental replicates of RASY11. 
 
6.7 Analysis of all four cell populations 
6.7.1 Unsupervised clustering of all four cell populations 
Once normalised the data from all four cell populations (36 samples) was exported to the TMEV 
software package where, without any statistical analysis, a hierarchical cluster analysis was 
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performed, using the information from 37632 genes (appendix 1). Figure 6.5 shows the very top 
of the hierarchical cluster figure, including the clustering tree and the information on 50 genes, 
although all 37632 genes were used to determine the clustering tree. Due to the amount of data 
involved it is impossible to show the entire figure however an example of a complete 
hierarchical clustering figure can be seen in figure 6.8. At the top of figure 6.5 is the clustering 
tree, samples that have very similar transcriptomes will cluster closer together than samples 
that have more diverse transcriptomes. Just because a sample is next to another though does 
not mean they are closely related, it is important to look at the length of the branches between 
samples, the smaller the distance the more closely related the samples and vice versa. Samples 
and branches are colour coded and these colours will remain throughout all the analyses, 
serum-free fibrocytes represented in red, serum-containing fibrocytes in blue, macrophages in 
black and fibroblasts in pink. Below the hierarchical tree information on 50 genes is shown, in 
no particular order, carrying on from the clustering tree a column of blocks indicates the results 
from one sample, labelled at the top. One row of blocks indicates a particular gene across all 
samples. Each block is coloured based on the log(2) ratio reading of the normalised reference 
sample divided by cell sample intensity reading. The more negative a log(2) ratio, the greener it 
will appear, and the more positive the redder it will appear. A gene that is more highly 
expressed in the cell sample compared to the reference sample will be negative and so green, 
and those expressed to a lower extent in the sample compared to the reference will be positive 
and so red. Those genes that have a very similar expression level in the cell sample and 
reference are shown in black. As the colour in the HCL represents the ratio of the cell sample to 
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reference of a gene, two samples that are completely different could still be represented as 
different shades of the same colour, as, even when different they may still both have either 
more or less than the reference sample. 
 
Figure 6.5 Hierarchical cluster analysis tree of unsupervised data from all four cell populations. 
Hierarchical cluster analysis was performed on the normalised data for all thirty six samples 
across all four cell populations. The hierarchical cluster analysis tree is shown and information 
on 50 genes, although all 37632 genes were used to determine the tree. Samples are colour 
coded and labelled at the top, serum-free fibrocytes in red, serum-containing fibrocytes in blue, 
macrophages in black and fibroblasts in pink. Samples are clustered based on their similarities 
with the length of the branches being important rather than their proximity of the samples to 
each other. 
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Despite being completely unsupervised a great deal of clustering can be seen within this 
hierarchical cluster analysis. All but one of the fibroblasts samples cluster closely together, as do 
the majority of the macrophage samples. There are however a few outlying samples that have 
their own branches and don’t seem to cluster with any other samples in particular (T08.21 
Macrophage 1, T08.21 Serum-free fibrocyte 2 and RASY19 2). Figure 6.6 shows the same data 
that has been used to form this hierarchical clustering tree in the form of a Principal component 
plot. Principal component plots show the data along the three axes that show the largest 
amount of variation within the data. Principal component 1, (x axis), shows the largest variation, 
Principal component 2, (y axis), the second largest amount of variation and Principal component 
3, (z axis- not currently seen), shows the third. As you can see from figure 6.6, other than a few 
samples, all four populations cluster separately from one another. There is a serum-free 
fibrocyte (red) sample with the serum-containing fibrocytes (blue) and one with the fibroblasts 
(pink). However on the whole they separate well, suggesting that the transcriptomes of all four 
populations are different.  
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Figure 6.6 Principal component plot of unsupervised data from all four cell populations. 
Principal component analysis was performed on the normalised data for all thirty six samples 
across all four cell populations. The Principal component plot plots the data along the three axes 
that show the largest amount of variation between the examples, (although only the first two 
are seen in this figure).  
 
6.7.2 Significance analysis of all four cell populations 
A SAM analysis of all four cell populations was performed using the TMEV software and those 
genes significantly different between them all identified. Figure 6.7 shows the SAM plot used, 
the x-axis represents the expected reading if there is no difference between the samples, and 
the y-axis the observed. All information is then plotted, the more divergent the plotted line is 
from the gray diagonal line the more significantly different genes there are. The number of 
significantly different genes is also dependent on the false discovery rate (FDR) used in the 
analysis. The FDR estimates how many genes SAM is wrongly identifying as significantly 
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different, the lower the FDR the better. For example in this four way analysis an FDR of 1% gave 
18508 genes as being significantly different (approximately 50% of the number of genes put into 
the analysis), and in doing so suggests that 185 genes are being identified as significantly 
different when they are not, or are falsely discovered. However if an FDR of 0.1% is applied 
12602 (33% of initial gene number) significantly different genes are identified with only 13 
genes being falsely discovered. In the case of this analysis an FDR which is any lower than 0.1%, 
gives 0 genes as falsely discovered, which is not significantly relevant, so cannot be used, 
therefore an FDR of 0.1% was applied (Figure 6.7, appendix 2).  
 
 
Figure 6.7 SAM plot of four way analysis of microarrays using a 0.1% FDR. Identification of 
significantly different genes between all four populations was performed using SAM, the x axis 
represents the expected reading if there is no difference between the samples and the y axis 
the observed. When plotted the more divergent the data is from the grey line the more 
significant genes there are. The number of significant genes is determined by using a false 
discover rate (FDR) cut off, depicted by the dashed lines. 
 
0.1% FDR 
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Once 12602 genes had been identified as being significantly different between all four cell 
populations hierarchical clustering analysis was performed using them (Figure 6.8). The full 
hierarchical clustering figure shown in figure 6.8 allows for gene clusters and for the global 
separations of samples to be identified, however the most interesting part is the hierarchical 
tree at the top, which has been highlighted. This figure shows a definite separation of the 
fibroblast cell lines from the in vitro derived populations, however clustering of the different in 
vitro derived cells is also seen. One of the serum-free fibrocyte samples (T08.21 serum-free 
fibrocyte 3) is clustering strongly with the fibroblasts, despite the other technical replicates for 
that donor clustering nicely with other serum-free fibrocyte samples. Also observed, when 
looking at the hierarchical tree branches, is that three replicates of one particular donor of the 
serum-free fibrocytes (T08.120) appear to be more closely related to the fibroblasts than the 
other in vitro derived cells. However when the Principal component analysis for this list of 
12602 genes is examined (figure 6.9) the three T08.120 serum-free fibrocyte samples cluster 
completely separately from anything else (identified by the ellipse), so rather than being like 
fibroblasts, these samples just don’t cluster with any other samples at all. Interestingly all the 
macrophages samples and all the serum-containing fibrocyte samples form two separate 
clusters. 
Chapter 6: Transcriptome analysis  Marianne Fairclough 
 190
 
Figure 6.8 Hierarchical cluster analysis tree of samples based on 12602 significantly different 
genes from SAM analysis. Hierarchical cluster analysis was performed on the data for the 12602 
genes identified as being significantly different by SAM analysis. The full hierarchical cluster 
analysis is shown on the left with the hierarchical cluster analysis tree and information on 50 
genes magnified on the right to allow branch information to be seen. Samples are colour coded 
and labelled at the top, serum-free fibrocytes in red, serum-containing fibrocytes in blue, 
macrophages in black and fibroblasts in pink. Samples are clustered based on their similarities 
with the length of the branches being important rather than their proximity of samples to each 
other. 
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Figure 6.9 Principal component plot of samples based on 12602 significantly different genes 
from SAM analysis. Principal component analysis was performed on the data for the 12602 
genes identified as being significantly different by SAM analysis. The T08.120 serum-free 
fibrocytes are identified by an ellipse in the bottom right hand section of the figure. 
 
Despite clustering of the different populations of the in vitro derived cells (serum-free 
fibrocytes, serum-containing fibrocytes and macrophages) being seen, further investigation of 
the significantly different genes identified show that they are mainly due to the differences 
between the fibroblasts and everything else; and are not suitable for identifying more subtle 
similarities and differences between the two types of fibrocytes and macrophages. To be able to 
identify these differences between the monocyte derived cells the decision was made to 
exclude the fibroblast cell lines from the following analyses. 
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6.8 Analysis of serum-free fibrocytes, serum-containing fibrocytes and 
macrophages 
6.8.1 Unsupervised analysis 
The spot intensity data from the microarrays was re-normalised with the fibroblast samples 
removed, the log(2) ratio data for the remaining 27 samples (appendix 3) was then used to 
perform both unsupervised hierarchical clustering and Principal component analysis. Figure 6.10 
(a) shows the hierarchical clustering tree and the log(2) ratio data on 50 genes, and figure 6.10 
(b) the Principal component analysis. Again, despite no supervision a large degree of clustering 
is seen within the three cell populations, with the macrophage samples clustering the most 
tightly. Importantly however is the observation that serum-free and serum-containing fibrocytes 
clearly do not cluster together. The serum-free fibrocytes from donor T08.120 can be seen 
clustering quite separately from all other samples, however when looking at the Principal 
component analysis these samples are closest to the other serum-free fibrocytes rather than 
either of the other two cell populations.  
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Figure 6.10 Unsupervised cluster analysis of serum-free fibrocyte, serum-containing fibrocyte 
and macrophages samples. a. Hierarchical cluster analysis was performed on the normalised 
data for the twenty seven samples across the three cell populations. The hierarchical cluster 
analysis tree is shown and information on 50 genes, although all 37632 genes were used to 
determine the tree. Samples are clustered based on their similarities, with the length of the 
branches between them being important rather than their proximity of the samples to each 
other. b. Principal component analysis was performed on the same data.  
 
6.8.2 Statistical analysis of microarrays 
SAM was performed on the normalised log(2) ratio data of the two types of fibrocytes and 
macrophages at an FDR of 0.01% and 4563 significantly different genes were identified (12% of 
the initial gene number; appendix 4). Hierarchical cluster and Principal component analyses 
were then performed on these genes (Figure 6.11). The hierarchical cluster analysis tree shows, 
again, that the three T08.120 serum-free fibrocytes cluster separately from all the other 
samples. The remaining serum-free fibrocyte and macrophage samples are on a separate 
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branch to the serum-containing fibrocytes, however, other than one macrophage sample, they 
do separate into two clusters. Interesting to note in context to the aims of this chapter are that 
serum-free and serum-containing fibrocytes are not clustering together in any way. In fact by 
Principal component analysis all three populations cluster completely separately. 
 
  
Figure 6.11 Cluster analysis of serum-free fibrocyte, serum-containing fibrocyte and 
macrophage samples based on 4563 significantly different genes from SAM analysis. Samples 
are colour coded, serum-free fibrocytes in red, serum-containing fibrocytes in blue and 
macrophages in black. a. Hierarchical cluster analysis was performed on the 4563 significantly 
different genes found between the three cell populations. The hierarchical cluster analysis tree 
and log(2) ratio information on 50 genes are shown, although all 4563 genes were used to 
determine the tree. Samples are clustered based on their similarities, with the length of the 
branches between them being important, rather than their proximity of the samples to each 
other. b. Principal component analysis was performed on the same data set.  
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6.8.3 Predictive analysis of microarrays 
PAM was performed on the normalised data for the three monocyte derived cell populations, 
figures 6.12 and 6.13 are plots from one example of a PAM. The program uses the prediction set 
of samples to come up with a list of genes, ranked in order of importance, which it can use to 
identify those samples into the correct cell populations. Figure 6.12 shows how well it does this 
by plotting the probability that each sample is each of the three cell populations and all 18 
samples are correctly identified. However as it used this set of samples to determine the gene 
list the more important test is how well they classify the nine samples in the test set. Figure 6.13 
shows the test probabilities for the test set and all but one of the samples is correctly classified. 
The one macrophages sample that it failed to classify correctly is the same one that did not 
cluster with all the other macrophage samples in the hierarchical cluster analyses in figures 6.10 
and 6.11. 
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Figure 6.12 Cross validation probabilities of prediction set in PAM analysis. Using the 
predictive set of samples a set of genes was determined that can be used to predict the 
population type of samples. Using this set the probability that a sample is one of the three 
possible populations is shown on the plot, with the actual population type shown above.   
Chapter 6: Transcriptome analysis  Marianne Fairclough 
 197
 
Figure 6.13 Cross validation probabilities of test set in PAM analysis. Using the predictive set of 
samples in a PAM analysis a set of genes was determined that can be used to predict the 
population type of samples. To test the ability of this predictive set a set of samples (test set) 
not involved in determining the predictive set of genes, were used. The probability that a 
sample is one of the three possible populations is shown on the plot, with the actual population 
type shown above.    
 
Ten iterations of PAM were performed on the twenty seven samples, which consisted of nine 
samples of each of the three cell populations. In each iteration six samples of each population 
were put in the prediction set and three into the test set. The genes provided as good predictors 
of cell types in these ten different analyses were ranked by the number of times they appeared, 
and those genes which had been used in at least eight out of the ten iterations selected. 
Chapter 6: Transcriptome analysis  Marianne Fairclough 
 198
 
For the ten different iterations of PAM the ability of the predictive genes to identify the test set 
samples is summarised in table 6.2. In four out of the ten PAM analyses the gene list that had 
been determined misclassified a macrophage sample in the test set as a serum-free fibrocyte, 
every time it was the sample T08.21 Macrophage 2. Also on one occasion a serum-free fibrocyte 
sample was misclassified as a macrophage but at no point were any serum-containing fibrocyte 
samples misclassified. 
  
Predicted Population 
 
 
Macrophage Serum-free fibrocyte 
Serum-containing 
fibrocyte 
True 
Population 
Macrophage 26/30 4/30 
 
Serum-free 
fibrocyte 1/30 29/30  
Serum-containing 
fibrocyte   30/30 
 
Table 6.2 Summary of test probability results for PAM analysis. Using the predictive set of 
samples in a PAM analysis a set of genes was determined that can be used to predict the 
population type of samples. To test the ability of this predictive set a set of samples (test set) 
not involved in determining the predictive set of genes, were used. This was performed on ten 
different iterations of the PAM analysis and the results tabulated here. The population 
predicted by the gene lists is shown across the top and the true population down the side.    
 
The genes that PAM used eight times and above to classify these samples in the ten different 
iterations of PAM are listed in table 6.3, and the log(2) ratio readings for each sample in figure 
6.14. Figure 6.14 also shows the results of a Friedman non-parametric statistical test for each 
gene, all are significantly different with at least P < 0.05. By looking at the log(2) ratio data the 
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cell type most different, so probably causing that gene to be predictive can also be identified, in 
most cases it was the serum-containing fibrocytes. As this is ratio data, compared to the 
reference sample, it is important to remember that the more negative a reading the higher the 
expression level of that gene in those samples is, therefore the cell type with the lowest ratio 
reading has the highest expression. Also to note is that all 28 genes listed as being highly 
predictive of these three cell populations are also present in the gene list of significantly 
different genes produced by SAM.  
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Gene  Full name 
ALPK3 Alpha kinase 3 
ALOX5 Arachidonate 5-lipoxygenase 
BRE Transcription Factor II B Recognition Element 
C19orf59 Chromosome 19 open reading frame 59 
CCL2 Chemokine (C-C motif) ligand 2 
CCNB1 Cyclin B1 
CD300LF CD300 molecule-like family member f 
CYBB Cytochrome b-245, beta polypeptide  
CYP1B1 Member of cytochrome p450 family 
DLK1 Delta-like 1 homolog (Drosophila), 
GJB2 Gap junction protein, beta 2 
GPC4 Glypican 4 
HIST1H2AH Histone cluster 1, H2ah 
hsa-mir-27b Homo sapiens miR-27b stem-loop 
IL1B Interleukin 1, beta 
JAKMIP2 Janus kinase and microtubule interacting protein 2 
KRT8 Keratin 8 
KRT81 Keratin 81 
LMO4 LIM domain only 4 
MMD Monocyte to macrophage differentiation-associated 
PSD3 Pleckstrin and Sec7 domain containing 3 
PTGS1 Prostaglandin-endoperoxide synthase 1 
Q6ZUB2_HUMAN Unknown 
SLC6A12 Solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12 
TIE1 Tyrosine kinase with immunoglobulin-like and EGF-like domains 1 
TMEM54 Transmembrane protein 54  
VSIG4 V-set and immunoglobulin domain containing 4 
ZFYVE16 Zinc finger, FYVE domain containing 16, 
 
Table 6.3 List of genes used eight times and above in the ten iterations of PAM to classify the 
28 samples. Ten different iterations of PAM analysis were performed on the serum-free, serum-
containing fibrocytes and macrophages. Using a predictive set of samples in a PAM analysis a set 
of genes was determined that could be used to predict the population type of samples. These 
were then tested on a test set of samples. The genes in the gene lists created in the ten 
iterations were ranked according to the number of times a gene was used and any genes used in 
eight lists or above were listed above. The shortened and full gene name are shown. 
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Figure 6.14 Log(2) ratio data on genes used eight times and above in the ten iterations of PAM 
to classify the 27 samples. Ten different iterations of PAM analysis were performed on the 
serum-free, serum-containing fibrocytes and macrophages. Using a predictive set of samples in 
a PAM analysis a set of genes was determined that could be used to predict the population type 
of samples. These were then tested on a test set of samples. The genes in the gene lists created 
in the ten iterations were ranked according to the number of times a gene was used and any 
genes used in eight lists or above were chosen. Log(2) ratio data for each cell population for 
each gene is shown. Each sample is shown as a dot, with the median depicted by a line, serum-
free fibrocytes are colour coded red, serum-containing fibrocytes blue and macrophages black. 
The population data for each gene was statistically tested using Freidman non-parametric 
statistical test, all are significantly different with at least P < 0.05. NB This is ratio data of 
reference divided by sample therefore the more negative a reading the higher the expression 
level of that gene. 
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Using just the 28 genes identified by the PAM analysis hierarchical cluster and Principal 
component analyses were performed (Figure 6.15, log(2) ratio data in appendix 5). As with 
figure 6.11 all three cell populations clustered separately, other than one macrophage sample 
(T08.21 Macrophage 3), however in tighter clusters than was seen in figure 6.11. These analyses 
indicate that the genes selected for their predictive nature are able to cluster the three different 
cell populations. They also show that although all three populations cluster separately the 
macrophages and serum-free fibrocytes appear to be more closely related to each other than 
either is to the serum-containing fibrocytes. 
 
Figure 6.15 Cluster analysis of serum-free fibrocyte, serum-containing fibrocyte and 
macrophage samples based on 28 predictive genes from PAM analysis. Samples are colour 
coded, serum-free fibrocytes in red, serum-containing fibrocytes in blue and macrophages in 
black. a. Hierarchical cluster analysis was performed on the 28 predictive genes. The hierarchical 
cluster analysis tree and the log(2) ratio information on all of the genes is shown. Samples are 
clustered based on their similarities, with the length of the branches between them being 
important, rather than their proximity of the samples to each other. b. Principal component 
analysis was performed on the same data set. 
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6.9 Analysis of serum-free fibrocytes versus serum-containing 
fibrocytes 
Although the gene list provided by comparing all three in-vitro derived cells is informative, 
supporting the hypothesis that serum-free and serum-containing fibrocytes are different it does 
not provide any genes that are significantly different between just these two populations, 
therefore analyses of just those was performed.  
 
6.9.1 SAM analysis of serum-free fibrocytes versus serum-containing fibrocytes 
An unpaired SAM analysis of the two fibrocyte populations at 0.1% FDR provided 6614 
significantly different genes (appendix 6). Using these genes hierarchical cluster and Principal 
component analyses were performed, figure 6.16, and in both cases a clear separation can be 
seen between the two populations. However the samples T08.120 serum-free fibrocytes are still 
on a separate branch from the rest of the serum-free fibrocytes.  
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Figure 6.16 Cluster analysis of serum-free fibrocyte and serum-containing fibrocyte samples 
based on 6614 significantly different genes from SAM analysis. Samples are colour coded, 
serum-free fibrocytes in red and serum-containing fibrocytes in blue. a. Hierarchical cluster 
analysis was performed on the 6614 significantly different genes found between the two cell 
populations. The hierarchical cluster analysis tree and information on 50 genes are shown, 
although all 6614 genes were used to determine the tree. Samples are clustered based on their 
similarities, with the length of the branches between them being important, rather than their 
proximity of the samples to each other. b. Principal component analysis was performed on the 
same data set. 
 
6.9.2 Functional annotation of genes identified by SAM analysis of serum-free 
versus serum-containing fibrocytes 
The database for annotation, visualization and integrated discovery, or DAVID, is a web-based 
tool that can be used to put biological meaning behind lists of genes determined by microarray 
analysis186. It maps the genes contained in the list to an associated biological annotation, then 
statistically highlights the most over-expressed or enriched biological annotations187 to perhaps 
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give some idea of the potential role of these genes in biological systems. The ideal gene number 
to analyse with DAVID is between 200-2000 genes187, the SAM of serum-free versus serum-
containing fibrocytes provided 6614 significantly different genes, which is too high. To reduce 
this a three-fold difference cut off was introduced, only those genes whose ratio to reference 
was three fold different or more between the two cell populations were used (appendix 7). This 
provided 808 genes, which were split into two gene lists, using the mean log(2) ratio reading 
across the samples for each population. The two lists contained those higher in serum-free 
fibrocytes (appendix 8) and those higher in serum-containing fibrocytes (appendix 9) and were 
inputted separately into DAVID. DAVID highlighted many biological processes however a cut off 
of an enrichment score of greater than 2 and a FDR of less than 5 were used. Table 6.4 shows 
the six processes that were highlighted by the gene list of just those genes higher in serum-free 
fibrocytes, compared to serum-containing. The gene count indicates the number of genes out of 
the inputted list involved in each process; and the percentage indicates those genes as a 
percentage of the number of genes put in. Table 6.5 shows the thirty seven processes enriched 
by the genes higher in serum-containing fibrocytes compared to serum-free. These gene 
ontology terms can act as a guide to which processes may be important when determining the 
roles of a cell population in the body. 
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Gene Ontology term Gene Count Percentage (%) FDR 
Chromatin assembly or disassembly 10 0.9 0 
Chromatin assembly 8 0.7 0.1 
Nucleosome assembly 7 0.6 0.3 
Protein-DNA complex assembly 8 0.7 0.9 
Establishment and/or maintenance of 
chromatin architecture 10 0.9 3.9 
DNA Packaging 10 0.9 4.4 
 
Table 6.4 Processes enriched in DAVID when looking at those genes that were higher in 
serum-free fibrocytes than serum-containing fibrocytes. The gene list provided by a 2 way SAM 
analysis of serum-free versus serum-containing fibrocytes was cut down to 808 genes by a 
three-fold difference threshold. Of those genes just those with more expressed in serum-free 
fibrocytes than serum-containing fibrocytes were inputted into DAVID (appendix 7). The 
processes classified as being enriched with this gene list, based on an enrichment score of 2, 
with an FDR of less than 5, are listed above with the number of genes out of the imputed list 
involved in the process, what percentage of imputed genes this is and the FDR. 
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Gene Ontology term Gene Count 
Percentage 
(%) FDR 
Localisation 96 26.1 0 
Establishment of localisation 78 21.2 3.8 
Cell proliferation 33 9 0.3 
Regulation of cell proliferation 23 6.2 1 
Defence response 29 7.9 0 
Inflammatory response 16 4.3 2.4 
Response to wounding 20 5.4 2.4 
Chemical homeostasis 18 4.9 0.1 
Cellular cation homeostasis 14 3.8 0.2 
Cation homeostasis 14 3.8 0.2 
Cellular chemical homeostasis 15 4.1 0.2 
Cellular ion homeostasis 15 4.1 0.2 
Ion homeostasis 15 4.1 0.6 
Cellular homeostasis 17 4.1 1.3 
Homeostatic process 20 5.4 1.7 
Cellular di-,tri-,valent inorganic cation homeostasis 11 3 3 
di-,tri-,valent inorganic cation homeostasis 11 3.0 3.1 
Carboxylic acid metabolic process 29 7.9 0 
Organic acid metabolic process 29 7.9 0 
Icosanoid metabolic process 8 2.2 0 
Icosanoid biosynthetic process 7 1.9 0 
Cellular lipid metabolic process 30 8.2 0.1 
Monocarboxylic acid metabolic process 17 4.6 0.1 
Organic acid biosynthetic process 8 2.2 1.4 
Carboxylic acid biosynthetic process 8 2.2 1.4 
Alkene metabolic process 5 1.4 2.4 
Leukotriene metabolic process 5 1.4 2.4 
Fatty acid biosynthetic process 7 1.9 3.5 
Signal Transduction 100 27.2 3.4 
Localisation of cell 19 5.2 4.5 
Cell motility 19 5.2 4.5 
Tricarboxylic acid cycle intermediate metabolic process 5 1.4 4.3 
Hydrogen Transport 10 2.7 0.2 
Proton Transport 9 2.4 0.8 
Coenzyme metabolic process 12 3.3 4.3 
Vitamin Metabolic process 9 2.4 0.2 
Water soluble vitamin metabolic process 6 1.6 4.7 
 
Table 6.5 Processes enriched in DAVID when looking at those genes that were higher in 
serum-containing fibrocytes than serum-free fibrocytes. The gene list provided by a 2 way SAM 
analysis of serum-free versus serum-containing fibrocytes was cut down to 808 genes by a 
three-fold difference threshold. Of those genes just those with more expressed in serum-
containing fibrocytes than serum-free fibrocytes were inputted into DAVID (appendix 8). The 
processes classified as being enriched with this gene list, based on an enrichment score of 2, 
with an FDR of less than 5, are listed above with the number of genes out of the imputed list 
involved in the process, what percentage of imputed genes this is and the FDR. 
Chapter 6: Transcriptome analysis  Marianne Fairclough 
 208
 
Of the 808 genes to be imputed into DAVID 151 had no name attached to the gene ID, and so 
could not be included. Of the remaining genes, 225 (28%) were higher in serum-free than 
serum-containing fibrocytes and 432 (53%) were higher in serum-containing than serum-free 
fibrocytes.  
 
6.9.3 PAM analysis of serum-free fibrocytes versus serum-containing fibrocytes 
Predictive analysis of microarrays was performed on the two fibrocyte populations, serum-free 
and serum-containing. As with the three way analysis performed earlier six samples from each 
population were classified into the predictive set and three as the test set. Ten different 
iterations of PAM were performed with the samples in the predictive and test sets changing. A 
summary of all the test probability results of the test sets for all 10 iterations of PAM is shown in 
table 6.6. In all ten PAM analyses the gene list that had been determined classified all the 
samples correctly.  
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Predicted Population 
 
 
Serum-free 
fibrocyte 
Serum-containing 
fibrocyte 
True 
Population 
Serum-free 
fibrocyte 30/30  
Serum-containing 
fibrocyte  30/30 
 
Table 6.6 Summary of test probability results for PAM analysis of serum-free and serum-
containing fibrocytes. Using the predictive set of samples in a PAM analysis a set of genes was 
determined that can be used to predict the population type of samples. To test the ability of this 
predictive set a set of samples (test set) not involved in determining the predictive set of genes, 
were used. This was performed on ten different iterations of the PAM analysis and the results 
tabulated above. The population predicted by the gene lists is shown across the top and the 
true population down the side. 
 
The genes within the gene lists used in these ten different analyses were ranked by the number 
of times they appeared and those genes which had been used 8 times and above selected. 
There were 36 genes selected, listed in table 6.7 along with their full name. Figure 6.17 shows 
the log(2) ratio data for each gene and the results of a Wilcoxon signed rank non-parametric 
statistical test, all are significantly different between the two cell populations, with at least P < 
0.05. These genes were also identified as being present in the 6614 genes listed as being 
significantly different by SAM analysis at 0.1% FDR. To note is that this is again ratio data 
therefore the more negative a reading the higher the expression level of that gene in those 
samples is, therefore the cell type with the lowest ratio reading has the highest expression. 
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Gene Full Name 
ACSL1 Fatty acid coenzyme a ligase, long chain 1 
ALOX5AP Arachidonate 5-lipoxygenase-activating protein 
BHLHB2 Basic helix-loop helix domain containing, class b, 2 
BRE Brain and reproductive organ-expressed 
CACNB3 Calcium channel, voltage dependent, beta 3 subunit 
CCL2 Chemokine (C-C motif) ligand 2 
CCL7 Chemokine (C-C motif) ligand 7 
CIR_HUMAN CBF1-interacting corepressor 
CKB Cretine kinase, brain 
CLEC12A c-type lectin domain family 12, member a  
CLN5 Ceroid-lipofuscinosis, neuronoal 5 
CYBB Cytochrome b-245, beta polypeptide  
CYP1B1 Member of cytochrome p450 family 
DDEF1 Development and differentiation enhancing factor 1 
GJB2 Gap junction protein, beta 2 
HBEGF Proheparin-binding EGF-like growth factor 
HIST1H2AH Histone cluster 1, H2ah 
IL1B Interleukin 1, beta 
JAKMIP2 Janus kinase and microtubule interacting protein 2 
KRT81 Keratin 81, 
ME1 Malic enzyme 1 
MMD Monocyte to macrophage differentiation-associated 
MMP7 Matrix metallopeptidase 7 
NSMAF Neutral sphingomyelinase (n-smase) activation associated factor 
PSD3 Pleckstrin and Sec7 domain containing 3 
PTGS1 Prostaglandin-endoperoxide synthase 1 
Q6ZUB2_HUMAN Unknown 
RAB31 rab31, member ras oncogene family 
SERPINB1 Serpinpeptidase inhibitor, clade b (ovalbumin) 
SLC23A2 Solute carrier family 23 (nucleobase transporters), member 2 
SLC6A12 Solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12 
TIE1 Tyrosine kinase with immunoglobulin-like and EGF-like domains 1 
TXNRD1 Thioredoxin reductase 1 
UBE2J1 Ubiquitin-conjugating enzyme e2,i1 
VSIG4 V-set and immunoglobulin domain containing 4 
ZFYVE16 Zinc finger, FYVE domain containing 16, 
 
Table 6.7 List of genes used eight times and above in the ten iterations of PAM to classify the 
serum-free and serum-containing fibrocyte samples. Ten different iterations of PAM analysis 
were performed on the serum-free and serum-containing fibrocytes. Using a predictive set of 
samples in a PAM analysis a set of genes was determined that could be used to predict the 
population type of samples. These were then tested on a test set of samples. The genes in the 
gene lists created in the ten iterations were ranked according to the number of times a gene 
was used and any genes used in eight lists or above were chosen and listed above. The 
shortened and full gene names are shown. 
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Figure 6.17 Log(2) ratio data on genes used eight times and above in the ten iterations of PAM to 
classify the serum-free and serum-containing fibrocyte samples. Ten different iterations of PAM 
analysis were performed on the serum-free and serum-containing fibrocytes. Using a predictive set of 
samples in PAM a set of genes was determined that could be used to predict the population type of 
samples. These were then tested on a test set of samples. The genes in the gene lists created in these 
ten iterations were ranked according to the number of times a gene was used and any genes used in 
eight lists or above were chosen. Log(2) ratio data for each cell population for each gene is shown. Each 
sample is shown as a dot, with the median depicted by a line, serum-free fibrocytes are colour coded red 
and serum-containing fibrocytes blue. The population data for each gene was statistically tested using 
Wilcoxon signed rank non-parametric statistical test, all are significantly different with at least P < 0.05. 
NB This is ratio data of reference divided by sample therefore the more negative a reading the higher the 
expression level of that gene. 
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The log(2) ratio data of these 36 genes was used in hierarchical and Principal component 
analyses, (Figure 6.18). Even with these few genes, a clear separation of the two populations 
can be seen (log(2) ratio data in appendix 10). This provides further evidence that these are two 
different cell types, not the same cell type differentiated under different conditions.  
 
Figure 6.18 Cluster analysis of serum-free and serum-containing fibrocytes samples based on 
36 predictive genes from PAM analysis. Samples are colour coded, serum-free fibrocytes in red 
and serum-containing fibrocytes in blue. a. Hierarchical cluster analysis was performed on the 
36 predictive genes. The hierarchical cluster analysis tree and the log(2) ratio information on all 
of the genes is shown. Samples are clustered based on their similarities, with the length of the 
branches between them being important, rather than their proximity of the samples to each 
other. b. Principal component analysis was performed on the same data set. 
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6.10 Analysis of fibrocytes versus macrophages 
Although in some cases the literature discusses that fibrocytes are a type of macrophage85;86 the 
majority of literature and data in this thesis does suggest that they are separate cell types as 
they have different characteristic morphologically, phenotypically and mechanistically84;87;88;145. 
To determine that the differences noted between serum-free and serum-containing fibrocytes 
by this microarray analysis are enough to be able to ascertain that these are different cell types 
a comparison between both serum-free and serum-containing fibrocytes to macrophages was 
also performed. If the level of separation seen between the fibrocyte populations and 
macrophages is clear then there can be confidence in the differences seen between the two 
types of fibrocytes.  
 
6.10.1 SAM analysis of fibrocytes versus macrophages 
Unpaired SAM analysis of serum-free or serum-containing fibrocytes and macrophages, at 0.1% 
FDR provided 2419 or 5565 significantly different genes respectively (appendices 11 and 12). 
Using these genes hierarchical cluster and Principal component analyses were performed, figure 
6.19, and in both cases a clear separation can be seen between both types of fibrocytes and 
macrophages. These results indicate that although related both types of fibrocytes are different 
cell populations to macrophages. 
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Figure 6.19 Cluster analysis of fibrocytes and macrophage samples. Samples are colour coded, serum-
free fibrocytes in red, serum-containing fibrocytes in blue and macrophages in black. a. Hierarchical 
cluster analysis was performed on the 2419 significantly different genes found between serum-free 
fibrocytes and macrophages. The hierarchical cluster analysis tree and information on 50 genes are 
shown, although all 2419 genes were used to determine the tree. b. Principal component analysis was 
performed on the same data set. c. Hierarchical cluster analysis was performed on the 5565 significantly 
different genes found between serum-containing fibrocytes and macrophages. Again the hierarchical 
cluster analysis tree and information on 50 genes are shown, although all 5565 genes were used to 
determine the tree. d. Principal component analysis was performed on the same data set. Samples are 
clustered based on their similarities, with the length of the branches between them being important, 
rather than their proximity of the samples to each other. 
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6.10.2 PAM analysis of fibrocytes versus macrophages 
Predictive analysis of microarrays was performed on both serum-free and serum-containing 
fibrocytes with macrophages. As previously six samples from each population were classified 
into the predictive set and three as the test set. Ten different iterations of PAM were performed 
with the samples in the predictive and test sets changing. In all ten PAM analyses the gene list 
that had been determined classified all the samples correctly in both comparisons. The genes 
within the gene lists used in these ten different analyses were ranked by the number of times 
they appeared and those genes which had been used 8 times and above selected. For serum-
free fibrocytes versus macrophages 21 genes were selected, listed in table 6.8 along with their 
full name. Figure 6.20 shows the log(2) ratio data for each gene and the results of a Wilcoxon 
signed rank non-parametric statistical test, all are significantly different between the two cell 
populations, with at least P < 0.05. To note is that this is ratio data of reference divided by 
sample, therefore the more negative a reading the higher the expression level of that gene in 
those samples is, therefore the cell type with the lowest ratio reading has the highest 
expression. These genes were also identified as being present in the 2419 genes listed as being 
significantly different by SAM analysis at 0.1% FDR. 
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Gene  Full name 
ADCY7 Adenylate cyclase 7 
ALPK3 Alpha kinase 3 
AMD1 Adenosylmethionine decarboxylase 1 
CAPN3 Calpain 3 
CCNB1 Cyclin B1 
CHKA Choline kinase alpha 
COX7AP2 Cytochrome c oxidase subunit via peeudogene 2 
CXCL5 Chemokine (c-x-x motif) ligand 5 
E2F2 e2f transcription factor 2 
GGH Gamma-glutamyl hydrolase 
GLRA2 Glycine receptor, alpha 2 
GREM1 Gremlin 1, cysteine knot superfamily  
hsa-mir-27b Homo sapiens miR-27b stem-loop 
KIF2A Kinesin heavy chain member 2 
LRP1 Low density lipoprotein-related protein 1 
MMD Monocyte to macrophage differentiation-associated 
PALM2 Paralemmin 2 
PTTG1 Pituitary tumour transforming 1 
RRM2 Ribonucleotide reductase m2 polypeptide 
SLC2A5 Solute carrier family 2 (facilitated glucose/fructose transporter), member 5 
VSIG4 V-set and immunoglobulin domain containing 4 
 
Table 6.8 List of genes used eight times and above in the ten iterations of PAM to classify the 
serum-free fibrocyte and macrophage samples. Ten different iterations of PAM analysis were 
performed on the serum-free fibrocytes and macrophages. Using a predictive set of samples in a 
PAM analysis a set of genes was determined that could be used to predict the population type 
of samples. These were then tested on a test set of samples. The genes in the gene lists created 
in the ten iterations were ranked according to the number of times a gene was used and any 
genes used in eight lists or above were chosen and listed above. The shortened and full gene 
names are shown. 
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Figure 6.20 Log(2) ratio data on genes used eight times and above in the ten iterations of PAM to 
classify the serum-free fibrocytes and macrophage samples. Ten different iterations of PAM analysis 
were performed on the serum-free fibrocytes  and macrophages. Using a predictive set of samples in 
PAM a set of genes was determined that could be used to predict the population type of samples. These 
were then tested on a test set of samples. The genes in the gene lists created in these ten iterations 
were ranked according to the number of times a gene was used and any genes used in eight lists or 
above were chosen. Log(2) ratio data for each cell population for each gene is shown. Each sample is 
shown as a dot, with the median depicted by a line, serum-free fibrocytes are colour coded red and 
macrophages black. The population data for each gene was statistically tested using Wilcoxon signed 
rank non-parametric statistical test, all are significantly different with at least P < 0.05. NB This is ratio 
data of reference divided by sample therefore the more negative a reading the higher the 
expression level of that gene. 
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For serum-containing fibrocytes versus macrophages 37 genes were selected, listed in table 6.9 
along with their full name. Figures 6.21a and 6.21b show the log(2) ratio data for each gene and 
the results of a Wilcoxon signed rank non-parametric statistical test, all are significantly 
different between the two cell populations, with at least P < 0.05. To note is that this is ratio 
data of reference divided by sample, therefore the more negative a reading the higher the 
expression level of that gene in those samples is.  These genes were also identified as being 
present in the 5565 genes listed as being significantly different by SAM analysis at 0.1% FDR. 
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Gene  Full name 
AKR1C3 Aldo-keto reductase family 1, member c3 
AMICA1 Adhesion molecule, interacts with cxadr antigen 1 
BNIP3 bcl2/adenovirus elb 19kda interacting protein 3 
CCNB1 Cyclin b1 
CD209 CD209 
CSPG2 Chondroitin sulfate proteoglycan core protein 2 
CYBB Cytochrome b-245, beta polypeptide 
CYP1B1 Cytochrome P450, family 1, subfamily b, polypeptide 
DLK1 Delta-like 1 homolog 
IGF2 Insulin-like growth factor 2 
IL1B Interleukin 1, beta 
ITGAX Integrin, alpha x 
KRT81 Keratin 81 
KRT8L1 Keratin 8 pseudogene 11 
LMO4 Lim domain only 4 
MRPS6 Mitochondrial ribosomal protein s6 
NCF1C Neutrophil cytosolic factor 1c 
PSTPIP1 Proline-serine-threonine phosphatase interacting protein 1 
Q6ZUB2_HUMAN Unknown gene 
RFC5 Replication factor c5 
SLC6A12 Solute carrier family 6 member 12 
TMEM45A Transmembrane protein 45a 
TMEM54 Transmembrane protein 54 
C16orf75 Hypothetical protein 
CD300LF CD300 antigen like family member f 
CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 1 
GPC4 Glypican-4 
AKR1C4 Aldo-keto reductase family 1, member c4 
ALPK1 Alpha protein kinase 1 
CLEC12A c-type lectin domain 12, member A 
CSF1 Colony stimulating factor 1 (macrophage) 
EMR2 egf-like module containing, mucin-like hormone receptor-like 2 
hsa-mir-27b Homo sapiens miR-27b stem-loop 
LDHA Lactate dehydrogenase a 
MSRA Methionine sulfoxide reductase a 
NM_207376 Hypothetical gene 
PRAM1 pm1-rara regulated adaptor molecule 1 
 
Table 6.9 List of genes used eight times and above in the ten iterations of PAM to classify the serum-
containing fibrocyte and macrophage samples. Ten different iterations of PAM analysis were performed 
on the serum-containing fibrocytes and macrophages. Using a predictive set of samples in a PAM 
analysis a set of genes was determined that could be used to predict the population type of samples. 
These were then tested on a test set of samples. The genes in the gene lists created in the ten iterations 
were ranked according to the number of times a gene was used and any genes used in eight lists or 
above were chosen and listed above. The shortened and full gene names are shown. 
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Figure 6.21a Log(2) ratio data on genes used eight times and above in the ten iterations of PAM to 
classify the serum-containing fibrocytes and macrophage samples. Ten different iterations of PAM 
analysis were performed on the serum-containing  fibrocytes  and macrophages. Using a predictive set of 
samples in PAM a set of genes was determined that could be used to predict the population type of 
samples. These were then tested on a test set of samples. The genes in the gene lists created in these 
ten iterations were ranked according to the number of times a gene was used and any genes used in 
eight lists or above were chosen. Log(2) ratio data for each cell population for each gene is shown. Each 
sample is shown as a dot, with the median depicted by a line, serum-containing fibrocytes are colour 
coded blue and macrophages black. The population data for each gene was statistically tested using 
Wilcoxon signed rank non-parametric statistical test, all are significantly different with at least P < 0.05. 
NB This is ratio data of reference divided by sample therefore the more negative a reading the 
higher the expression level of that gene. 
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Figure 6.21b Log(2) ratio data on genes used eight times and above in the ten iterations of PAM to 
classify the serum-containing fibrocytes and macrophage samples. Ten different iterations of PAM 
analysis were performed on the serum-containing  fibrocytes  and macrophages. Using a predictive set of 
samples in PAM a set of genes was determined that could be used to predict the population type of 
samples. These were then tested on a test set of samples. The genes in the gene lists created in these 
ten iterations were ranked according to the number of times a gene was used and any genes used in 
eight lists or above were chosen. Log(2) ratio data for each cell population for each gene is shown. Each 
sample is shown as a dot, with the median depicted by a line, serum-containing fibrocytes are colour 
coded blue and macrophages black. The population data for each gene was statistically tested using 
Wilcoxon signed rank non-parametric statistical test, all are significantly different with at least P < 0.05. 
NB This is ratio data of reference divided by sample therefore the more negative a reading the 
higher the expression level of that gene. 
 
The log(2) ratio data of these genes were used in hierarchical and Principal component analyses, 
figure 6.22, in which, even with these few genes, a clear separation of the two populations can 
be seen with macrophages (log(2) ratio data for serum-free and serum-containing fibrocytes in 
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appendices 13 and 14 respectively). Although the macrophage sample which was not clustering 
with the other macrophages previously is again distant from the macrophage cluster. 
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Figure 6.22 Cluster analysis of fibrocytes and macrophage samples based on predictive genes from 
PAM analysis. Samples are colour coded, serum-free fibrocytes in red, serum-containing fibrocytes in 
blue and macrophages in black. a. Hierarchical cluster analysis was performed on the 21 predictive genes 
identified in the serum-free fibrocyte versus macrophage PAM. b. Principal component analysis was 
performed on the same data set. c.  Hierarchical cluster analysis was performed on the 37 predictive 
genes identified in the serum-containing fibrocyte versus macrophage PAM. d. Principal component 
analysis was performed on the same data set. The hierarchical cluster analysis tree and the log(2) ratio 
information on all of the genes are shown. Samples are clustered based on their similarities, with the 
length of the branches between them being important, rather than their proximity of the samples to 
each other. 
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6.11 Predictive analysis of fibroblasts versus fibrocytes and 
macrophages. 
Using the normalised data of all four cell populations predictive analysis of microarrays was 
performed between fibroblasts and each of the in vitro derived cell types, serum-free, serum-
containing fibrocytes and macrophages. For each PAM analysis PAM six samples of each cell 
type were classified into the predictive set and three as the test set. Ten different iterations of 
PAM were performed with the samples in the predictive and test sets changing. In all ten PAM 
analyses the gene list that had been determined classified all the samples correctly in both 
comparisons. The genes within the gene lists used in these ten different analyses were ranked 
by the number of times they appeared and those genes which had been used 8 times and above 
selected.  
 
For serum-free fibrocytes versus fibroblasts 49 genes were selected, listed in table 6.10 along 
with their full name. Figures 6.23a and 6.23b shows the log(2) ratio data for each gene and the 
results of a Wilcoxon signed rank non-parametric statistical test, all are significantly different 
between the two cell populations, with at least P < 0.05. To note is that this is ratio data of 
reference divided by sample, therefore the more negative a reading the higher the expression 
level of that gene in those samples is. 
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Gene  Full name Gene  Full name 
A2M Alpha-2-microglobulin HLA-DPB1 Major histocompatibility complex, class II, DR beta 1 
ACP5 Acid Phosphatase 5 HLA-DRB3 Major histocompatibility complex, class II, DR beta 3 
AMY2B Amylase, alpha 2 IGFBP4 Insulin-like growth factor binding protein 4 
AQP9 Aquaporin 9 IGSF6 Immunoglobulin superfamily member 6 
AXL AXL receptor tyrosine kinase KIAA1199 Transmembrane protein 2-Like 
BCL2A1 BCL2-related protein A1 LAPTM5 Lysosomal protein transmembrane 5 
C13orf33 Chromosome 13 open reading frame 33 LCP1 Lymphocyte cytosolic protein 1 
C1S Complement component 1 MXRA7 Matrix-remodelling associated 7 
CALD1 Caldesmon 1 NP_001009555.2 Unknown 
CAV1 Caveolin 1 NP_061984.2 Major histocompatibility complex, class II, DR alpha. (HLA-DRA) 
CD74 CD74 molecule PCOLCE2 Procollagen C-endopeptidase enhancer 2 
CD84 CD84 molecule (member of CD2 
subgroup of Ig superfamily) PLA2G7 Phospholipase A2 
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) PLS3 Plastin 3 
COL1A2 Collagen type I, alpha 2 PRRX1 Paired related homeobox 1 
DCN Decorin PTGIS Prostaglandin 12 synthase 
DDAH1 Dimethylarginine dimethylaminohydrolase 1 Q2TVT3_HUMAN Unknown 
DDR2 Discoidin domain receptor tyrosine kinase 2 RAB23 RAB23, member RAS oncogene family 
EGFR Epidermal growth factor receptor RGMB RGM domain family, member B 
EXT1 Exostoses 1 SERPINE2 Serpin peptidase inhibitor, clade E, 
member 2 
FAIM3 Fas apoptotic inhibitory molecule 3 SULF1 Sulfatase 1 
FAT FAT tumour suppressor homolog THBS1 Thrombospondin 1 
FBN1 Fibrillin 1 TMEM98 Transmembrane protein 98 
FCER1G 
Fc fragment of IgE. High affinity 
receptor 1. receptor for; gamma 
polypeptide 
TNFRSF11B Tumour necrosis factor receptor 
superfamily, member 11b 
FN1 Fibronectin 1 TREM2 Triggering receptor expressed on myeloid 
cells 2 
FRMD6 FERM domain containing 6 
    
 
Table 6.10 List of genes used eight times and above in the ten iterations of PAM to classify the serum-
free fibrocyte and fibroblast samples. Ten different iterations of PAM analysis were performed on the 
serum-free fibrocytes and fibroblasts. Using a predictive set of samples in a PAM analysis a set of genes 
was determined that could be used to predict the population type of samples. These were then tested 
on a test set of samples. The genes in the gene lists created in the ten iterations were ranked according 
to the number of times a gene was used and any genes used in eight lists or above were chosen and 
listed above. The shortened and full gene names are shown. 
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Figure 6.23a Log(2) ratio data on genes used eight times and above in the ten iterations of PAM to 
classify the serum-free fibrocytes and fibroblast samples (Part one). Ten different iterations of PAM 
analysis were performed on the serum-free fibrocytes and fibroblasts. Using a predictive set of samples 
in PAM a set of genes was determined that could be used to predict the population type of samples. 
These were then tested on a test set of samples. The genes in the gene lists created in these ten 
iterations were ranked according to the number of times a gene was used and any genes used in eight 
lists or above were chosen. Log(2) ratio data for each cell population for each gene is shown. Each 
sample is shown as a dot, with the median depicted by a line, serum-free fibrocytes are colour coded red 
and fibroblasts green. The population data for each gene was statistically tested using Wilcoxon signed 
rank non-parametric statistical test, all are significantly different with at least P < 0.05. NB This is ratio 
data of reference divided by sample therefore the more negative a reading the higher the 
expression level of that gene. 
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Figure 6.23b Log(2) ratio data on genes used eight times and above in the ten iterations of PAM to 
classify the serum-free fibrocytes and fibroblast samples (Part two). Ten different iterations of PAM 
analysis were performed on the serum-free fibrocytes  and fibroblasts. Using a predictive set of samples 
in PAM a set of genes was determined that could be used to predict the population type of samples. 
These were then tested on a test set of samples. The genes in the gene lists created in these ten 
iterations were ranked according to the number of times a gene was used and any genes used in eight 
lists or above were chosen. Log(2) ratio data for each cell population for each gene is shown. Each 
sample is shown as a dot, with the median depicted by a line, serum-free fibrocytes are colour coded red 
and fibroblasts green. The population data for each gene was statistically tested using Wilcoxon signed 
rank non-parametric statistical test, all are significantly different with at least P < 0.05. NB This is ratio 
data of reference divided by sample therefore the more negative a reading the higher the 
expression level of that gene. 
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For serum containing fibrocytes versus fibroblasts 65 genes were selected, listed in table 6.11 
along with their full name. Figures 6.24a and 6.24b shows the log(2) ratio data for each gene 
and the results of a Wilcoxon signed rank non-parametric statistical test, all are significantly 
different between the two cell populations, with at least P < 0.05. To note is that this is ratio 
data of reference divided by sample, therefore the more negative a reading the higher the 
expression level of that gene in those samples is. 
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Gene  Full name Gene  Full name 
ACP5 Acid Phosphatase 5 IGFBP4 Insulin-like growth factor binding protein 4 
ADAMDEC1 ADAM-like, decysin 1 IGSF6 Immunoglobulin superfamily member 6 
AMICA1 Adhesion molecule IL18 Interleukin 18 
AQP9 Aquaporin 9 ITGAL Integrin, alpha L 
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta ITGAX Integrin, alpha x 
AXL AXL receptor tyrosine kinase KIAA1199 Transmembrane protein 2-Like 
BCL2A1 BCL2-related protein A1 LAMA4 Laminin, alpha 4 
C15orf48 Chromosome 15 open reading frame 48 LAPTM5 Lysosomal protein transmembrane 5 
C1S Complement component 1 LCP1 Lymphocyte cytosolic protein 1 
C5AR1 Complement component 5a receptor 1 LILRB3 Leukocyte immunoglobulin-like receptor, 
subfamily B 
CA2 Carbonic anhydrase II LMO7 LIM domain 7 
CCDC80 Coiled-coil domain containing 80 LUM Lumican 
CCL22 Chemokine ligand 22 LYZ Lysozyme 
CCL4L1 Chemokine ligand 4-like 1 MCOLN3 Mucolipin 3 
CCRL2 Chemokine receptor-like 2 NP_061984.2 Major histocompatibility complex, class II, DR alpha. (HLA-DRA) 
CD48 CD48 molecule NP_079045.1 Adipocyte-specific adhesion molecule 
CD52 CD52 molecule NT5E 5'nucleotidase, ecto (CD73) 
CD84 CD84 molecule (member of CD2 
subgroup of Ig superfamily) PLA2G7 Phospholipase A2 
CENTA2 ArfGAP with dual PH domains 2 PLEK Pleckstrin 
COL1A1 Collagen type 1 alpha 1 PTPN6 Protein phosphatase, non-receptor type 6 
COL1A2 Collagen type I, alpha 2 Q5J7V3_HUMAN Unknown 
CTSS Cathepsin S Q9HBF5_HUMAN Unknown 
DCN Decorin S100A8 S100 calcium binding protein A8 
DTX4 Deltex homolog 4 SERPINE2 Serpin peptidase inhibitor, clade E, 
member 2 
FAT FAT tumour suppressor homolog SLAMF7 Slam family member 7 
FBN1 Fibrillin 1 SMAD3 SMAD family member 3 
FBP1 Fructose-1, 6-biphosphatase SPI1 Spleen focus forming virus (SFFV) proviral integration oncogene spi1 
FCER1G 
Fc fragment of IgE. High affinity 
receptor 1. receptor for; gamma 
polypeptide 
SUCNR1 Succinate receptor 1 
FRMD6 FERM domain containing 6 THY1 Thy-1 cell surface antigen 
GM2A GM2 ganglioside activator  TMEM98 Transmembrane protein 98 
HAVCR2 Hepatitus A virus cellular receptor 2 TPM1 Tropomyosin 1 
HLA-DRB3 Major histocompatibility complex, class II, DR beta 3 VAMP8 Vesicle-associated membrane protein 8 
IFI30 Interferon, gamma inducible protein 30     
 
Table 6.11 List of genes used eight times and above in the ten iterations of PAM to classify the serum-
containing  fibrocyte and fibroblast samples. Ten different iterations of PAM analysis were performed 
on the serum-containing fibrocytes and fibroblasts. Using a predictive set of samples in a PAM analysis a 
set of genes was determined that could be used to predict the population type of samples. These were 
then tested on a test set of samples. The genes in the gene lists created in the ten iterations were ranked 
according to the number of times a gene was used and any genes used in eight lists or above were 
chosen and listed above. The shortened and full gene names are shown. 
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Figure 6.24a Log(2) ratio data on genes used eight times and above in the ten iterations of PAM to 
classify the serum-containing fibrocytes and fibroblast samples. Ten different iterations of PAM analysis 
were performed on the serum-containing fibrocytes  and fibroblasts. Using a predictive set of samples in PAM a set 
of genes was determined that could be used to predict the population type of samples. These were then tested on 
a test set of samples. The genes in the gene lists created in these ten iterations were ranked according to the 
number of times a gene was used and any genes used in eight lists or above were chosen. Log(2) ratio data for each 
cell population for each gene is shown. Each sample is shown as a dot, with the median depicted by a line, serum-
containing fibrocytes are colour coded blue and fibroblasts green. The population data for each gene was 
statistically tested using Wilcoxon signed rank non-parametric statistical test, all are significantly different with at 
least P < 0.05. NB This is ratio data of reference divided by sample therefore the more negative a reading the higher 
the expression level of that gene. 
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Figure 6.24b Log(2) ratio data on genes used eight times and above in the ten iterations of PAM to 
classify the serum-containing fibrocytes and fibroblast samples. Ten different iterations of PAM analysis 
were performed on the serum-containing fibrocytes  and fibroblasts. Using a predictive set of samples in 
PAM a set of genes was determined that could be used to predict the population type of samples. These 
were then tested on a test set of samples. The genes in the gene lists created in these ten iterations 
were ranked according to the number of times a gene was used and any genes used in eight lists or 
above were chosen. Log(2) ratio data for each cell population for each gene is shown. Each sample is 
shown as a dot, with the median depicted by a line, serum-containing fibrocytes are colour coded blue 
and fibroblasts green. The population data for each gene was statistically tested using Wilcoxon signed 
rank non-parametric statistical test, all are significantly different with at least P < 0.05. NB This is ratio 
data of reference divided by sample therefore the more negative a reading the higher the 
expression level of that gene. 
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For macrophages versus fibroblasts 44 genes were selected, listed in table 6.12 along with their 
full name. Figures 6.25a and 6.25b shows the log(2) ratio data for each gene and the results of a 
Wilcoxon signed rank non-parametric statistical test, all are significantly different between the 
two cell populations, with at least P < 0.05. To note is that this is ratio data of reference divided 
by sample, therefore the more negative a reading the higher the expression level of that gene in 
those samples is. 
Gene  Full name Gene  Full name 
ACP5 Acid Phosphatase 5 KIAA1199 Transmembrane protein 2-Like 
ANTXR1 Anthrax toxin receptor 1 LAMA4 Laminin, alpha 4 
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta LCP1 Lymphocyte cytosolic protein 1 
AXL AXL receptor tyrosine kinase LMO7 LIM domain 7 
C1S Complement component 1 LUM Lumican 
CA2 Carbonic anhydrase II MMP2 Matrix metalloproteinase 2 
CAV1 Caveolin 1 NP_995327.1 FAM180A family with sequence similarity 180, 
member A 
CD84 CD84 molecule (member of CD2 subgroup 
of Ig superfamily) NT5E 5'nucleotidase, ecto (CD73) 
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) PARVA Parvin, alpha 
CYR61 Cysteine-rich, angiogenic inducer, 61 PLEK Pleckstrin 
DCN Decorin PRRX1 Paired related homeobox 1 
DDAH1 Dimethylarginine dimethylaminohydrolase 1 PTGIS Prostaglandin 12 synthase 
DDR2 Discoidin domain receptor tyrosine kinase 2 PTPRC Protein tyrosine phosphatase, receptor type C 
EFEMP1 EGF-containing fibrulin-like extracellular 
matrix Q5J7V3_HUMAN Unknown 
EGFR Epidermal growth factor receptor SERPINE1 Serpin peptidase inhibitor, clade E, member 1 
FCER1G Fc fragment of IgE. High affinity receptor 1. 
recpeotr for,; gamma polypeptide SERPINE2 Serpin peptidase inhibitor, clade E, member 2 
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64) SULF1 Sulfatase 1 
FRMD6 FERM domain containing 6 SYK Spleen tyrosine kinase 
GJA1 Gap junction protein, alpha 1 THY1 Thy-1 cell surface antigen 
H2AFY H2A histone family TMEM98 Transmembrane protein 98 
IGSF6 Immunoglobulin superfamily member 6 TNC Tenascin C 
JAM3 Junctional adhesion molecule 3 VAMP8 Vesicle-associated membrane protein 8 
 
Table 6.12 List of genes used eight times and above in the ten iterations of PAM to classify the 
macrophage and fibroblast samples. Ten different iterations of PAM analysis were performed on the 
macrophage and fibroblasts. Using a predictive set of samples in a PAM analysis a set of genes was 
determined that could be used to predict the population type of samples. These were then tested on a 
test set of samples. The genes in the gene lists created in the ten iterations were ranked according to the 
number of times a gene was used and any genes used in eight lists or above were chosen and listed 
above. The shortened and full gene names are shown. 
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Figure 6.25a Log(2) ratio data on genes used eight times and above in the ten iterations of PAM to 
classify the macrophages and fibroblast samples. Ten different iterations of PAM analysis were 
performed on the serum-free fibrocytes  and macrophages. Using a predictive set of samples in PAM a 
set of genes was determined that could be used to predict the population type of samples. These were 
then tested on a test set of samples. The genes in the gene lists created in these ten iterations were 
ranked according to the number of times a gene was used and any genes used in eight lists or above 
were chosen. Log(2) ratio data for each cell population for each gene is shown. Each sample is shown as 
a dot, with the median depicted by a line, macrophages are colour coded black and fibroblasts green. 
The population data for each gene was statistically tested using Wilcoxon signed rank non-parametric 
statistical test, all are significantly different with at least P < 0.05. NB This is ratio data of reference 
divided by sample therefore the more negative a reading the higher the expression level of that 
gene. 
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Figure 6.25b Log(2) ratio data on genes used eight times and above in the ten iterations of PAM to 
classify the macrophages and fibroblast samples (Part two). Ten different iterations of PAM analysis 
were performed on the serum-free fibrocytes  and macrophages. Using a predictive set of samples in 
PAM a set of genes was determined that could be used to predict the population type of samples. These 
were then tested on a test set of samples. The genes in the gene lists created in these ten iterations 
were ranked according to the number of times a gene was used and any genes used in eight lists or 
above were chosen. Log(2) ratio data for each cell population for each gene is shown. Each sample is 
shown as a dot, with the median depicted by a line, macrophages are colour coded black and fibroblasts 
green. The population data for each gene was statistically tested using Wilcoxon signed rank non-
parametric statistical test, all are significantly different with at least P < 0.05. NB This is ratio data of 
reference divided by sample therefore the more negative a reading the higher the expression 
level of that gene. 
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6.12 Discussion of chapter  
The aims of this transcriptome analysis were to try to determine the transcriptional relationship 
between in vitro derived, donor-matched serum-free and serum-containing fibrocytes to each 
other, and to donor matched macrophages and fibroblast cell lines together, or in various 
combinations. Ultimately this was to help determine whether serum-free and serum-containing 
fibrocytes are the same cell types, differentiated under different conditions, or two different cell 
types with similar phenotypic and morphologically characteristics. The first unsupervised cluster 
analyses (Figures 6.5 and 6.6) show a degree of separation between all four cell populations. 
This is a very important observation as it shows that despite 37632 genes being used to do the 
clustering there are enough differences to allow the division of samples into the different cell 
types. Especially when many of the 37632 genes are likely to be involved in defining a cell as just 
being a cell, and therefore whose expression is expected to be very similar among all cells. Not 
every sample clusters perfectly, however the general degree of clustering between samples of 
the same cell type is very promising. Once SAM had been performed and the genes significantly 
different between the populations (12602 genes) identified, the clustering was repeated and 
even tighter clustering was seen within the cell types (figures 6.8 and 6.9), indicating that all 
four cell types can be separated. It also needs to be noted that the purity of the T08.255 serum-
containing fibrocytes, based on cell morphology in table 6.1 was very low, however was still 
used for consistency between the donors. Despite this all serum-containing fibrocytes samples 
cluster very closely together, indicating perhaps that those cells without a fibroblast like 
morphology are still a form of fibrocyte.  
Chapter 6: Transcriptome analysis  Marianne Fairclough 
 236
 
Although the 12602 significantly different genes identified by SAM could cluster the samples 
into four different populations the biggest difference between the samples appeared to be 
between the fibroblasts and everything else, with the exception being of one serum-free 
fibrocyte sample which clusters with the fibroblasts (Figures 6.8 and 6.9). Why this serum-free 
fibrocyte sample clustered with the fibroblasts is unknown as the replicates for that donor 
clustered with the other serum-free fibrocytes. Due to the major differences in the way the 
fibroblast and other cells are cultured we were concerned that this would be contributing 
largely to the effect seen between them. Fibrocytes and macrophages were differentiated from 
peripheral blood and cultured for a relatively short period of time in vitro. However the 
fibroblasts were proliferating cell lines, although only at passage four following isolation and 
culturing may have introduced a bias that was uncontrollable in this experimental set up. The 
presence of genes involved in proliferation in the fibroblasts could also mask more subtle 
differences seen between the other three cell types. Therefore the decision was made to 
exclude the fibroblasts from much of the further analysis to prevent any bias that they may 
introduce and to allow for a more refined analysis of the differences within the remaining three 
cell populations. Although it is important to compare the transcriptomes of fibrocytes and 
fibroblasts, due to the linkage between the two populations described in the literature124;145;183, 
comparing fibroblasts immediately after isolation, rather than as an established cell line may be 
more informative. This may also prevent the introduction of bias due to continuous cell culture 
as seen when using cell lines, however, until specific cell markers for both fibroblasts and 
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fibrocytes can be determined, so that populations of each one are not contaminated with the 
other, it will be not be possible to perform this investigation. However the data from the 
normalisation of all four populations was used to do predictive analysis of microarrays between 
fibroblasts and the other three cell populations. When doing this 49 genes were found to be 
sufficient to predict whether samples were serum-free fibrocytes or fibroblasts (table 6.10 
figures 6.23a and 6.23b), 65 genes could predict whether samples were serum-containing 
fibrocytes or fibroblasts (table 6.11 and figures 6.24a and 6.24b) and 44 genes were able to 
predict  macrophages and fibroblasts (table 6.12 and figures 6.25a and 6.25b).  
 
Once the fibroblast samples had been removed unsupervised clustering of the three remaining 
cell types, serum-free, serum-containing fibrocytes and macrophages, was repeated. Again, 
despite being unsupervised a large amount of clustering between samples of the same cell type 
was seen (Figure 6.10). Once SAM analysis was performed and only those genes found to be 
significantly different between the three cell types used to perform cluster analysis (4563 
genes), more stringent clustering was seen, in which there was only 1 macrophage sample 
which did not cluster as expected, it clustered with the serum-free fibrocytes in the hierarchical 
cluster analysis (Figure 6.11 a.), although in the Principal component plot all macrophage 
samples clustered closely together (Figure 6.11 b). Again it is unknown why this one 
macrophage sample did not cluster as expected, with its replicates, however as it clustered with 
the other macrophage samples in the PCA we were not concerned. Interesting to note is that 
the biggest difference observed (along principal component 1) is between serum-free fibrocytes 
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and serum-containing fibrocytes, giving more credence to the hypothesis that the two types of 
fibrocytes are not the same cell type. Also the macrophage samples seemed to cluster closer to 
the serum-free fibrocytes than to the serum-containing, perhaps suggesting the closer 
relationship between these two.  
 
When performing PAM on these three populations just 28 genes were found to be sufficient to 
identify each cell population (Table 6.3). These 28 genes were also able to clearly separate the 
three populations by cluster analysis, HCL and PCA, other than the one macrophage sample 
which clustered with the serum-free fibrocytes (Figure 6.15). Of these 28 genes 24 showed the 
major difference in the expression level to be between the serum-containing fibrocytes and the 
other two populations (Figure 6.14), further suggesting that serum-free fibrocytes and 
macrophages are more closely related to each other than either are to the serum-containing 
fibrocytes. Also interesting to note is that of the remaining four genes three (ALPK3, CCNB1 and 
hsa-mir-27b) show macrophages being different from the two types of fibrocytes, and only one, 
MMD show serum-free fibrocytes being different from the other two cell populations, although 
this is because the level of expression of MMD in the serum-free fibrocytes is less than that in 
the other two populations, rather than a gene that is specific to this cell type. The role of MMD 
is not completely known, it was first described in 1995 as a macrophage maturation associated 
transcript, which, although having 7 transmembrane domains has little homology to G-protein 
receptors and has not been positively described as a receptor, however it has been suggested 
that it might be an ion channel protein188;189.  
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Although the three way analysis of the two types of fibrocytes and macrophages is informative, 
suggesting the presence of three different cell populations, a two way analysis of the fibrocytes 
would provide a more definitive answer and allow for specific transcriptome differences 
between them to be identified. A SAM analysis of serum-free and serum-containing fibrocytes 
at 0.1% FDR provided 6614 significantly different genes between them which, when used in 
cluster analysis, clearly separated out the two cell types (Figure 6.17). These results indicate that 
although morphologically and phenotypically very similar there is strong evidence to suggest 
that serum-free and serum-containing fibrocytes are not the same cell type.  
 
The 6614 genes identified by SAM as being significantly different between serum-free and 
serum-containing were cut down to be entered into the web based computer programme 
DAVID. Of the 225 genes found to be higher in serum-free fibrocytes than serum-containing 
only 6 processes were found that these genes were enriched in (Table 6.4). Unfortunately all 6 
appeared to be to do with chromatin and DNA mechanisms, giving no real insight into the 
potential roles of these cells in the body compared to serum-containing fibrocytes. However 
there were 432 genes higher in serum-containing fibrocytes compared to serum-free, providing 
37 enriched processes (Table 6.5). These include processes involved in localisation, defence and 
inflammatory responses as well as a response to wounding. These results seemed biologically 
relevant as fibrocytes have been reported as being very important in wound healing45;87;90;142;170, 
as well as the immune system89;91, and may suggest the importance of serum-containing 
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fibrocytes, compared to serum-free, in localising to sites where they are needed and restoring 
homeostasis. It is important to remember that the biological processes provided by DAVID are 
based on previously published information on the roles of different genes in different processes, 
therefore just because the processes come up as being enhanced in these genes lists does not 
mean that these cell populations are definitely involved in these processes. It just means that 
these genes have been reported as being important in these processes at some point. Therefore 
processes provided by DAVID act only as a guide to the potential biological roles these cell 
populations may have within the body. There are quite a few processes enriched in the serum-
containing fibrocyte genes list (Table 6.5) which are also involved in a form of homeostasis, as 
well as metabolic processes, which could suggest that as well as being involved in the defence 
system of the body and wound healing, these serum-containing fibrocytes may also be involved 
in returning the body to its normal homeostasis following an immune response. 
 
PAM of serum-free fibrocytes versus serum-containing fibrocytes produced a list of 36 
predictive genes (Table 6.7 and Figure 6.17), all of which were also seen within the 6614 genes 
found to be significantly different between the cell types by SAM. When used in cluster analysis 
these 36 genes were also able to clearly separate all 18 samples by HCL and PCA (Figure 6.18). 
Of these 36 genes both CCL2 and CCL7 were present and higher expression was observed in 
serum-containing fibrocytes compared to serum-free. CCL2 and CCL7 are chemokines that share 
the chemokine receptor CCR2, and the interactions of these chemokines and receptor have 
been reported as being important not only in wound healing and fibrosis, but also in the role of 
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fibrocytes in both of these processes as they are involved in their recruitment to sites of 
injury124;126;190;191. Also, although MMP7 and fibrocytes have not been associated within the 
literature, MMP7 has been reported as a signature protein found in peripheral blood, thought 
to indicate asymptomatic interstitial lung disease, or pulmonary fibrosis as well as disease 
progression192. As there is a reported role of fibrocytes in pulmonary fibrosis112;116;125;131;183 the 
expression of MMP7 may also be related to fibrocytes.  
 
Very few of the 36 genes highlighted by PAM between the two types of fibrocytes are reported 
in the literature as being related to fibrocytes, whether serum-free or serum-containing. 
However, of the genes highlighted some have been reported to be involved in inflammation. 
ALOX5AP is an activating protein which has a key role in the production of leukotrienes from 
leukocytes. Leukotrienes are fatty molecules involved in autocrine and paracrine signalling to 
regulate the immune response, often contributing to the inflammation in various inflammatory 
diseases including chronic obstructive pulmonary disease, asthma and rheumatoid arthritis193-
195. Also, although only reported in endothelial cells to date, TIE1 has been reported as being 
important in inducing a pro-inflammatory response when expressed, as well as being up-
regulated in inflammatory diseases such as atherosclerosis and rheumatoid arthritis196. IL1β, a 
member of the IL1 cytokine family, is known to be produced by activated macrophages and is an 
important mediator of the inflammatory response, as well as inducing the production of PTGS2, 
one of the two genes involved in the production of prostaglandins, however, in the case of this 
gene, only in times of inflammation. 
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As well as genes involved in inflammation genes involved in homeostasis were also highlighted 
in the PAM list. PTGS1 was listed and is the other gene involved in the production of 
prostaglandins, however rather than at times of inflammation as with PTGS2, it maintains 
baseline levels of prostaglandins for tissue homeostasis. The protein produced by the gene BRE, 
although initially thought to only be in the brain and reproductive systems, has now been 
reported as being expressed in many sites including the digestive system, respiratory organs as 
well as the lymphoid tissue and endocrine organs. As well as being reported as being involved in 
mediating anti-apoptosis197, it has also been suggested as possibly being a house-keeping gene 
for tissues constantly subjected to environmental hazards198. The gene CLEC12A produces a c-
type Lectin also known as MICL known to be present on monocytes and macrophages199 which 
has been suggested to play a role in homeostasis200;201. As has VSIG4, which is so far specific to 
macrophages and thought to be important in the maintenance of T cell unresponsiveness in 
healthy tissues202.  
 
The protein produced by the gene HBEGF was first identified as a product secreted by 
macrophages like cells and has been implicated in angiogenesis as well as wound healing203;204, 
both processes of which fibrocytes are linked to45;87;90. Looking at the information on all of these 
gene we can see that the processes highlighted by the DAVID analysis as being different 
between the serum-free and serum-containing fibrocytes are backed up by the genes used by 
PAM to separate the two cell types.  
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The results of both DAVID and PAM suggest the importance of serum-containing fibrocytes in 
inflammation, tissue homeostasis and wound healing, but give very little insight into the role of 
serum-free fibrocytes in the body. Within the PAM gene list only five genes had a higher 
expression in serum-free fibrocytes compared to serum-containing fibrocytes, however very 
little is known about these five genes, other than CKB. The production of which is reported as 
being greatly increased in osteoclast formation205 and its inhibition saw a suppression in bone-
reabsorbing activity in vitro and in vivo in CKB knock-out mice205.  
 
To investigate the relationship of both serum-free and serum-containing fibrocytes to 
macrophages two-way SAM and PAM were performed for both comparisons. In both cases each 
type of fibrocyte was found to be significantly different to macrophages, and clear separation 
was seen between the two cell populations (Figures 6.19).  
 
When performing PAM 21 genes were found to successfully separate serum-free fibrocytes and 
macrophages (Table 6.8 and Figures 6.20 and 6.22). Of these 21 only 3 had a log(2) ratio higher 
in serum-free fibrocytes compared to the macrophages (figure 6.20). When looking at serum-
containing versus serum-free fibrocytes only 5 of the 36 genes which could separate the two 
populations had a log(2) ratio value higher in serum-free fibrocytes. The fact that serum-free 
fibrocytes are mainly separated from other cell populations by the lack of genes rather than the 
expression of certain genes may suggest that they are potentially a type of default population 
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that monocytes differentiate into when there are no signals to differentiate into anything else, 
or to remain as a monocyte. As a default population they could retain some level of 
pluripotency, enabling them to continue to differentiate into other cell types if required, such as 
osteoclasts. As discussed in the introduction there are cells thought to be derived from CD14+ 
peripheral blood cells that have the ability to differentiate into several mesenchymal type cell 
lineages147;148. 
 
Further investigation of the gene lists provided by SAM and PAM is needed to elucidate 
potential candidate genes that could be used to both validate these results and to act as 
markers for separating out these populations in further investigations. Unfortunately the 
downside to using microarrays of the entire human genome are that very little is known about a 
large number of genes on the microarray, therefore when it comes to understanding the 
importance of these genes in context to the biological systems being looked at it can become 
very difficult, as in some cases very little may be published on them.  
 
The results seen in this chapter indicate that serum-free and serum-containing fibrocytes are 
two different cell populations as 6614 genes were found to be significantly different between 
them by SAM and 36 genes found to be able to separate them by PAM. 
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7.0 FINAL DISCUSSION 
Although fibroblasts-like cells that differentiate from a haematopoietic origin have been 
described for over a hundred years (reviewed in Postlewaite et al 200484) it has only been in the 
last twenty years that people have really started investigating their roles in the human body and 
disease. In 1994 Bucala et al termed these cells fibrocytes and described them as being 
morphologically similar to fibroblasts, however expressing different surface markers, and most 
importantly being haematopoietic rather than mesenchymal87 in origin. As well as their 
fibroblast-like morphology fibrocytes are identified by their expression of both stromal and 
haematopoietic makers, such as collagen, vimentin, CD45 and CD13, and are described as being 
important in both wound healing and fibrotic diseases47;87;113;134;142. The role of fibrocytes in 
both of these processes is not surprising as fibrotic diseases are thought to often be due in part 
to an excess of wound healing components106;108;206. In the majority of research into fibrotic 
diseases fibroblasts have been implicated as the critical cell of the disease104;106;108;122;206-208, 
however more recent studies have suggested that as well as the resident fibroblasts, fibrocytes 
have an important role in the disease process84;122;145;183. Mouse models of both pulmonary and 
hepatic fibrosis have implicated fibrocytes in the development of these fibrotic 
disorders111;116;134 and fibrocytes have also been implicated in mouse models of wound 
healing87;111;142. However before the particulars of the role of fibrocytes in fibrosis and wound 
healing can be elucidated further investigation into the differentiation, development and 
recruitment of these cells is required to be able to understand their complex role in both wound 
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healing and fibrotic disorders, and so allow for therapeutic strategies of treatment to be 
determined.  
 
In 2003 Pilling et al reported that fibrocyte differentiation is inhibited in vitro by the plasma 
protein SAP and its interaction with Fcγ receptors47;48, this was supported by a mouse model of 
fibrotic ischemia/reperfusion cardiomyopathy (I/RC) where the administration of SAP saw a 
reduction of cells with a fibrocyte-like morphology from the site of injury in vivo but did not 
suppress the development of inflammation or chemokine expression111;113. The inhibition of 
fibrocyte differentiation by SAP in vitro was determined by the study of fibrocytes in a serum-
free environment47;48 as these cells were seen to appear from PBMC after 3 days of cell culture. 
This is in contrast to many of the other reports on fibrocytes in which they are differentiated in 
a serum-containing environment, with differentiated cells appearing after 10-14 days45;87;89-91. 
Fibrocytes differentiated in both a serum-free and serum-containing environment 
morphologically look very similar and have the same expression profile, which has been shown 
in this thesis (chapter 3) as well as reported47;87; this has led to the belief that that they are the 
same cell differentiated through different methods. It has also been reported that serum-free 
derived fibrocytes express high levels of the enzyme required for collagen synthesis, prolyl 4-
hydroxylase48, whereas in a separate report fibrocytes generated in a serum-containing 
environment have a low level of prolyl 4-hydroxylase150, although a direct comparison has not 
been made. This thesis addresses whether serum-free and serum-containing fibrocytes are the 
same cell differentiated under different methods or whether they are actually two different, 
Chapter 7: Discussion  Marianne Fairclough 
 247
although related cell types; and this has been investigated by using both in vitro cell culture and 
molecular microarray profiling.  
 
The optimum culture conditions for fibrocyte differentiation in both serum-free and serum-
containing environment were initially addressed in this thesis due to discrepancies seen 
throughout the literature. Slightly different culture conditions have been used across the 
various reports; such as different starting concentrations of PBMC, whether or not the non-
adherent cells were washed off, and at what time point45-48;87;89-91;103;116;146. In our hands the 
optimum culture conditions for fibrocyte differentiation were PBMC at 1x106cell/ml, washing 
off the non-adherent cells 96 hours later; and to plate out CD14+ selected cells at 2x106cell/ml 
(Figures 3.7-3.9). Once the optimum culture conditions had been determined the expression 
profile of these cells were examined for a limited number of markers to ensure consistency 
between the cells used in this thesis and the reported expression profile of fibrocytes. The 
expression profile of the two types of fibrocytes were identical and concurred with reported 
results (Figures 3.15-3.17, Table 3.1). 
 
Despite reports that fibrocytes can be detached by ice cold 0.05% EDTA/ PBS45;46;89;91;146, this 
was not seen in this thesis when tested on serum-free derived fibrocytes (Figures 3.10 and 
3.12). As fibrocytes could not be detached a method of quantifying results in situ was required. 
Following testing, counting the number of fibrocytes and none fibrocytes then taking a mean 
reading from three fields of view from three wells from each condition was found to be a 
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suitable protocol (Figures 3.3-3.6). Therefore for each condition when looking at fibrocyte 
differentiation or the effects agents have on them a minimum of three wells was required. 
 
If serum-free and serum-containing derived fibrocytes are the same cell type differentiated 
under different conditions it was speculated that once differentiated they could be switched 
into the opposite media and survive. This thesis shows that serum-containing fibrocytes, once 
differentiated, will survive happily in a serum-free environment (Figures 4.8 and 4.9), however 
serum-free derived fibrocytes role up in the presence of serum, at whatever time point it is 
added and do not return to their original morphology for at least two weeks afterwards (Figures 
4.8-4.10, 4.18). This effect was found to occur in the presence of both bovine and human serum, 
and the effects seen within four hours (Figures 4.11- 4.16). These rolled-up fibrocytes kept a 
fibrocyte expression profile though, continuing to express fibronectin when rolled-up (Figure 
4.19), the expression of which is not seen in other monocyte-derived progeny, such as the 
macrophage (Figure 3.15). When trying to elucidate the cause of this effect of the serum 
preliminary experiments suggest it is a very heat stable, large protein or particle (Figures 4.20-
4.21), which fits with the description of the plasma protein SAP. However commercial SAP, 
although found to prevent fibrocyte differentiation (Figure 4.23), did not cause fibrocytes to 
roll-up when administered once fibrocyte differentiation had taken place (Figure 4.22), this 
observation however requires further investigation as is only based on preliminary work.  
 
Chapter 7: Discussion  Marianne Fairclough 
 249
Fibrocyte differentiation is known to occur form CD14+ cells of the peripheral blood or 
monocytes45;47-49;85;86. Despite reports that the presence of T cells, or at least T cell conditioned 
media are required for fibrocyte differentiation45;46, we found that both serum-free and serum-
containing fibrocytes differentiated from PBMC and CD14 positively selected cells (although 
PBMC derived serum-containing fibrocyte numbers were very low) Interestingly however it was 
found that significantly more fibrocytes differentiated in a serum-free environment than a 
serum-containing environment from PBMC, and in contrast significantly more fibrocytes 
differentiated in a serum-containing environment than serum-free from CD14+ selected cells 
(Figure 4.1). Further investigation into this is required to elucidate the causes of it whether it be 
due to factors present or the interaction of the CD14 molecule or both. However this 
observation is important as under the same culture conditions, from the same donors PBMC 
respond differently in the two culture environments. It is important to elucidate the cause of 
this phenomenon as if the hypothesis that these two related cells occur at different time points 
of a wound healing response is correct and subtly different signals are involved in their 
differentiation what these signals are would need to be known so that further work on these 
cells can be performed 
 
Three populations of human monocytes have been described in the literature51;52, with the 
major population being CD14+CD16- and two other smaller populations identified as 
CD14+CD16+ and CD14loCD16+. As discussed in the introduction it has been suggested that these 
three different populations have different roles within the immune system40;53-55;61;179;180, and 
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due to the differences seen in this thesis between serum-free and serum-containing derived 
fibrocytes, whether the monocyte population they differentiated from was also different was 
investigated. Results showed that although macrophages will differentiate from all three 
monocyte populations both serum-free and serum-containing fibrocytes only differentiate from 
the CD14+CD16- and CD14+CD16+, and not CD14loCD16+ (Figures 5.3-5.4). 
 
When examining these serum-free and serum-containing derived fibrocytes by molecular genes 
arrays, spotted microarrays of the complete human genome were used, containing 
approximately 37,000 genes. Ideally a comparison of the transcriptomes of the serum-free and 
serum-containing derived fibrocytes would be done on pure cultures of cells, however, as 
neither fibrocyte population differentiates in a homogeneous fashion in vitro, and a 
representative population of serum-free derived fibrocytes could not be detached, whole 
cultures had to be used to do the comparisons and were lysed in situ, despite the presence of 
non-morphological fibrocytes in the culture. However although under the criteria used in this 
thesis non-spindle shaped cells in a fibrocyte culture are not defined as fibrocytes ‘rolled’ up 
fibrocytes or round cells in figure 4.19 (serum-free fibrocytes which had been treated with 
serum) did still express fibrocyte markers. Also one of the serum-containing fibrocyte donors for 
the transcriptome analysis only produced cultures that were 8% pure based on morphology, 
however these went to on cluster well with the other serum-containing samples, therefore the 
lack of a spindle shaped morphology may not mean the absence of fibrocytes.  
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Following two way comparisons of the serum-free and serum-containing fibrocytes they were 
seen to cluster completely separately (Figures 6.17 and 6.19) and by statistical analysis 6614 
genes were found to be different between them (Figure 6.17). Even when the clustering of the 
two populations was examined in the presence of other cell populations, namely macrophages 
and fibroblasts, in an unsupervised fashion, these two populations were still seen to separate 
(Figures 6.6, 6.7, 6.11, 6.12, 6.16). Further work within the department on the clustering of cell 
populations based on their transcriptome has included these samples plus other monocyte 
derived progeny, as well as monocytes themselves. They have found that even with other 
populations included (monocytes, osteoclasts, immature dendritic cells and mature dendritic 
cells) serum-free and serum-containing fibrocytes continue to cluster separately, supporting the 
hypothesis that these are two separate populations based on gene expression (Figure 7.1).  
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Figure 7.1 PCA of Monocytes, monocyte derived progeny and fibroblasts. Triplicate samples of 
donor matched monocytes and monocyte derived progeny, as well mismatched fibroblasts cell 
lines were analysed by transcriptome analysis and clustering based on all 37,000 genes, depicted 
by 3D Principal component analysis. Cell populations identified by the key, 3 separate donors/ 
cell lines were used for each population. 
 
The genes determined to be significantly different between serum-free and serum-containing 
fibrocytes by SAM analysis were used in the analysis programme DAVID to provide potential 
biological processes that these two cell populations are involved in (Tables 6.4-6.5). The list of 
genes found to have a higher expression in serum-containing fibrocytes compared to serum-
free provided many more processes than the genes found to be more highly expressed in the 
serum-free fibrocytes. There were not only more processes but also processes that fibrocytes 
have already been reported to being involved in such as response to wounding and the 
inflammatory response (Table 6.5). As well as this PAM analysis provide a list of just 36 genes 
required to separate these two populations (Table 6.7), and of these genes the majority had a 
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higher expression value in serum-containing fibrocytes than serum-free (Figure 6.18). In fact 
rather than a set of genes or processes emerging as indicators of serum-free fibrocytes these 
cells actually appear to be identified by the lack of gene expression.  
 
Although very little has been reported in the literature linking any of the genes highlighted by 
PAM to fibrocytes, by looking at what has been reported on these genes, the potential 
pathways determined from DAVID and the in vitro work in this thesis it could be suggested that 
although related serum-free and serum-containing derived fibrocytes are two different cell 
types that have very similar roles within the body. In the initial research by Bucala et al in a 
murine wound healing model a rapid influx of inflammatory cells prior to the emergence of 
fibrocytes was seen very soon after the initiation of the inflammation87. Further work on these 
cells in vitro went on to suggest their importance in not only angiogenesis but also in presenting 
antigen to T cells90; and all this work was done in a serum-containing environment.  
 
One hypothesis that links all this data is that what are termed here as serum-containing 
fibrocytes appear very soon within sites of inflammation and wound healing to not only assist 
the macrophages and other immune cells in the removal of the cause of the inflammation, but 
also to begin the repair of the site with the production of extra cellular matrix components such 
as collagen and fibronectin. In vitro these serum-containing fibrocytes do take longer to appear 
than serum-free derived fibrocytes however there is currently no reported single signal that 
causes fibrocyte differentiation and it may be that the complex combination of signals a 
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monocyte receives on entering a site causes a more rapid differentiation of these cells than is 
seen in vitro. Plus it has also been suggested that monocytes are required to migrate through 
endothelial cells to be able to mature into fibrocytes rapidly111.  
 
Once a site of inflammation or wound healing begins to recover and the environment changes, 
with the loss of serum factors ‘serum-free derived’ fibrocytes may enter the site and take over 
the role of repair, as they are more suited to that environment, in a less inflammatory 
environment they do not need the high expression of as many inflammatory mediating 
molecules, hence the lower expression of these factors in comparison to serum-containing 
fibrocytes. Although serum-containing derived fibrocytes can remain in the site it allows them 
to move on to other areas if required. It maybe the recruitment of these serum free derived 
fibrocytes that are involved in excessive fibrosis and so the development of fibrotic diseases, as 
SAP treatment in mouse models reduced the level of fibrosis seen112;113. This is all speculation 
and much more investigation would be required, however it would explain the need for two 
very similar cell types within the body and the sometimes conflicting reports in the literature 
seen.  
 
A more precise transcriptome analysis between the two fibrocyte populations could be 
determined if a pure population of these two cell types could be obtained. Due to the 
difficulties in detaching these cells a protocol whereby individual cells could be laser 
microdissected and so a pure population obtained is being investigated. Using this technology a 
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sample of 20 or 30 cells can be collected for each population and RNA extracted. This RNA was 
found to be viable, as once reverse transcribed, product was seen following L27 gene PCR, 
however to be able to use this material on the human genome microarrays much more material 
would be required, and so cDNA amplification needed. So far testing of amplification protocols 
from this small amount of material have resulted in far too much none specific artefact being 
produced, making any microarray analysis of the material questionable. Therefore the current 
technology available does not allow for these more precise comparisons to be made at the 
moment.  
 
However laser microdissected material could be used to validate the results of the 
transcriptome analysis performed so far, following up on the genes that have been found to be 
significantly different between the two types of fibrocytes. If a set of genes can be found to 
identify these two potential populations the role of serum-containing and serum-free fibrocytes 
in wound healing and diseased could be further investigated. Cells of a ‘fibroblast-like’ 
morphology could be laser micro-dissected out of tissue samples of repairing or diseased tissue 
and the expression of these identifying genes looked at to see if a particular type of fibrocyte 
can be identified. Dependant on the tissue used a clearer idea of the role of these cells could be 
determined. As fibrocytes have been shown to be important factors involved in fibrosis and 
fibrotic diseases if there are two types the ability to determine them would be extremely 
important as it would lead to a clearer understanding of their role in the disease and 
consequently help in determine suitable treatments. 
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